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Mitochondrial dysfunction not only occurs in patients with mitochondrial diseases, but in other 
neuromuscular conditions as well as the normal ageing process. In patients with mitochondrial 
disease, both nuclear and mitochondrial genetic defects cause a range of symptoms that are 
extremely heterogeneous. These symptoms predominantly affect tissues with a high metabolic 
demand such as the skeletal muscle, and often present as oxidative phosphorylation (OXPHOS) 
deficiency. This disease phenotype is further complicated by the multicopy nature of 
mitochondrial DNA (mtDNA), which means that mtDNA populations can be heteroplasmic, 
with variable mutation loads leading to a mosaic pattern of OXPHOS deficiency. This project 
aims to understand mitochondrial defects within skeletal muscle in both ageing and 
mitochondrial myopathy. 
An immunohistochemical investigation was undertaken to assess biochemical changes in 
skeletal muscle biopsies from participants aged 84-85. This study provided a more thorough 
understanding into what is happening to the muscle with age and revealed that active 
participants aged 84-85 have a preserved mitochondrial function comparable to young, healthy 
controls. However, although current methods such as immunohistochemistry and 
immunocytochemistry can reveal specific aspects of the mitochondrial OXPHOS defect, they 
fail to assess individual cell changes in all OXPHOS complexes within a single tissue 
cryosection.   
The advent of imaging mass cytometry (IMC) addresses this limitation and permits the 
investigation of more proteins at a single cell level than is possible with current techniques. 
Henceforth, this project was aimed at developing a novel workflow and bespoke analysis for 
applying IMC in skeletal muscle to investigate OXPHOS deficiency more thoroughly. Once 
optimised, this technique was used to investigate patients with different genetically 
characterised mitochondrial diseases, followed by a larger cohort of single, large-scale mtDNA 
deletion patients.  
There are several novel findings from this work: (i) IMC can be used to successfully quantify 
mitochondrial dysfunction in skeletal muscle; (ii) compared to controls and normal muscle 
fibres, patients with a deficiency of complex I present with an increase in unaffected respiratory 
chain complexes; (iii) complex III and V deficiency occur at low levels in muscle fibres from 
some patients with defects in mitochondrial translation; (iv) the successful optimisation and use 
of novel antibodies that target mtDNA-encoded subunits; (v) the amount of OXPHOS 
deficiency detected in single, large-scale mtDNA deletion patients correlates with the size and 
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1.1 The origins of mitochondria 
Mitochondria are highly dynamic, double-membraned organelles present in every nucleated 
mammalian cell. Since their evolution, mitochondria have played a central role in many cellular 
processes including adenosine triphosphate (ATP) production, iron-sulphur (Fe-S) cluster 
formation, calcium handling, apoptosis and haem production (Duchen, 2004). 
 It is well known that mitochondria arose through an endosymbiotic relationship, however there 
is much speculation as to how this origin happened. Two main theories have been proposed: 
the first, known as the Archezoan hypotheses (Cavalier-Smith, 1987), postulates the capture of 
an α-probacterial endosymbiont by a nucleated archezoa host, and is based on the small subunit 
ribosomal RNA (rRNA) phylogenetic tree (Yang et al., 1985); the second, known as the 
symbiogenesis hypotheses, suggests an endosymbiotic event took place before the diversion of 
eukaryotes from prokaryotes which resulted in subsequent diversion and development of a 
nucleus to form the eukaryotic cell (Martin and Müller, 1998). Of these, it is the Archezoan 
hypothesis which is considered by most to explain the endosymbiotic origin of mitochondria 
(Roger et al., 2017). 
1.2 Mitochondrial structure  
The structure of a mitochondrion was first explained by Palade (1953) who, using electron 
microscopy, recognised a characteristic structural pattern in all mitochondria irrespective of 
species or cell type. The mitochondria comprise of two membrane systems (the outer and the 
inner membrane), a relatively homogenous and structureless material known as the matrix, and 
a system of internal cristae. Palade described the outer mitochondrial membrane (OMM) 
enclosing the intermembrane space, and the inner mitochondrial membrane (IMM) enclosing 
the matrix. A schematic representation of the mitochondrial structure can be found in Figure 
1.1. 
The ‘baffle’ model of cristae structure (Palade, 1953) suggested the cristae were formed by 
random folds of the IMM, however more advanced microscopy has offered proof against this 
theory and provided evidence that the cristae are formed by invaginations of the membrane 




Figure 1.1: Schematic representation of mitochondrial structure and organisation.  
The double membrane is pivotal for the regulated transport of metabolites and ions both into 
and out of the mitochondria. The OMM is relatively porous and is freely traversed by ions and 
small, uncharged molecules through pore-forming membrane proteins such as the voltage-
dependant anion channel (VDAC). Other proteins housed on the OMM include protein 
transporters such as translocase of the outer mitochondrial membrane (TOMM). Due to its 
porosity, there is no membrane potential across the OMM. 
The IMM encloses the matrix space and can be subdivided into two distinct domains: the inner 
boundary membrane (IBM) and the cristae membrane (CM), with crista junctions connecting 
the two. The IBM is situated close to the OMM and is considered a second envelope structure 
– interacting heavily with the OMM whilst the CM forms the majority of the IMM surface – 
and is rich in proteins that are responsible for a range of processes such as oxidative 
phosphorylation, protein transport and protein synthesis (Vogel et al., 2006).  In contrast to the 
OMM, the IMM is less permeable, and even small solutes such as ions and metabolic substrates 
cannot pass through without the assistance of specific transport proteins such as inner 
mitochondrial membrane translocases (TIMM)(Kulawiak et al., 2013). With a protein/lipid 
ratio of ~ 75:25 (Claypool, 2009), the IMM is relatively rich in protein and harbours the 
complexes of the respiratory chain as well as the protein translocases required for the import of 
precursor proteins (Bauer et al., 2000). 
The mitochondrial matrix contains the mitochondrial genome (mtDNA) along with the 
machinery required for transcription and translation. In addition, the matrix is the location of 




1.3 Mitochondrial dynamics 
Although initially depicted in the literature as bean-shaped organelles, it is now well known 
that mitochondria have highly dynamic structures with the ability to change both shape and 
location inside a cell  (Bereiter-Hahn and Vöth, 1994). Furthermore, mitochondria may either 
fuse together, helping to mitigate stress by mixing the contents of partially damaged 
mitochondria, or separate into two different entities to assist with the selective removal of 
damaged mitochondria. These two processes, termed fusion and fission respectively, play a 
critical role in maintaining mitochondrial function and are mediated by GTPases in the dynamin 
family (Youle and van der Bliek, 2012). 
1.3.1 Fission 
Fission is the process by which one mitochondrion divides to form two separate mitochondria, 
and is mediated primarily by the cystolic Dynamin related protein 1 (Drp1) (Bleazard et al., 
1999, Smirnova et al., 2001) (Figure 1.2). Once recruited from the cytoplasm, Drp1 forms 
spirals around mitochondria and, with the further binding and hydrolysis of GTP promoting a 
conformational change in Drp1, results in the constriction and severing of both inner and outer 
membranes (Mears et al., 2011, Youle and van der Bliek, 2012). The importance of Drp1 in 
fission has been supported by many studies and it has been found that loss of this protein can 
induce both highly connected networks of mitochondria (Smirnova et al., 2001) and increased 
fusion (Lee et al., 2004). 
Other membrane proteins associated with fission and thought to play a role in Drp1 recruitment 
include mitochondrial fission protein (Fis1), Mitochondrial fission factor (Mff), MiD49 and 
MiD51 (Richter et al., 2015). Recent work has also suggested that the endoplasmic reticulum 
(ER) has a role in DRP1 recruitment. Studies have shown that the ER wraps around 
mitochondria to form mitochondria-ER contacts, initiating mitochondrial constriction at contact 




Figure 1.2: Mitochondrial Fission. Schematic diagram representing mitochondrial fission and 

























Mitochondrial fusion (Figure 1.3) is the process whereby two mitochondria merge to form a 
single mitochondrion. Mitochondrial fusion is controlled, in a double membrane fusion event, 
by a number of dynamin-related proteins (DRPs) with GTPase activity. Fusion of the OMM is 
regulated by the mitofusin proteins 1 and 2 (Mfn1 and Mfn2), both of which contain two 4,3 
hydrophobic heptad repeats (HR1 and HR2) (Koshiba et al., 2004). It has been posited that the 
HR2 domain dimerises with another HR2 domain to form a long, antiparallel coil which 
functions as a tether between adjacent mitochondria before membrane fusion occurs (Formosa 
and Ryan, 2016). 
IMM fusion is governed by another DRP called optic atrophy 1 (Opa1), which is localised in 
the inner membrane and intermembrane space (Meeusen et al., 2006). Opa1 exists as two 
isoforms – one is a long, membrane-anchored isoform (l-Opa1) which protrudes into the IMS 
and promotes tethering of the two IMM from fusing mitochondria, whilst the other is a short 
isoform (s-Opa1). A combination of both long and short Opa1 isoforms are required for 
effective fusion (Mishra et al., 2014, DeVay et al., 2009). 
 
Figure 1.3: Mitochondrial Fusion. Schematic diagram representing mitochondrial fusion. Opa1 
coordinates the fusion of the IMM and MFN1/2 coordinates the fusion of the OMM.  
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1.4 Oxidative phosphorylation and ATP production 
Mitochondria are key in oxidative metabolism and primarily function to produce cellular energy 
in the form of adenosine triphosphate (ATP). The generation of this ATP relies on three major 
respiratory pathways: anaerobic glycolysis; the tricarboxylic acid (TCA) cycle; and 
mitochondrial electron transport, via the electron transport chain.  
1.4.1 Glycolysis and the TCA cycle 
The anaerobic process of glycolysis takes place in the cytoplasm and is responsible for the 
metabolism of glucose to produce two molecules of pyruvate alongside the net production of 
two ATP molecules (Equation 1.1). The pathway is comprised of two stages: stage one begins 
with the conversion of glucose to fructose-1,6-bisphosphate, which is then further cleaved into 
three carbon fragments (there is no ATP generation in this stage); stage two harvests ATP by 
the oxidisation of the three carbon fragments to pyruvate. During stage two, NAD+ is reduced 
to NADH. Since limited amounts of NAD+ exist in the body, the final stage is to regenerate 
NAD+ through pyruvate metabolism (Berg et al., 2015a). 
Glucose + 2 Pi + 2 ADP + 2 NAD+ → 2 pyruvate + 2 ATP + 2 NADH + 2 H+ + 2 H2O 
Equation 1.1: Glycolysis reaction (Berg et al., 2015a). 
The TCA cycle, which takes place in the mitochondrial matrix, is responsible for the aerobic 
processing of glucose and functions to harvest electrons which can be used by the electron 
transport chain in the production of ATP. Under aerobic conditions the pyruvate generated by 
glycolysis is oxidatively decarboxylated to form acetyl coenzyme A, which subsequently feeds 
into the TCA cycle. After a series of oxidation and reduction reactions, the production of one 
ATP molecule and two molecules of CO2 generates electrons that can be used in the electron 
transport chain to power the synthesis of ATP (Equation 1.2) (Berg et al., 2015b). 
Acetyl-CoA + 3 NAD+ + FAD + ADP + Pi + 2 H2O → 2 CO2 + 3 NADH + FADH2 + 
ATP + 2 H+ + CoA 






1.4.2 Oxidative phosphorylation 
Oxidative phosphorylation (OXPHOS) comprises the mitochondrial respiratory chain 
complexes (complexes I-IV) and ATP synthase (complex V) (Figure 1.4), embedded in the 
inner mitochondrial membrane. Complex I catalyses the first step of OXPHOS and accepts 
electrons derived from NADH, with complex II accepting electrons derived from FADH2. 
Subsequently, these are transferred along the chain to complex III via coenzyme Q and to 
complex IV through cytochrome c. The transfer of these electrons, coupled with the active 
pumping of protons from complexes I, III and IV into the intermembrane space, produces a 
chemiosmotic gradient which results in the flow of electrons back through ATP synthase, 




Figure 1.4: Oxidative phosphorylation. The inner mitochondrial membrane housing complexes I-V. The transfer of electrons through complexes I-IV is coupled 
with the pumping of protons from the matrix to the intermembrane space. This creates an electrochemical gradient which causes protons to flow back through 
complex V to convert ADP to ATP.
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1.4.3 Complex I 
Complex I, also known as NADH dehydrogenase, is the major entry point for electrons and, 
with a molecular mass of ~1000kDa, it is the largest of the five enzyme complexes. It consists 
of 45 subunits (Carroll et al., 2006) – of which, seven are encoded by the mtDNA (ND1-ND6 
and ND4L) and 38 are nuclear-encoded. 
When fully assembled, complex I forms an L shape with a hydrophobic arm embedded in the 
IMM and a hydrophilic peripheral arm protruding into the matrix (Hunte et al., 2010). 
Schematically represented in Figure 1.5, the complex presents three functional modules: the 
N-module, the Q-module and the P-module (Zickermann et al., 2015). The N-module, located 
in the matrix arm, contains the NADH oxidation site and transfers electrons from NADH to a 
flavin mononucleotide (FMN) to produce FMNH2. The resultant electrons are transferred to Q, 
which is also located in the matrix arm, via a chain of Fe-S clusters. The Q-module contains the 
ubiquinone reduction site and is responsible for reducing ubiquinone to ubiquinol. The final P-
module, which is embedded in the IMM, holds all the proton pumping machinery necessary for 
electrons to move through the complex and contains all of the seven mtDNA encoded subunits 
(Mimaki et al., 2012). The overall reaction catalysed by complex I is presented in Equation 
1.3. 
NADH + Q + 5[H+]matrix → NAD+ + QH2 + 4[H+]cytoplasm 





Figure 1.5: Complex I. Schematic diagram of the complex I structure. The reduction of NADH allows 
electrons to be donated to FMN, passed along a chain of Fe-S clusters, and transferred to ubiquinone 
(Q). This shuttling of electrons is coupled to the transfer of a proton from the matrix to the 
intermembrane space.   
Using a recently developed complexome profiling approach, Guerrero-Castillo et al. (2017) 
successfully studied the assembly of complex I and were able to demonstrate a step wise 
approach (Figure 1.6). The 45 subunits come together in a regulated fashion with accessory 
subunits binding peripherally to the conserved core forming a protective cage-like structure 




















1.4.4 Complex II 
Complex II (succinate dehydrogenase) is the smallest complex of the OXPHOS system 
(~123kDa) and is the only complex to be solely encoded by the nuclear genome. The complex 
has a duel role: in the Krebs cycle it catalyses the oxidation of succinate to fumarate, generating 
FADH2 in the process; within the ETC it transfers electrons from FADH2 to ubiquinone, which 
is subsequently reduced to ubiquinol (Cecchini, 2003). The complex consists of four subunits: 
SDHA and SDHB are located in the matrix and form the catalytic core, whilst SDHC and 
SDHD are embedded in the IMM and anchor the complex to the membrane (Rutter et al., 2010). 
A schematic diagram and overall reaction of complex II are presented in Figure 1.7 and 
Equation 1.4 respectively. The assembly of complex II is shown in Figure 1.8. 
 
 
Figure 1.7: Complex II. Schematic diagram of complex II, which is the second point of entry for 
electrons. Electrons are passed from succinate to FAD following the oxidation of succinate. Electrons 
are then shuttled along Fe-S clusters to ubiquinone (Q).  
 
Succinate + FAD + 2[H+] + Q → Fumarate + FADH2 + Q → Fumarate + FAD + QH2 




Figure 1.8: Complex II assembly. Schematic diagram showing the assembly of complex II. Image 












1.4.5 Complex III 
Complex III (cytochrome c reductase) was first isolated from bovine heart mitochondria in 1961 
(Hatefi, 1976). Schematically presented in Figure 1.9, complex III consists of 11 subunits, of 
which only one, cytochrome b, is encoded by the mitochondrial genome (Bénit et al., 2009). 
The reaction in complex III is a two-step process: first, ubiquinol is oxidised to ubiquinone, 
with the release of each electron reducing cytochrome c. This process is coupled with the 
translocation of two protons into the intermembrane space which contributes to the proton 
motive force (Equation 1.5). The assembly of complex III is shown in Figure 1.10. 
 
 
Figure 1.9: Complex III. Schematic of complex III showing the transfer of electrons from ubiquinol 
(QH2) to ubiquinone (Q) and cytochrome c. The shuttling of electrons is coupled with the translocation 
of protons from the matrix to the intermembrane space. 
 
2[QH2] + Q + 2[Cyt c]ox + 2[H+]matrix → 2[Q] + QH2 2[Cyt c]red +[4H+]cytoplasm 















1.4.6 Complex IV 
Complex IV, also known as cytochrome c oxidase (COX), is the terminal complex of the 
electron transport chain and is responsible for catalysing the reduction of oxygen to water (Li 
et al., 2006). The complex (Figure 1.11) comprises 13 subunits, of which three (MTCO1, 
MTCO2 and MTCO3) are encoded by the mtDNA and form the functional core of the enzyme. 
The assembly of complex IV is shown in Figure 1.12. The complex acts as a dimer 
(Shoubridge, 2001) and mediates the transfer of electrons (through various prosthetic groups) 
from reduced cytochrome c to molecular oxygen. This oxygen is further reduced to water and 
is coupled with the translocation of four protons into the intermembrane space (Equation 1.6) 
(Diaz, 2010).  
4[Cyt c]red + O2 + 8[H+]matrix → 4[Cyt c]ox + 2H2O + 4[H+]cytoplasm 
Equation 1.6: Complex IV reaction (Berg et al., 2015c). 
 
 
Figure 1.11: Complex IV: Schematic diagram of complex IV demonstrating the transfer of electrons 
from cytochrome c through haem groups and copper centres. This transfer of electrons is coupled with 




Figure 1.12: Complex IV assembly. Schematic diagram showing the assembly of complex IV. Image taken from Signes and Fernandez-Vizarra (2018).
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1.4.7 Complex V 
Complex V, or ATP synthase, is the final subunit in the OXPHOS system and synthesises ATP 
from ADP in the matrix by utilising the energy provided by the proton electrochemical gradient 
(Nijtmans et al., 1995). The structure consists of two domains; F0 is located in the inner 
mitochondrial membrane, whilst F1 is situated in the mitochondrial matrix (Figure 1.13). The 
assembly of complex V is shown in Figure 1.14. The F0 contains subunits a, b, c, d, F6 and 
OSCP as well as the accessory subunits e, f, g and A6L which are organised into a ring structure 
to form a proton channel allowing the movement of protons across the IMS to the matrix. 
Subunits a and A6L are the only subunits to be encoded by mitochondrial genes, ATP6 and 
ATP8 respectively (Anderson et al., 1981). F1 is the catalytic unit of complex V and is 
comprised of five polypeptide chains – three α, three β, γ, δ and ϵ – which constitute the central 
stalk of the complex (γ and δ) connecting both regions together, as well as a hexameric ring 
structure to catalyse the synthesis of ATP (α3 β3) (Devenish et al., 2008, Jonckheere et al., 
2012). A proton motive force across the inner membrane drives the c ring rotor, causing 
conformational changes in the F1 domain. This turning generates the energy required to 
phosphorylate ADP and release ATP, resulting in ATP generation. 
 
Figure 1.13: Complex V. Schematic diagram of complex V (or ATP synthase) showing the structural 
subunits that comprise the F0 and F1 sections. Powered by the transport of protons from the 
intermembrane space, through the complex, into the matrix, ATP synthase catalyses the synthesis of 











Through the use of electron cryotomography, it has been shown that ATP synthase is arranged 
in long rows of dimeric supercomplexes along the tip of the mitochondrial cristae, enforcing a 
tight curvature of the structure (Davies et al., 2012). It is thought that this morphology at the 
apex of the structure holds a high charge density and therefore has a higher proton-motive force, 
pivotal for ATP synthesis (Strauss et al., 2008). 
1.4.8 Supercomplexes 
It has been demonstrated that respiratory chain complexes can assemble into larger structures 
known as supercomplexes, which are believed to improve complex stability and lead to more 
efficient substrate channelling. Using BN-page, Schägger et al found that almost all of complex 
I associates with complexes III and IV in the stoichiometry I1III2IV1 to form a model known as 
the ‘respirasome’ (Schägger and Pfeiffer, 2000, Schagger, 2002). Other supercomplexes have 
also been assigned the stoichiometries III2IV1, I1III2 and I2III2IV1-2, known as the respiratory 
megacomplex (Guo et al., 2017). The association of individual complexes into supercomplexes 
is now well established but their functional role is still undetermined (Acin-Perez and Enriquez, 
2014, Milenkovic et al., 2017). Despite this unclear function, it has been hypothesised that the 
formation of supercomplexes maximises the efficiency of electron flux across the respiratory 
chain (Schägger and Pfeiffer, 2000), and this is supported by experimental evidence 
demonstrating that complex I in the stoichiometry I+III2 has half the activity of that in 
I+III2+IV1 (Schäfer et al., 2006). Furthermore, it is believed that the formation of 
supercomplexes improves the stability of individual components within complexes – complex 
I in particular (Schägger et al., 2004) – and also plays a role in the modulation of ROS 











1.5  Other functions of the mitochondria  
Mitochondria are commonly referred to as the “powerhouse of the cell”, however they have 
many other functions besides ATP production pivotal to cell survival, including calcium 
handling, iron-sulphur cluster formation, ROS production and their role in apoptotic signalling. 
1.4.9 Calcium handling  
The importance of calcium (Ca2+) in the regulation of many key cellular processes such as 
muscle contraction and glycogen breakdown has long been recognised, and as such, the 
regulation of calcium is essential.  The relationship between mitochondria and calcium was first 
discovered in 1961 when Deluca and Engstrom (1961) demonstrated that mitochondria were 
able to rapidly take up large quantities of calcium when exposed to Ca2+ pulses. The 
mitochondrial uptake of calcium is dependent on the mitochondrial Ca2+ uniporter (MCU), 
found on the IMM, alongside an intact mitochondrial membrane potential (Kirichok et al., 2004, 
De Stefani et al., 2011). Calcium efflux has been shown to be regulated by two major 
transporters, the 2H+/ Ca2+ antiporter and the 3(or 4) Na+/ Ca2+ exchanger, with the latter being 
most dominant in excitable tissues (Palty et al., 2010).  
Calcium is crucial for muscle contraction; following an action potential which results in 
membrane depolarisation and an influx of Ca2+, acetylcholine (ACh) vesicles come into contact 
with the membrane and ACh is released into the synaptic cleft where it binds to ACh receptors. 
This binding results in depolarisation of the muscle fibre sarcolemma and propagation of an 
action potential from the neuromuscular junction (NMJ) outwards, causing the sarcoplasmic 
reticulum (SR) to release calcium. The calcium ions bind to troponin (the actin filament 
regulatory protein) which releases the inhibition on actin, permitting an interaction between 
actin and myosin filaments and resulting in the formation of actin-myosin cross bridging and a 
subsequent muscle contraction (Lieber, 2010). 
1.4.10 Fe-S cluster formation 
Fe-S clusters are involved in many catalytic processes and are particularly fundamental for 
OXPHOS. Using an ability to switch between oxidative states +2 and +3, Fe-S clusters can act 
as electron donors and acceptors, thus performing a large role in the transfer of electrons along 
the respiratory chain (Beinert et al., 1997). Aside from electron transfer, Fe-S clusters are also 
involved in binding activation of substrates and stabilisation of radicals (Staples et al., 1996), 
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and play a central role in metabolic catalysis and the sensing of iron and oxygen levels (Beinert 
et al., 1997, Cammack, 1992, Muhlenhoff et al., 2002, Lill, 2009).  
1.4.11 Reactive oxygen species (ROS) production 
Reactive oxygen species are a chemically reactive species that are formed upon the incomplete 
reduction of oxygen to generate a number of toxic products, such as the superoxide anion (O2-
), hydrogen peroxide (H2O2) and the hydroxyl radical (HO) (Harman, 1956). Although these 
species have the capacity to cause damage to cellular macromolecules such as lipids, proteins 
and DNA, they also play important roles in cell signalling (Droge, 2002). Regulation of ROS 
are important in a variety of physiological systems such as differentiation, immunity, autophagy 
and metabolic adaption (Sena and Chandel, 2012).  
1.4.12 Apoptotic signalling 
Apoptosis, or programmed cell death, was first described by Kerr et al. (1972) as a process 
critical for tissue homeostasis and, since then, it has been shown that mitochondria have a 
significant role in the control of this process (Hockenbery et al., 1990). There are two major 
pathways associated with apoptosis: the extrinsic pathway, also known as the death receptor-
dependant pathway, is activated from outside the cell by death receptors of the tumour necrosis 
factor (TNF) receptor superfamily; the intrinsic pathway, also known as the mitochondrial 
pathway – named due to the essential involvement of the mitochondria (Wang and Youle, 2009) 
– is stimulated in response to death stimuli such as DNA damage, radiation and hypoxia. These 
stimuli cause changes to the inner mitochondrial membrane that results in the opening of the 
mitochondrial permeability transition pore (MPTP) and loss of membrane potential. This loss 
of membrane potential causes a downstream signalling cascade and the release of proapoptotic 
proteins, eventually leading to cell death (Elmore, 2007). Regulation of the intrinsic pathway is 
via the BCL-2 family of proteins, which include both the pro-apoptotic Bax and Bak, and the 













1.6  Mitochondrial turnover 
1.6.1 Mitochondrial biogenesis 
Biogenesis is defined as the growth and division of pre-existing mitochondria and is tightly 
regulated to cater for cell-specific energy requirements. Central to the process is peroxisome 
proliferator-activated receptor gamma (PPARγ) coactivator 1-alpha (PGC1α), a co-
transcriptional regulation factor that activates a number of different transcription factors 
including nuclear respiratory factor-1 (NRF-1), oestrogen related receptor alpha (ERRα) and 
peroxisome proliferator-activated receptor alpha (PPARα) (Wu et al., 1999). The activation of 
these factors promotes the expression of mitochondrial transcription factor A (TFAM), driving 
transcription and replication of mtDNA (Virbasius and Scarpulla, 1994).   
1.6.2 Mitophagy 
Mitophagy is the selective degradation of damaged mitochondria and is under the control of 
two main proteins, PINK1 and Parkin. Under basal conditions, PINK1 is imported into the IMS 
and is rapidly cleaved and degraded by presenilin-associated rhomboid-like protein (PARL) 
(Jin et al., 2010). However, in dysfunctional mitochondria, where the membrane potential is 
reduced, PINK1 is no longer imported and cleaved but instead accumulates on the OMM where 
it recruits the E3 ubiquitin ligase Parkin (Lazarou et al., 2012). This leads to the ubiquitination 
of a number of OMM proteins including MFN and VDAC1, which in turn recruit other proteins 
to mitochondria to initiate mitophagy through the formation of an autophagosome (Tanaka et 
al., 2010, Geisler et al., 2010, Narendra et al., 2008). In addition to the PINK1/Parkin pathway, 
there have been several other mitophagy pathways described which occur under different 












1.7  Mitochondrial genetics 
1.7.1 Mitochondrial genome 
Mitochondria are the only organelles that contain their own genome. Maternally inherited, the 
mtDNA is a double-stranded molecule – measuring 16569bp – which encodes 37 genes: 13 
OXPHOS subunits, 22 tRNAs and 2 rRNAs (Figure 1.15) (Anderson et al., 1981). The genome 
contains a heavy and a light strand and is highly compact, with no introns present and only a 
single non-coding region known as the displacement loop (D-loop) to which key transcriptional 
machinery bind. It is also the site of origin for heavy strand replication (Shadel and Clayton, 
1997). 
The genome exists in numerous copies per cell, with the number of copies dependent on the 
specific cell type and energy requirement of that cell or tissue. It is estimated that there are 
approximately 3600 copies in skeletal muscle fibres (Miller et al., 2003). The mtDNA is 
packaged into stable nucleoprotein structures known as nucleoids which are found in the 
mitochondrial matrix (Satoh and Kuroiwa, 1991) and have a close association with the inner 
mitochondrial membrane (Wang and Bogenhagen, 2006, Albring et al., 1977) . 
 
Figure 1.15: Mitochondrial genome. The genome encodes 37 genes – 13 OXPHOS subunits (complex 
I = orange, complex III = pink, complex IV = green, complex V = purple), 22 mt-tRNAs (blue) and 2 
mt-rRNAs (grey). Origins of heavy (OH) and light (OL) strand are shown as well as the D-loop. 
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1.7.2 Mitochondrial DNA replication 
Replication of mtDNA occurs independently of the cell cycle and is reliant on its own 
replication machinery including ‘the minimal replisome’, consisting of the mitochondrial DNA 
polymerase gamma (POLG), the DNA helicase twinkle, the single-stranded DNA-binding 
protein (mtSSB) and the mitochondrial RNA polymerase (POLRMT) (Milenkovic et al., 2013, 
Young and Copeland, 2016). At the core of the replication machinery, POLG is responsible for 
the replication of the mtDNA while TWINKLE is the helicase that catalyses the 5’ to 3’ 
nucleotide triphosphate dependant unwinding of the double stranded mtDNA to single stranded 
molecules. The homo-tetrameric mtSSB has a role in stabilising the singe stranded mtDNA and 
POLRMT is responsible for synthesising RNA primers to initiate DNA synthesis of the heavy 
strand. 
A scientific consensus as to how mtDNA replicates is yet to be reached and thus several models 
of replication exist (Figure 1.16). The first model, the ‘strand displacement’ model (SDM) (also 
known as strand asynchronous replication), was first proposed by Clayton (1982). It suggests 
that replication initiates within the D-loop at the origin of heavy strand synthesis (OH), and 
proceeds unidirectionally  for a distance of two-thirds around the circular genome until the 
origin of light strand synthesis (OL) is exposed and light strand replication is initiated (Brown 
et al., 2005). Because replication of the light strand lags behind that of the heavy strand, the 
strands can also be termed lagging and leading strands. 
The next model, the ‘strand coupled’ or ‘synchronous’ model of replication, was initially 
proposed by Robberson et al. (1972) and further refined and supported by Holt et al. (2000) by 
the use of two-dimensional agarose gel electrophoresis (2D AGE) leading to the discovery of 
replication intermediates. The model suggests that replication is initiated at the zone of 
replication (OriZ) and proceeds bidirectionally. The OriZ region is thought to encompass the 
genes ND5, ND6 and CYB and is present at the same loci for both the leading and lagging 
strands (Holt et al., 2000). 
The use of 2D agarose gel electrophoresis (AGE) found that replication intermediates were 
predominantly double stranded (Holt et al., 2000). Using purer preparations of mitochondria, 
these were discovered to contain long stretches of RNA/DNA hybrids (Yang et al., 2002) which 
led to the formation of the RNA incorporation throughout the lagging strand (RITOLS) model 
(Holt and Reyes, 2012). According to this model, the leading H strand replicates as usual from 
OH whereas the lagging strand replicates as short segments of RNA which then hybridise with 
the leading strand and subsequently mature to DNA. The RITOLS model is similar to that of 
27 
 
the SDM; both initiate at the OH and include unidirectional replication. The main difference is 




Figure 1.16: Models of mtDNA replication. (a) strand-displacement model, (b) RNA incorporation 
throughout the lagging strand (RITOLS) model, (c) strand-coupled model. Image adapted from 



















Transcription is the process by which information in a strand of DNA is copied into a molecule 
of messenger RNA (mRNA), with transcription of mtDNA dependent on specialized, nuclear-
encoded transcriptional machinery. Transcription of the heavy-strand is initiated in the D-loop 
at the heavy-strand promotor (HSP) at two specific sites (HSP1 and HSP2), while light-strand 
transcription is initiated at the light-strand promotor. Transcription occurs bidirectionally and 
produces polycistronic precursor RNA transcripts which encompass all of the genetic 
information encoded in each individual strand. These transcripts are subsequently processed to 
produce molecules of mRNA, rRNA and tRNA (reviewed in Falkenberg et al. (2007)). 
Transcription is mediated by a number of key proteins: mitochondrial RNA polymerase 
(POLRMT), mitochondrial transcription factor A (TFAM) and mitochondrial transcription 
factor B2 (TFB2M). POLRMT cannot interact with promotor DNA and initiate transcription 
without the assistance of both TFAM and TFB2M. Initially, TFAM binds specifically to a 
region 10-15bp upstream of the HSP and LSP, causing unwinding of DNA as well as a 
structural alteration in the promotor region. These TFAM-induced changes allow recruitment 
of POLRMT to the promotors, where it binds to TFAM and recruits TFB2M thus completing 
the transcription complex (Morozov et al., 2015) (Figure 1.17). Following recruitment of 
TFB2M, the pre-initiation complex is converted to a transcription competent initiation complex 
and the elongation step of transcription is executed. Transcription termination is mediated by 
the protein mTERF which binds to a 28bp region in the tRNALeu(UUR) gene, resulting in 




Figure 1.17: Transcription initiation. Transcription is initiated by the binding of TFAM upstream of 
the promotor region. This facilitates the binding of POLRMT which undergoes a conformational change 








Mitochondrial translation differs from cytosolic translation in that the ribosome that facilitates 
the process is much smaller. Further to this, the process only requires 22tRNAs due to a 
phenomenon known as the ‘wobble hypothesis’. The hypothesis proposes that one tRNA 
molecule can recognise and bind to more than one codon due to non-Watson-Crick pairing 
between the third base of the mRNA codon and the base at the first position on the tRNA 
anticodon (Crick, 1966). 
Translation of mitochondrial transcripts is dependent on nuclear-encoded regulatory proteins 
and includes three phases: initiation, elongation and termination (Figure 1.18). The process of 
translation is reviewed by Mai et al. (2017). Initiation of translation is dependent on two 
initiation factors (IFs), IF3 and IF2 (Gaur et al., 2008). Starting the process, IF3 brings the 
mRNA into contact with the mitochondrial small subunit (mt-SSU) by positioning the initiation 
codons of the mRNA (AUG or AUA) at the peptidyl site of the mt-SSU, thus preventing the 
premature association of the large subunit (mt-LSU) (Bhargava and Spremulli, 2005, Haque 
and Spremulli, 2008). Following this, in the presence of GTP, IF2 directs the association of 
fMet-tRNAMet with the mRNA to form the “mitochondrial monosome” and initiate transcription 
(Ma and Spremulli, 1996, Kummer et al., 2018). 
The elongation phase of translation is mediated by three mitochondrial elongation factors: EF-
Tu, EF-Ts and EF-G1. EF-Tu, together with GTP and a charged mt-tRNA, form a complex 
which is directed towards, and enters, the aminoacyl (A) site. From here, provided the tRNA 
base pairs with the mRNA at the codon:anticodon site, GTP is hydrolysed triggering the release 
of EF-Tu as an EF-Tu:GDP complex. This allows the tRNA to move to the peptidyl (P) site 
(Cai et al., 2000b) and the formation of a peptide bond in the peptidyl transferase centre in the 
mt-LSU. The GTP:EFTu complex is re-established by EF-Ts, and the interaction of EF-G1 
causes a conformational change that leads to the release of the deacetylated tRNA from the P 
site as well as the translocation of the peptidyl-tRNAs from the A and P site to the P site and 
exit (E) site (Cai et al., 2000a).  
Termination of translation is initiated when a stop codon enters the A site of the mitoribosome 
(Richter et al., 2010a). A number of release factors (RFs) have been associated with termination, 
including mtRF1, mtRF1a, C12orf65 and ICT1 (Richter et al., 2010b). These factors recognise 
the stop codons and promote hydrolysis of the ester bond between the mt-tRNA in the P site 
and the polypeptide chain. Following this action, the mitoribosome is recycled by the action of 




Figure 1.18: Mitochondrial translation. Translation is broken down into three phases: initiation, 











1.7.5 Heteroplasmy and the threshold effect 
Due to the polyploid nature of mtDNA, it is possible for wildtype and mutant genomes to co-
exist within a cell. The cell is said to be homoplasmic if all copies of the mtDNA within the cell 
are identical, however a cell is heteroplasmic if more than one mtDNA species is present. 
Heteroplasmy is measured as a percentage of the total copy number and can vary throughout 
different cells. It is only when the proportion of mutated mtDNA exceeds a certain threshold 
that a phenotypic manifestation of the genetic defect occurs (Figure 1.19). This threshold level 
varies across different tissues depending on their energy demand, and is lower in tissues which 
are highly dependent upon OXPHOS metabolism. Usually the threshold level falls between 60-
90% mutant to wild type mtDNA (Rossignol et al., 2003, Tuppen et al., 2010). Furthermore, 
this threshold has been found to vary between mutation types; point mutations have been 
reported to have a threshold of around 90% (Moslemi et al., 1998), with this percentage lower 
for deletions (anywhere between 50% (Porteous et al., 1998) and 90% (Sciacco et al., 1994)). 
The large variability in threshold that is seen in deletion patients is likely due to the considerable 
variation in deletion size and location (Rocha et al., 2018). 
  
Figure 1.19: Heteroplasmy and the threshold effect. Respiratory chain function (blue line) is 
maintained around 100% until the heteroplasmy level (proportion of mutant to wildtype DNA) reaches 
a threshold level (indicated by the red dotted line). After this threshold is reached, the percentage of 
respiratory chain function begins to decline. 
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1.7.6 Maternal inheritance and the bottleneck 
In contrast to the nuclear genome, mtDNA is exclusively maternally inherited (Giles et al., 
1980). Although there is some evidence of a paternal contribution of mtDNA in humans (Luo 
et al., 2018, Schwartz and Vissing, 2002), this occurrence is rare and maternal inheritance is 
still favoured. As a result, pathogenic variants in mtDNA are passed from mother to child but 
with great variability in the heteroplasmy levels between individuals (Taylor and Turnbull, 
2005), which is attributed to a phenomenon termed the genetic bottleneck. It is suggested that 
the bottleneck occurs as a result of an initial reduction in mtDNA copy number during 
embryonic development (Cree et al., 2008b), and that heteroplasmy levels in offspring are 
determined by random genetic drift (defined as random fluctuations in numbers of gene variants 
in a given population over time) occurring in early oogenesis (Jenuth et al., 1996, Brown et al., 
2001).  
1.7.7 Clonal expansion 
Clonal expansion is described as the process by which a single mtDNA species accumulates to 
predominate within a single cell, but there have been a number of different hypotheses 
describing the occurrence of this process. 
Clonal expansion was initially hypothesised to be driven by a replicative advantage mechanism. 
This model, also known as the ‘survival of the smallest’, assumed that smaller mtDNA 
molecules carrying a deletion would replicate more quickly than wild-type mtDNA, thus 
permitting mtDNA deletion accumulation (Wallace, 1989). However, this theory only explains 
the accumulation of mtDNA deletions, and does not fit with the clonal expansion of point 
mutations despite this mutation not significantly altering the size of mtDNA molecules. 
Furthermore, Campbell et al. (2014) demonstrated that smaller mitochondrial genomes do not 
appear to have any replicative advantage in human muscle. An alternative to this theory was 
proposed by De Grey (1997), and termed the ‘clonal expansion by selective advantage’ model 
or ‘survival of the sickest’. Here, it was suggested that mitochondria with reduced respiratory 
function associated with mtDNA damage have reduced free radical production. As such, the 
turnover of dysfunctional mitochondria is slower, allowing for the accumulation of mutant 
mtDNA. This theory is not widely accepted however as it assumes that mtDNA mutations have 




A contrasting theory offered by Elson et al. (2001) suggested that selective advantage is not 
necessary for clonal expansion of mutant mtDNA, and that relaxed replication of mtDNA alone 
can lead, through random genetic drift, to clonal expansion of a single mtDNA mutation. 
Although this is supported by mathematical models – that predict 4% of post-mitotic cells will 
be COX-deficient over a span of 80 years – there is some dispute between predictions of COX-
deficiency and physiological observations; Kraytsberg et al. (2006) demonstrates 40% of 
substantia nigra neurons COX-deficient at 80 years. Furthermore, random genetic drift assumes 
free mixing of mtDNA which is unlikely to be true in muscle where a restriction of 
mitochondrial movement is observed (Eisner et al., 2014). 
An alternative theory by Kowald and Kirkwood (2014) proposes that it is the connection 
between transcription and replication that drives clonal expansion and that transcription rate is 
controlled by a negative feedback loop that deceases transcription if there is product in excess.  
More recently, to overcome the limitations of previous models using cell populations and 
invertebrate models, Vincent et al. (2018) studied muscle fibres from patients with 
mitochondrial disease. They looked to address the question of how a single mtDNA mutation 
proliferates and expands through post-mitotic cells during clonal expansion, and found that 
skeletal muscle mtDNA rearrangements originate as a proliferative perinuclear niche and begin 
as subsarcolemmal foci adjacent to the nuclei. Because of this, it has been suggested that the 
perinuclear proximity may offer a proliferative advantage which could enable favourable 
expansion of the mutated niche. These foci are also associated with increased protein content 
and increased copy number, both of which are suggestive of mitochondrial biogenesis. 
Furthermore, Vincent et al. (2018) also demonstrated that the spread of the deficiency favours 
the transversely orientated mitochondria while propagating more slowly longitudinally along 














1.8 Mitochondrial DNA mutations 
Genetic defects associated with the human mitochondrial genome were first demonstrated in 
1988 (Holt et al., 1988, Wallace et al., 1988), and since then, a vast number of mutations have 
been identified and linked with disease. Studies evaluating adults in the North East of England 
with suspected mitochondrial disease found the prevalence rate for mtDNA mutations to be 20 
per 100,000 (Gorman et al., 2015). The clinical manifestation of mitochondrial disorders is very 
heterogeneous and can involve multiple organ systems, particularly those with the highest 
energetic demands such as the brain, heart and muscle. 
1.8.1 Point mutations 
Point mutations are described as a single base pair substitution and are present in the adult 
population at a prevalence of 1 in 5000 (Gorman et al., 2015), with 50% reported in tRNA genes 
(Schon et al., 2012). These mutations, which can either be maternally inherited or sporadic, are 
hugely heterogeneous and cause a vast range of mitochondrial diseases (Figure 1.20). The most 
common point mutations, and thus the most well characterised, are those occurring within the 
mitochondrial tRNA leucine (m.3243A>G MT-TL1) and the mitochondrial tRNA lysine 
(m.8344A>G MT-TK).  
The m.3243A>G MT-TL1 mutation is the most prevalent point mutation and is the most 
common cause of the mitochondrial encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS) phenotype, with 80% of MELAS patients harbouring this defect (Urata et al., 2004). 
However, there is great phenotypic variability between m.3243A>G patients (Pickett et al., 
2018) and, aside from MELAS, other phenotypic traits are also displayed such as maternally-
inherited diabetes and deafness (MIDD) and chronic progressive external ophthalmoplegia 
(CPEO) (Nesbitt et al., 2013).  
The m.8344A>G MT-TK mutation was first characterised in patients presenting with 
myoclonic epilepsy and ragged red fibres (MERRF) (Shoffner et al., 1990), and the mutation 
found in around 80% of MERRF patients. The minimum prevalence of this mutation is lower 
than that of m.3243A>G (0.7/100,000) but similar to the m.3243A>G mutation; there is great 
clinical variability between carriers of the same mutation. Patients can present with other 
features such as ataxia, diabetes mellitus, optic atrophy, hearing loss and dementia (Mancuso 





Figure 1.20: Point mutations associated with mitochondrial disease. Mutations span a wide range of 
the mitochondrial genome. Abbreviations: CPEO = chronic progressive external ophthalmoplegia; 
LHON = Leber’s hereditary optic neuropathy; LS = Leigh’s syndrome; MELAS = mitochondrial 
encephalopathy, lactic acidosis and stroke-like episodes; MERRF = myoclonic epilepsy and ragged red 
fibres; MIDD = maternally inherited diabetes and deafness; NARP = neuropathy, ataxia and retinitis 






















1.8.2 Single, large-scale mtDNA deletions  
Single, large-scale mtDNA deletions are a typical form of mtDNA rearrangement that are 
thought to occur sporadically during early stages of development. The most commonly reported 
deletion encompasses 4,977bp (Schon et al., 1989), but deletions can vary in size from 1.3 to 
10 kb. Accounting for approximately 16% of adult mtDNA mutations and with a prevalence of 
1.5/100,000, deletions are a common cause of mitochondrial disease (Gorman et al., 2015). 
There are three main clinical syndromes associated with deletions: CPEO, Kearns-Sayre 
syndrome (KSS) and Pearson syndrome (Magner et al., 2015). There have been reports of a 
correlation between genotype of the deletion and the phenotype of patients, with Yamashita et 
al. (2008) demonstrating a moderate correlation between the length of deletion and the age of 
onset. Furthermore, in the patients examined, they found that KSS patients appeared to have 
significantly longer deletions and more deleted tRNAs than patients with CPEO. These findings 
have been confirmed by subsequent studies (López-Gallardo et al., 2009, Grady et al., 2014). 
These studies have also demonstrated that deletions including the MT-CYB gene are related to 
faster progression and a more severe phenotype. 
More recently, Rocha et al. (2018) investigated the relationship between the genetic defect and 
molecular phenotype in skeletal muscle of patients with single, large-scale mtDNA deletions, 
and found that the pattern of deficiency differed based on size and location of the deletion. 
Furthermore, they demonstrated that fibres with greater respiratory chain deficiency harboured 
higher levels of the deletion. 
1.8.3 Nuclear DNA mutations 
Mitochondria are under dual control of both mtDNA and nuclear DNA (nDNA). Although 
mtDNA encodes for 37 genes that are critical for protein synthesis, the remaining proteins that 
are required for respiratory chain complex assembly, mtDNA replication, repair, transcription 
and translation are encoded for by nuclear DNA (nDNA). Currently there are approximately 
1100 nuclear genes encoding mitochondrial-localized proteins (Calvo et al., 2016). Therefore, 
some mitochondrial diseases are caused by defects in nuclear genes which follow the mendelian 
pattern of inheritance. Some of these will have a secondary effect on mtDNA, resulting in 
deletions and mtDNA depletion causing a wide range of conditions (Ylikallio and Suomalainen, 
2012). The first pathogenic mutation in a nuclear gene associated with mitochondrial disease 
was identified by Bourgeron et al. (1995), who reported a mutation in a nuclear-encoded subunit 
of succinate dehydrogenase (SDH) in siblings with complex II deficiency presenting with Leigh 
syndrome. Those nuclear genes associated with mtDNA deletions encode proteins involved in 
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replication (POLG (Naviaux and Nguyen, 2005), TWNK (Hakonen et al., 2007)), biogenesis 
(TFAM (Stiles et al., 2016)), mitochondrial maintenance (RRM2B (Fratter et al., 2011), TK2 
(Tyynismaa et al., 2012)) and mitochondrial fusion (OPA1 (Amati-Bonneau et al., 2008) and 
MFN2 (Rouzier et al., 2012)). 
A recent review by Frazier et al. (2019) reports that, since 2012, an average of 22 nuclear genes 
have been discovered per year and have been linked to mitochondrial diseases, totalling 254 
identified involved nuclear genes as of 2017. These genes can be further grouped into a number 
of different categories: (1) OXPHOS subunits, assembly factors and electron carriers, (2) 
mtDNA maintenance, (3) mtDNA expression, (4) Enzyme cofactors, (5) Mitochondrial 
homeostasis and quality control and (6) General metabolism. A full list of known nuclear genes 
























1.9  Skeletal muscle 
1.9.1 Skeletal muscle structure  
Skeletal muscle is a highly structured tissue organised into a hierarchical formation. It is 
comprised of individual myofibres which themselves consist of myofibrils arranged in parallel. 
The myofibres are bundled together into ‘fascicles’ which are held together by a type of 
connective tissue known as the perimysium. Each myofibril comprises many repeating 
contractile units called sarcomeres, which in turn are made up of thin and thick contractile 
myofilaments called actin and myosin respectively (Figure 1.21) (Lieber, 2010).  
 
 




1.9.2 Muscle fibre types 
In humans, muscle fibres can be grouped into different classes depending on differences in 
morphological, contractile and metabolic properties (Lieber, 2010). Type I fibres, also known 
as slow twitch fibres, present a high oxidative capacity and have a high mitochondrial content, 
but require less ATP and generate less power due to their slow contraction rate. Type II fibres 
can be further subdivided into two groups: type IIa, or fast oxidative glycolytic fibres, are an 
intermediate between type I and IIx and have a high mitochondrial content as well as high ATP 
consumption and a fast contraction rate; type IIx fibres are also fast glycolytic fibres with a high 
ATP consumption and fast contraction rate, but have a lower mitochondrial content and are thus 
sensitive to fatigue (Lieber, 2010). There is evidence that fibre type properties are modulated 
by electronic stimulations from motor neurons, with higher frequencies inducing faster 
contracting fibres and lower frequencies inducing slower contracting fibres (Buller et al., 1960). 
Skeletal muscle is a heterogeneous tissue and displays variable proportions of each fibre type 
which are highly versatile and can shift in response to a number of different factors. This 
plasticity in response to stimuli allows for adaption to a number different functional demands 
(Pette and Staron, 1997) such as inactivity (Grossman et al., 1998) and age (Lexell, 1995). 
1.9.3 Skeletal muscle mitochondria 
Skeletal muscle mitochondria can be found in two subcellular populations; 80% are classified 
as intermyofibrillar (IMF) mitochondria whilst 20% are classified as the subsarcolemmal (SS) 
mitochondria – both are compositionally and biochemically different to each other (Ferreira et 
al., 2010). IMF mitochondria are located between the myofibrils, form a rigid lattice structure 
and display a distinctly higher mitochondrial inner membrane and matrix enzyme activity to 
that of SS mitochondria, which are located just beneath the sarcolemma and are usually found 
in small perinuclear clusters (Cogswell et al., 1993, Milner et al., 2000, Alessandro et al., 2005). 
Furthermore, studies show that IMF mitochondria are more susceptible to apoptotic stimuli 
such as H2O2 and release a greater level of some apoptotic proteins; Cytochrome c levels are 3-








1.10 Skeletal muscle in mitochondrial diseases 
Although mitochondrial diseases are a clinically heterogeneous group of disorders (Gorman et 
al., 2016), muscle is commonly affected. It is thought that this is due to muscle having a high 
metabolic demand, thus making it more sensitive to deficiencies of mitochondrial energy 
production than other tissues (Larsson and Oldfors, 2001). Skeletal muscle is affected primarily 
by defects in respiratory chain function, however this can theoretically give rise to any 
symptom, in any tissue and at any age (Munnich et al., 1996).   
Due to the clinical and genetic heterogeneity exhibited by mitochondrial myopathies, disease 
diagnosis is challenging. However, the introduction of genetic techniques such as next 
generation sequencing (NGS) has revolutionised the way in which these diseases are 
investigated, and has made the process more simple and less time consuming. The increasing 
application of NGS to mitochondrial disease diagnostics has led to an increase in the diagnostic 
prevalence of these disorders, from 10-20% pre-NGS to more than 50% in some cohorts post-
NGS (reviewed by Rahman and Rahman (2018)). Although NGS is dominating the 
investigative process, in order to gain a greater understanding of the genetic defects a stepwise, 
multidisciplinary approach is still needed (McFarland et al., 2010).  
Histochemical analysis of skeletal muscle biopsies is still a widely-used diagnostic screen for 
detecting mitochondrial abnormalities. One method, the Gomori trichrome stain, shows the 
subsarcolemmal regions of mitochondria, which selectively uptake the red component of the 
stain. A pathological accumulation of these regions are recognised as a ‘ragged red fibre’ (RRF) 
and are often found in many mitochondrial myopathies (Engel and Cunningham, 1963). 
Although this technique is still in use, finding methods that assess mitochondrial involvement 
by looking at specific mitochondrial enzymes is much more valuable. COX/SDH dual 
histochemistry (Old and Johnson, 1989) is a technique that highlights a mosaic pattern of COX 
deficiency in fibres by the sequential reaction demonstrating the reactivity of the complex IV 
protein COX (producing a brown precipitate) and the complex II protein SDH (producing a 
blue precipitate). When COX is absent, due to the lack of brown precipitate, the fibres appear 
blue. Although this allows the categorisation of fibres into COX-positive, intermediate or COX-
negative, only complex IV deficiency is evaluated, and so any deficiency in other OXPHOS 
complexes such as complex I, III and V cannot be detected.  
Nitrotetrazolium blue exclusion (NBTx) is another enzyme histochemical assay that can be 
used as an alternative to COX/SDH (Simard et al., 2018). It allows for the direct visualisation 
of respiratory-deficient cells by the catalysis of formazin where COX activity is dysfunctional. 
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Because formazin is only catalysed in COX-dysfunctional cells, the advantage of the NBTx 
assay is that COX-deficiency can be measured unambiguously. This is in contrast to COX/SDH, 
where a reduction in the predicted COX activity is measured (Simard et al., 2018). However, 
similar to COX/SDH, deficiency in other respiratory chain complexes will be overlooked. 
This issue is addressed by an immunofluorescent technique that quantifies the levels of complex 
I and IV together with a marker for mitochondrial mass (Rocha et al., 2015) (discussed further 
in section 4.1.1.2). To complement histochemical analysis of patient muscle, biochemical 
assessments can be carried out to determine the activity of individual respiratory chain enzyme 
complexes, which require fresh tissue homogenates (Taylor et al., 2004). Although the assays 
can detect both isolated complex deficiencies and deficiencies in multiple complexes, they may 
fail to detect more subtle deficiencies and require a significant amount of tissue (up to 10mg in 
size). Further to histochemical and biochemical assessment, genetic tests are undertaken using 
small amounts of DNA extracted from muscle homogenates. These include analysis of both 
mtDNA, through techniques such as PCR and pyrosequencing, as well as nuclear DNA, through 





























1.11  Overall aims and objectives 
Due to the increasing prevalence of sarcopenia and age-related conditions, there was a need to 
explore the biology of ageing skeletal muscle. This project was designed to investigate the 
following areas: 
1) Understand what changes occur within skeletal muscle with both age and mitochondrial 
myopathy 
2) Understand the downstream consequences of mitochondrial respiratory chain deficiency 
at the cellular level 
Soon after this project started, there was an opportunity to adapt and develop imaging mass 
cytometry (IMC) for novel use in skeletal muscle – a novel approach to understand changes 
occurring with disease and age. For this reason, the research was refined to meet the following 
aims: 
1) Optimise mitochondrial markers that can be used with IMC to identify mitochondrial 
deficiencies within skeletal muscle 
2) Develop a workflow and analysis software (in collaboration with Dr Conor Lawless) 
that successfully quantifies mitochondrial dysfunction in diseased and healthy aged 
muscle 
3) Use the IMC and developed software to identify and quantify mitochondrial dysfunction 































































































Equipment or Software Supplier 
Axio Imager M1 microscope Carl Zeiss 
Centrifuge  Eppendorf 
Cryostat (Cryo-star HM 560M) Microm International 
Dry heat block Techne 
Helios Imaging Mass Cytometer Fluidigm 
MitoCyto In house Python based software 
Nanodrop ND-1000 Spectrophotometer Labtech International 
3510 pH meter Jenway 
Prism v5.0 GraphPad Software Inc. 
ImmunoAnalyser  In house MatLab (mathworks) based 
software 
Vortex genie 2 Scientific Industries 
Zen 2011 (blue edition) image capture software Carl Zeiss 
Consumables  Supplier 
Aerosol resistant pipette tips Starlab 
Coverslips (22x50mm) Merck 
Eppendorf tubes (0.6ml, 1.5ml, 2.0ml) Starlab 
Falcon tubes (5ml, 15ml, 50ml) BD Biosciences 
Gilson pipette (P2, P10, P20, P100, P200, P1000) Anachem 
Gloves Starlab 
Pasteur pipettes VWR 
Superfrost slides Merck 
Weigh boats  VWR 
Whatman filter paper Fisher Scientific 
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Reagents: tissue preparation Supplier 
Iso-pentane Merck 
Liquid Nitrogen BOC 
OCT cryo-embedding matrix Raymond Lamb 
 
Reagents: immunohistochemistry Supplier 
 Avidin/biotin blocking kit Vector Laboratories 
DPX BDH 
Eosin Cell path 
Ethanol Merck  
Haematoxylin  TCS Biosciences Ltd. 
Histoclear National diagnostics 
Hydrochloric acid VWR 
Hydrophobic pen Sigma-Aldrich 
Methanol Merck 
Normal goats serum (NGS) Sigma-Aldrich 
4% Paraformaldehyde (PFA)  Santa Cruz Biotechnology  
Phosphate Buffered Saline Sigma-Aldrich 
Prolong gold mounting media  Life Technologies  
Sodium chloride (NaCl) Sigma-Aldrich 












Protein target Reagents: Primary antibodies  Supplier 
Complex I Mouse IgG1 NDUFB8 Abcam (Ab110242) 
Complex I Mouse IgG2b NDUFA13 Abcam (Ab110240) 
Complex II Mouse IgG1 SDHA Abcam (Ab14715) 
Complex III Mouse IgG1 UqCRC2 Abcam (Ab14745) 
Complex IV Mouse IgG2a MTCO1 Abcam (Ab14705) 
Complex IV Mouse IgG2a COX4+4L2 Abcam (Ab110261) 
Complex V Mouse IgG1 ATP5O Abcam (Ab230325) 
Mitochondrial mass Mouse IgG2b VDAC1 Abcam (Ab14734) 
Membrane marker Mouse IgG1 Dystrophin  Merck (MAB1645) 
Membrane marker Rabbit polyclonal IgG Laminin Sigma-Aldrich (L9393) 
 Reagents: Secondary antibodies Supplier 
 Anti-rabbit Alexa Fluor 405nm Life Technologies 
 Anti-mouse IgG Alexa Fluor 488nm Life Technologies 
 Anti-mouse IgG2a Alexa Fluor 488nm Life Technologies 
 Anti-mouse IgG2b Alexa Fluor 546nm Life Technologies 
 Anti-mouse IgG1 Alexa Fluor 647nm Life Technologies 
 Streptavidin Alexa Fluor 647nm Life Technologies 
 Anti-mouse IgG1 biotin Life Technologies 
 Solutions Recipe 
 Tris buffered saline with tween (TBST 
pH 7.6) (concentrated 5x) 
 
121 g Trizma Base 
90 g NaCl 
5 ml Tween 
Concentrated HCl 





Ethical approval for use of mitochondrial disease patient tissue was granted by the Newcastle 
and North Tyneside Local Research Ethics Committee (reference 16NE/0267), and ethical 
approval for the project was issued under the generic research tissue bank approval for the 
Newcastle Mitochondrial Research Biobank (references 001, 004, 014 and 026). Control tissue 
was acquired with prior informed consent from the distal part of the hamstring of people 
undergoing anterior cruciate ligament (ACL) surgery, following approval by Newcastle 
biobank (NAHPB reference: 042). More detailed information of patients and control cases can 
be found in the relevant chapters. 
2.2.2 Muscle biopsies 
Patient muscle biopsies were taken from the vastus lateralis using the needle biopsy technique 
whilst control tissue was acquired from the distal part of the hamstring of people undergoing 
ACL surgeryTransversely orientated muscle blocks were snap-frozen in liquid nitrogen cooled 
isopentane, frozen muscle was then mounted on Whatman filter paper using OCT cryo-
embedding matrix before cryosectioning.  
2.2.3 Cryostat sections 
10µm serial sections from transversely orientated muscle blocks were obtained using a cryostat 
(Cryo-star HM 560M). Frozen muscle blocks were cut into sections at -20°C and collected onto 
superfrost slides (Merck). Sections were then dried at room temperature (RT) for 1h and stored 
at -80°C for subsequent use. 
2.2.4 Haematoxylin and eosin 
Tissue sections were removed from -80°C and air dried for 1h at RT. Slides were immersed in 
haematoxylin for 1 minute and washed in water until the water turned clear. A small drop of 
ammonia was added and the slides were rinsed again before immersion in eosin for 1 minute 
and washed as before until the water turned clear. Sections were then rapidly dehydrated in an 
ascending ethanol gradient (70%, 90%, 100%, 100%) and cleared in two washes of histoclear 




Tissues were removed from -80°C and aired dried for 1h at RT prior to initiating the protocol. 
Slides were labelled as either primary antibody or no primary control (NPC) and sections 
encircled using a hydrophobic pen to prevent leakage of medium from each muscle section. 
The sections were fixed in cold 4% paraformaldehyde (PFA) at RT for 3 minutes and washed 
3 times with 1x TBST for 5 minutes. For permeabilisation of the cell membrane, sections were 
dehydrated and rehydrated in a methanol gradient as follows: 70% (10 minutes), 95% (10 
minutes), 100% (20 minutes), 95% (10 minutes), 70% (10 minutes), followed by 3 x 5  minute 
washes in 1 x TBST. Subsequently, non-specific protein interactions were blocked by 
incubation with 10% normal goat serum (NGS) for 1h at RT and endogenous biotin, a 
component of many mitochondrial proteins, was blocked using an Avidin D/Biotin blocking kit 
(Vector laboratories) when necessary. After 3 x 5 minute washes in 1 x TBST, sections were 
either incubated with 100µl primary antibody cocktail or a corresponding NPC cocktail 
overnight at 4°C. Both cocktails were made with 10% NGS and primary antibody dilutions 
listed in Table 2.1. Sections were washed for 3 x 10 minutes in 1 x TBST and incubated with 
a cocktail of diluted secondary antibodies (Table 2.2) at 4°C for 2h. Sections were washed for 
3 x 5 minutes and if a streptavidin conjugated secondary antibody was being used, this was 
added next and sections incubated for 2h at 4°C. Subsequently slides were washed for 3 x 10 
minutes in 1 x TBST and mounted on a coverslip using Prolong Gold mounting medium (Life 
Technologies).  
Table 2.1: Primary antibody cocktails used for immunofluorescence. 
Primary antibody cocktail NPC cocktail 
Complex I marker: NDUFB8 (dilution 1/100) 
Complex IV marker: MTCO1 (dilution 1/100) 
Mitochondrial mass marker: VDAC1 (dilution 1/100) 
Fibre membrane marker: Laminin (dilution 1/50) 
Laminin (dilution 1/50) 
 
 
Table 2.2: Secondary antibody cocktail used for immunofluorescence.  
Secondary antibody cocktail 
Anti-Rabbit-Alexa 405 (dilution 1/100) 
Anti-IgG2a-Alexa 488 (dilution 1/200) 
Anti-IgG2b-Alexa 546 (dilution 1/200) 
Anti-IgG1- biotin (dilution 1/200) 









The antibodies to the mitochondrial proteins have been extensively validated. They were 
originally developed by MitoSciences (now supplied by Abcam) and shown by the producers 
to selectively immunocapture their target protein/complex. Further, this work and that of others 
have shown that the reaction of the antibody in western blot, immunocytochemistry as well as 
IF correlates well with the genetic loss of protein as determined spectrophotometrically and by 
activity assays (Schilling et al., 2006, Willis et al., 2009). 
 
2.2.6 Imaging 
Fluorescent images were acquired at 20x magnification using a Zeiss Axio Imager M1 and Zen 
2011 (blue edition) software using four filter cubes which allowed the detection of Alexa Fluor 
dyes excited at 405 nm, 488 nm, 546 nm and 647 nm. Automated scanning of the muscle section 
was conducted using a motorised stage and software tiling function. Exposure times were set 
for each channel to avoid over exposure and to minimise background on no primary controls. 
Exposure times were then maintained throughout each experiment for all cases and controls. 
Following imaging, .zvi files were stitched to generate a .czi file which was then used for further 
analysis.  
2.2.7 Image analysis  
The software used to analyse single muscle fibres was an in-house software called Quadruple 
Immuno Analyser. This software is coded for by Matlab2015a and was designed by Dr John 
Grady (Kinghorn Centre for Clinical Genomics Garvan Institute Sydney NSW Australia). The 
software was used to quantify fluorescent intensity per fibre for each channel and the individual 
fibres isolated using the membrane marker laminin as a template to create surfaces. Unwanted 
areas were removed either by thresholding of the analysis or by manual removal. 
2.2.8 Quantitative analysis of immunofluorescence 
Data generated by analysis of quadruple immunofluorescence using Quadruple Immuno 
Analyser was statistically analysed using an R-script written by Dr John Grady. The R-script 
corrected for background in each channel by subtracting the average optical density (OD) for 
each channel in the no primary control from the values generated from the sections that were 
labelled with the primary antibodies. The background corrected values were then log 
transformed to normalise data and the distribution of VDAC1 was assessed to ensure data was 
normally distributed. Mean and standard deviation of the control population were acquired and 
z-scores were determined for complex I, complex IV and VDAC1 based on the expected levels 
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of each, which was calculated using the levels of VDAC1 as a mitochondrial mass marker. z-
scores were generated for each individual fibre of both controls and patients for each channel. 
Fibres were then classified based on their z-scores: Normal (z-score > -3SD), Intermediate (+) 
(z-score between -3SD and -4.5SD), Intermediate (-) (z-score between -4.5SD and -6SD) and 
Negative (z-score < -6SD). Similarly, fibres were group according to their VDAC1 levels: Very 
low (<-3SD), low (between -3SD and -2SD), normal (between -2SD and +2SD), high (between 
+2SD and +3SD) and very high (above +3SD). This is represented in the mitochondrial 
respiratory chain (MRC) profiles. An example plot is shown in Figure 2.1. 
 
Figure 2.1: Example MRC plot. Plots show complex I and complex IV expression. X and Y axis indicate 
levels of NDUFB8 and MTCO1 respectively. Each dot represents an individual muscle fibre and is 
colour coded according to levels of mitochondrial mass (blue: very low, light blue: low, light orange: 
normal, orange: high and red: very high). Coloured boxes indicate classifications of deficiency based 
on z-scores (green: positive, blue: intermediate positive, pink: intermediate negative, red: negative) 
 
2.2.9 Statistical analysis 
Graphs were produced in prism v5.0 or plotIMC (see chapter 4 for more detail) and statistical 
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3.1.1 The ageing population 
Life expectancy is a measure of the average length of life within the population (Kirkwood 
Thomas, 2017). As life expectancy increases, there is a rapid expansion of the ageing population 
within the UK, with the proportion of those aged 65 and over increasing from 15.9% to 18.2% 
between the years of 1997 and 2017 (Coates, 2018). In addition, is it expected that by 2039, 
more than 1 in 12 of the population will be aged 80 or over (Nash, 2015). The expansion of the 
ageing population brings with it a higher prevalence of age-related conditions (Ferrucci et al., 
2008). 
3.1.2 Sarcopenia 
Sarcopenia is characterised by the age-related involuntary loss of skeletal muscle mass and 
function, which is closely associated with physical disability, poor quality of life and death 
(Santilli et al., 2014, Chumlea et al., 2011). It is known that muscle mass accounts for up to 
60% of body mass and so any changes to skeletal muscle can have a profound effect on an 
individual. Evidence suggests that both mass and strength decline in a linear fashion, with up 
to 50% of mass being lost by the 8th decade of life (Metter et al., 1997). In addition to its role 
in disease progression, loss of strength in sarcopenic muscle decreases the capacity of older 
individuals to carry out daily living tasks (Shiozu et al., 2015) and increases exercise difficulty. 
3.1.3 Identification of sarcopenia 
The European Working Group on Sarcopenia in Older People (EWGSOP) have developed a 
diagnostic criteria for age-related sarcopenia which involves various measurements to 
determine the presence of low muscle mass and function. Three common measurements 
assessed are grip strength, a Timed Up-and-Go (TUG) test and Skeletal Muscle Index (SMI) 
(Cruz-Jentoft et al., 2010). In brief, grip strength (kg) is measured with a Jamar handheld 
hydraulic dynamometer (Promedics, UK) following a standard protocol (Roberts et al., 2011). 
Measurements are taken three times in both hands and the maximum value obtained can be used 
for further analysis. During the TUG test, a stopwatch is used to measure the time taken to get 
up from a chair and walk as quickly and as safely as possible to and around a marker placed 3m 
away, walk back to the chair and sit down. The time is converted to an estimate of gait speed 




6/ [TUG time]* 1.62 
Equation 3.1: Estimate of gait speed. Taken from (Cooper et al., 2011, Cooper et al., 2015).  
Total body weight (kg) and estimated appendicular lean mass (kg) are measured using a Tanita 
MC-780MA body composition analyser (Tanita Corporation, Arlington Heights, IL). Height is 
estimated based on demi-span, measured twice to the nearest millimetre and averaged. Skeletal 
Muscle Index (SMI) (kg/m2) is calculated from appendicular lean mass divided by height-
squared. The definition of sarcopenia provided by the European Working Group is applied to 
results, using a recognised cut-off for grip strength (< 30 kg and < 20 kg for men and women 
respectively), for gait speed (≤ 0.8ms), and for SMI (< 7.26 kg/m2 in men and < 5.45 kg/m2 in 
women). Participants with weak grip strength and/or slow gait speed, in combination with low 
SMI, are considered sarcopenic. 
3.1.4 Potential causes of sarcopenia 
Sarcopenia is a multifactorial condition and there are many proposed mechanisms implicated 
in its development, including dysregulation of protein synthesis and degradation, satellite cells, 
neuronal and mitochondrial dysfunction (Bowen et al., 2015).  
Skeletal muscle mass is largely dependent upon protein turnover, that is, the balance between 
both synthesis and degradation, and sarcopenia can occur when this balance is disturbed 
(Murton, 2015). Amongst other pathways, insulin signalling via IGF-1 is important in the 
synthesis of proteins (Musaro et al., 2001), and studies have shown that the IGF-1 pathway can 
supress protein breakdown, leading to simulated muscle growth and hypertrophy of the muscle 
(Sacheck et al., 2004, Gelfand and Barrett, 1987, Fryburg et al., 1992). It is believed that lower 
sensitivity or impairments to the signalling pathways engaged in protein turnover are 
contributors to sarcopenia. 
Satellite cells, also known as muscle stem cells, are the sole source for the generation of new 
myonuclei in skeletal muscle tissue (Allen et al., 1999). As such, these cells are essential for 
the maintenance of skeletal muscle. Although usually quiescent, they can activate and 
proliferate in response to injury to remove any deleterious effects which have the potential to 
cause harm (Alway et al., 2014). Because satellite cells are so heavily responsible for the 
maintenance of skeletal muscle, any loss in either their number or function is likely to result in 
impaired structure or function of skeletal muscle (Shefer et al., 2006). Studies investigating the 
effects of ageing on skeletal muscle satellite cells have reported a decline in the regenerative 
function and number of satellite cells in the elderly (Sousa-Victor et al., 2014, Day et al., 2010, 
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Kadi et al., 2004). Further evidence also suggests that a decline in satellite cell number 
contributes to fibre atrophy (Brack et al., 2005). 
As well as complications with the muscle itself, there are two systems which are heavily 
involved in the development of sarcopenia: the nervous system and the connections between 
neurons and muscle fibres known as the neuromuscular junctions. Studies undertaken in both 
humans and animals have demonstrated that neurons become depleted with age (Rowan et al., 
2012, Tomlinson and Irving, 1977) and the loss of these motor neurons promote a process 
known as fibre type grouping. During this process, fibres which have been denervated by loss 
of neurons, are reinnervated by neighbouring nerves through a process known as collateral 
sprouting. This consequently means that fibres which have been denervated and reinnervated 
by neighbouring motor units will possess the same fibre type as its adjacent fibre and eventually 
lead to a motor unit group of the same type (Lexell and Downham, 1991). With regards to the 
neuromuscular junctions, an age-associated degeneration has been recognised, with changes 
being shown both structurally and functionally (Jang and Van Remmen, 2011). 
3.1.5 Mitochondrial involvement in sarcopenia and ageing 
3.1.5.1 The mitochondrial genome 
Abnormalities in the mitochondrial genome have been implicated in ageing and there are a vast 
number of studies that demonstrate an age-related increase in mtDNA mutations (Brierley et 
al., 1998, Bender et al., 2006, Michikawa et al., 1999, Taylor et al., 2003) as well as depletion 
of mtDNA (Short et al., 2005, Cree et al., 2008a, Laderman et al., 1996, Kaaman et al., 2007). 
In particular, Trifunovic and colleagues, who used a knock in PolgA mutator mouse as a model 
for ageing, successfully demonstrated a 3-5 fold increase in point mutations as well as increased 
amounts of deleted mtDNA – which were both associated with a premature onset of age-related 
phenotypes (Trifunovic et al., 2004). These mtDNA mutations have been shown to cause 
respiratory chain defects which subsequently means that many ATP dependant cellular 
processes will be impaired, thus contributing to the ageing process (Nooteboom et al., 2010). 
Within muscle specifically, the age-related accumulation of mtDNA mutations has been shown 
to be concomitant with mitochondrial deficiency. Brierley et al. (1998) studied skeletal muscle 
from elderly subjects and demonstrated that individual COX-deficient fibres were associated 
with high levels of mutant mtDNA. Furthermore, a study carried out by Bua et al. (2006) found 
that ~6% of fibres had some degree of COX-deficiency by 49 years, and this further increased 
to ~22% at 67 years and ~31% by 92 years. 
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3.1.5.2 Mitochondrial dynamics 
Mitochondria are highly dynamic organelles that are known to migrate through the cell, fuse 
and divide, undergo morphological changes and regulated turnover (Chen and Chan, 2009). 
The process of fission and fusion allows for effective communication and the exchange of 
content between individual mitochondria (Chen et al., 2010), and so any alterations in this 
process could negatively impact many mitochondrial functions which subsequently leads to 
muscle dysfunction with age. Furthermore, fused mitochondria are known to mitigate 
dysfunction by sharing their contents in a process called complementation, and so a halt in this 
process will increase the likelihood of mitochondrial dysfunction (Ono et al., 2001). 
Mitophagy is described as the selective degradation of damaged mitochondria (Kanki and 
Klionsky, 2008) and is one of the most efficient methods of removing damage. Mitophagy is 
closely linked to mitochondrial dynamics and is dependent on the presence of fission for 
subsequent removal of defective proteins or mtDNA (Burman et al., 2017), and so the inhibition 
of this process may promote an accumulation of damaged mitochondria within skeletal muscle 
(Grumati et al., 2010, Masiero et al., 2009). Further to this, it has been observed that enlarged 
mitochondria accumulate in old myocytes (Beregi and Regius, 1987), and it is thought that this 
hyperfusion could represent a compensatory mechanism by which the mitochondria attempt to 
cope with increased damage by mixing, and thus diluting the mutant contents (Sato et al., 2006). 
Supportive of this theory, a study by Chen et al. (2010) demonstrated that disruption of fusion 
via the generation of mtDNA mutator knockout mice, leading to a deficiency in MFn1 and 
Mfn2, increases mitochondrial dysfunction.  
3.1.5.3 Oxidative damage and ROS production 
Since the link between reactive oxygen species (ROS) and ageing was first proposed by Harman 
and colleagues in 1956 (Harman, 1956), there has been further evidence to suggest that 
oxidative stress is a key contributor to age-related muscle atrophy and sarcopenia. A number of 
studies have demonstrated an increase in markers of oxidative stress with advancing age 
(Bellanti et al., 2018, Fanò et al., 2001), as well as altered antioxidant enzyme activities 
(Sullivan-Gunn and Lewandowski, 2013). However, there have been a number of studies that 
contradict this theory, suggesting evidence against the idea of a universal role of ROS in the 







3.1.6 Physical activity and exercise as an intervention for sarcopenia 
Inactivity has been proven to be an important contributor to the loss of muscle mass and strength 
(Kortebein et al., 2007, Paddon-Jones et al., 2006) and thus it is speculated that physical activity 
could be an effective intervention for sarcopenia. The beneficial effects of exercise on the 
skeletal muscle, and in particular its effects on mitochondria, have been extensively researched, 
with a link between the two first reported by the Holloszy group in 1967, who demonstrated a 
rise in respiratory enzyme activity and mitochondrial protein content in response to treadmill 
training (Holloszy, 1967). Since then, exercise has proven to be an effective strategy to improve 
the oxidative capacity of muscle (Gollnick and Saltin, 1982, Holloszy and Booth, 1976, Howald 
et al., 1985), as well as increasing mitochondrial content and electron transport chain activity 
(Conley et al., 2013, Menshikova et al., 2006). 
There are two main types of training that dominate the literature in regards to benefits. Aerobic 
training involves carrying out low intensity exercise for prolonged periods of time and has been 
linked to improved cardiorespiratory fitness and endurance capacity in older individuals (Huang 
et al., 2016). There is extensive evidence showing the positive impact of aerobic training both 
physically and cognitively in older individuals (Blumenthal et al., 1989, Thompson et al., 2003, 
Kasch et al., 1999, Spina et al., 1998, Burzynska et al., 2014). 
Resistance training has shown the most promise in its effects on the ageing process. Designed 
to increase the body’s strength and power, it is most commonly implemented in the form of 
weight training and has been shown to protect against skeletal muscle loss, with a number of 
studies demonstrating muscle hypertrophy as a result of training (Staron et al., 1990, Taaffe et 
al., 2009). This hypertrophy is driven by the addition of satellite cell (SC) nuclei to myofibres. 
When the muscle is exercised or injured, SCs become activated and can proliferate, differentiate 
or fuse together. Interestingly, the SC-induced hypertrophic response to resistance exercise is 
thought to be gender-dependant, and studies show it to be generally higher in males (Kosek et 
al., 2006). 
Studies have either primarily focussed on resistance training or aerobic training independently, 
but no single type of exercise would fully fit the requirements of an exercise intervention for 
sarcopenic patients. Aerobic exercise has little effect on muscle mass and strength whereas 
resistance exercise fails to target cardiorespiratory fitness and can increase the risk of injury. 
As such, it is recommended that exercise interventions consist of a combined programme of 




3.2 Aims of this study 
The aim of this chapter is to investigate mitochondrial function and content amongst active 85-
year-olds. The quadruple immunofluorescent work carried out in this chapter is one component 
of a larger study which has now been published by Dodds et al. (2018) and I will discuss the 












































3.3.1 Patient cohort  
The selection of participants for this study was carried out by a research team led by Dr Richard 
Dodds (University of Southampton). Participants aged 85 years or born in 1931 (in their 85th 
year of life), who were registered with a general practice within the North East and North 
Cumbria Clinical Research Network, England, were eligible for recruitment. Participants were 
excluded if they had a cardiac pacemaker or any other metallic or programmable devices, or 
were taking antithrombotic or anticoagulant drugs. Individuals had to be considered suitable for 
approach by their general practitioner as well as having the capacity to provide written informed 
consent. Ethical approval was granted in the UK by the Tyne and Wear South Research Ethics 
Committee (reference 15/NE/0382). Information on controls and participants can be found in 
Table 3.1.  
Participants were examined for the presence of sarcopenia and this identification of sarcopenia 
was carried out by Dr Karen Davies of Newcastle University. Participants with weak grip 
strength and/or slow gait speed, in combination with low SMI, were considered sarcopenic. 
3.3.2 Muscle biopsy and cryo-sectioning  
Biopsies of the vastus lateralis muscle were obtained from 85 year old participants (n=7) using 
a Weil Blakesley conchotome. Control tissue (n=5) was acquired with prior informed consent 
from the distal part of the hamstring of people undergoing anterior cruciate ligament (ACL) 
surgery.  Samples were frozen in liquid nitrogen cooled isopentane. Serial sections (10µm 
thickness) from transversely orientated muscle blocks were obtained as described in methods 
section 2.2.3.  
3.3.3 Immunofluorescent analysis of respiratory chain protein expression 
Quadruple immunofluorescence was carried out according to the protocol described by Rocha 
et al. (2015) (see methods section 2.2.5). Images were acquired using Zeiss Axio Imager M1 
and Zen 2011 (Blue edition) and analysis was completed on an in-house software as described 







Table 3.1: Subject information. Information on controls and participants detailing age, gender and 
activity levels (measured by RAPA 1 and RAPA2). 
Subjects Gender Age at biopsy/years RAPA 1 RAPA 2 
Control 1 Male 17 n/a n/a 
Control 2 Male 33 n/a n/a 
Control 3 Male 28 n/a n/a 
Control 4 Female 25 n/a n/a 
Control 5 Female 23 n/a n/a 
Participant 1 Female 85 6 0 
Participant 2 Male 85 6 0 
Participant 3 Male 85 7 0 
Participant 4 Female 85 3 0 
Participant 5 Female 84 5 0 
Participant 6 Female 85 6 1 























3.4.1 Immunofluorescent analysis  
Quadruple immunofluorescence allowed objective quantification of complex I (CI) and 
complex IV (CIV) protein abundance and was performed on muscle sections from participants 
aged 85 years or in their 85th year of life (n=7). Representative immunofluorescent images from 
all controls and participants are presented in Figure 3.1. The mitochondrial respiratory chain 
(MRC) profiles from all participants are displayed in Figure 3.2, and demonstrate that the 
participants present with very little respiratory chain deficiency - comparable to the control 
cohort. This was confirmed quantitatively (Table 3.2), with the most deficient participant for 
CI (participant 3) still having 97.19% positive fibres for CI, and the most deficient participant 








Figure 3.1: Quadruple immunofluorescent analysis of mitochondrial respiratory chain deficiency in 
participants and controls. Representative images of NDUFB8 (complex I) (purple), VDAC1 
(mitochondrial mass) (red), MTCO1 (complex IV) (green) and a merge of all channels with fibre 
boundary marker (white outline). Scale bar: 50µm. Note staining patterns differ between individual 





Figure 3.2: MRC profiles. Plots show complex I and complex IV expression profiles from participants 
(n=7). X and Y axis indicate levels of NDUFB8 and MTCO1 respectively. Each dot represents an 
individual muscle fibre and is colour coded according to levels of mitochondrial mass (blue: very low, 
light blue: low, light orange: normal, orange: high and red: very high).  
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Table 3.2: Quantification of complex I (NDUFB8) and complex IV (MTCO1) deficiency. Percentage 
of deficient fibres in muscle sections of participants (n=7) and controls (n=5). Fibres are split into 
categories depending on their deficiency; pos=positive, int(+)=intermediate positive, int(-
)=intermediate negative, neg=negative 
 
The distribution of VDAC1 was also investigated as a marker of mitochondrial mass and fibres 
were grouped according to their VDAC1 levels as follows:  Very low (<-3SD), low (between -
3SD and -2SD), normal (between -2SD and +2SD), high (between +2SD and +3SD) and very 
high (above +3SD). Although there was variation in the distribution of VDAC1 between the 
controls (Figure 3.3), the majority of fibres in each case (>93%) fell into the “normal” range.  
This was the same for most of the aged participants (Figure 3.4), with five out of the seven 
participants (71%), having the majority of their fibres (>95%) falling into the “normal” category 
– similar to the controls. However, two of the participants (participant 2 and participant 6) had 
a lower percentage of fibres normal for VDAC1, with only 75.7% and 84.8% falling into this 
category for p2 and p6 respectively. Interestingly, the shift in the distribution of VDAC1 was 
not the same in these two participants, with a right shift in participant 2 indicating a higher level 
of VDAC1 compared to a left shift in participant 6 demonstrating lower levels of VDAC1 




Figure 3.3: VDAC1 levels of controls. z-scores for VDAC1 are displayed on the x-axis the distribution 
of VDAC1 is grouped into the following:  Very low (<-3SD), low (between -3SD and -2SD), normal 
(between -2SD and +2SD), high (between +2SD and +3SD) and very high (above +3SD). Graphs 







Figure 3.4: VDAC1 levels of participants. z-scores for VDAC1 are displayed on the x-axis the 
distribution of VDAC1 is grouped into the following:  Very low (<-3SD), low (between -3SD and -2SD), 
normal (between -2SD and +2SD), high (between +2SD and +3SD) and very high (above +3SD). 
Graphs produced with help from Tasnim Ahmed. 
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3.4.2 Validity of results  
To ensure there was no interpersonal variability, the results were reanalysed and compared to 
the original run – with the percentage difference between the two results displayed in Table 
3.3a. The greatest variation that was observed was a difference of 2.5%, which ruled out any 
interpersonal variability. Further to this, the results were also reanalysed by an independent 
researcher to ensure that there was no intrapersonal variability and the percentage difference 
between the two is displayed in Table 3.3b. The greatest variation that was observed was a 
difference of 1.06% which ruled out any intrapersonal variability. 
Table 3.3: Percentage difference in re-quantification of levels of deficiency. Re-quantification of 
complex I (NDUFB8) and complex IV (MTCO1) deficiency in muscle sections of participants (n=7) and 





3.5 Discussion  
3.5.1 Identification of sarcopenia 
When examined, the clinical measures used as identifiers of sarcopenia were either above the 
relevant cut-points (gait speed and SMI) or only just below (grip strength) for all seven 
participants. Further to this, the participants in this study had high levels of self-reported 
physical function and general health, when compared to normative data for the same age group 
(Bowling et al., 1999, Dodds et al., 2018), as well as regularly engaging in aerobic physical 
activity – measured by the rapid assessment of physical activity (RAPA) (Topolski et al., 2006). 
The RAPA scores for each of the participants are displayed in Table 3.4. RAPA1 is a measure 
of aerobic activity and is measured on a scale of 1-7, with sedentary scored as 1 and active 
scored as 7. RAPA2 is a measure of strength and flexibility and consists of two statements:  “I 
do activities to increase muscle strength once a week or more” and “I do activities to improve 
flexibility once a week or more”. A score of 3 indicates both these statements are true for an 
individual, a score of 2 indicates only the second statement is true, a score of 1 indicates that 
only the first statement is true, while a score of 0 indicates none of the above statements are 
true.  




(strength and flexibility) 
1 6 0 
2 6 0 
3 7 0 
4 3 0 
5 5 0 
6 6 1 
7 3 1 
 
Because identifiers of sarcopenia were either above the relevant cut-points or only just below 
for all seven participants, alongside high RAPA scores, these participants were not deemed 





3.5.2 Impact of physical activity on study results 
The participants in this study were not only considered non-sarcopenic, but were also 
recognised as being more active than expected for people of their age, and it is this level of 
activity that may explain why there was little mitochondrial deficiency throughout the group 
despite their age. There have been a plethora of studies that investigate the response of skeletal 
muscle mitochondria to exercise (reviewed by Lundby and Jacobs (2016)) and a beneficial 
effect has been consistently demonstrated, with exercise stimulating an increase in total 
mitochondrial protein and respiratory capacity, as well as triggering mitochondrial hypertrophy 
and structural changes. Furthermore, a number of studies have investigated both the effect of 
age and activity levels on mitochondrial function and content. Distefano et al. (2018) compared 
young active individuals with older active and older sedentary individuals and concluded that 
older adults who maintain high levels of physical activity have a mitochondrial capacity 
comparable to the younger active group. Similarly St-Jean-Pelletier et al. (2017) found that 
physical activity partially protects from the effects of ageing on mitochondrial content.   
In this study, there was one participant (p6) that had a lower distribution of VDAC1 than the 
other participants and controls. Hypothesising from work above (St-Jean-Pelletier et al., 2017), 
it was expected that a low level of physical activity resulting in a less protective effect could 
account for this low distribution of VDAC1. However surprisingly p6 had one of the highest 
RAPA scores when compared to the participants. There was also one participant (p2) that had 
a higher distribution of VDAC1 compared to other participants and controls so it was assumed 
that they would have higher levels of physical activity. Although the RAPA score of p2 was 
high, it was not significantly higher than other participants in the study. These unexpected 
findings could be a consequence of inaccurate self-reported physical activity levels amongst 
the individual participants. 
Further studies that assessed respiratory chain content in a similar manner to this one 
demonstrated that there was a positive association between complex I levels and physical 
performance, suggestive that mitochondrial dysfunction may have a role in sarcopenia and that 
physical activity may attenuate this (Rygiel et al., 2017).  The preservation of respiratory chain 
deficiency in this study reinforces this and suggests that the high levels of physical activity may 
have attenuated the age-related decline of respiratory chain enzymes. This is further confirmed 
by looking at previous data on the general ageing population, with studies demonstrating age-




3.5.3 Strengths of the study 
The work carried out for this chapter was part of a larger study to try and better understand 
mitochondrial content in participants aged 85 or in their 85th year of life, and is the first study 
to successfully investigate individuals of this age using a muscle biopsy technique.  
Quadruple immunofluorescent analysis was performed on each biopsy sample and further 
reanalysed by the same researcher and an independent researcher to account for any inter- and 
intra- individual/researcher variability. Results demonstrated that there was very little 
difference between each of the analyses suggesting that the technique is highly reproducible.  
3.5.4 Limitations of the study 
Although the study was only a pilot, the small sample size meant that no firm associations could 
be made between mitochondrial measures and components of sarcopenia. Furthermore, any 
observations that were made may not be representative of the general population and further 
investigations with an increased sample size will need to be carried out.  
A major limitation of this work was the potential of the participant cohort to confound results. 
Due to the exclusion criteria of the study, the participants selected for muscle biopsy were 
biased towards healthier and more active participants who were capable of coping with the 
biopsy procedure and not those that may have better represented the general population of that 
age group. Furthermore, physical activity was measured using a RAPA questionnaire. Although 
RAPA is an easy-to-use, valid measure of physical activity, it is a qualitative measure that relies 
on participants self-reporting. There was no procedure put in place to ensure that participants 
were reporting truthfully and correctly, and thus this method may not be entirely accurate and 
may explain why such striking similarities were observed in measurements when compared to 
young controls. Future studies should look to use an objective measure to assess activity levels 
of individuals such as a wearable activity monitor.  
Another limitation was the controls that were used, and it is clear that the cohort was not suitable 
for this particular study. Firstly, the site of biopsy differed between participants and controls, 
with control muscle taken from the hamstring compared to the vastus lateralis in participants. 
This could possibly have an impact on the detection of proteins within the muscle and it may 
be that measurements could vary between different muscle groups.  Another disadvantage of 
the control group selected was that the cohort was not aged matched to the experimental group. 
The aim of the whole study was to determine whether mitochondrial respiratory chain function 
and content were preserved among healthy 85-year-olds and therefore ideally the control cohort 
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should have included matched individuals who fulfil the criteria in regards to age and gender, 
but who differ in regards to activity (i.e. sedentary individuals in their 85th year of life). By 
matching for age, the effect that maintaining a physically active lifestyle has on respiratory 
chain function could be assessed. As it stands, it would be difficult to determine whether it is 
exercise alone driving the preservation of mitochondrial respiratory chain deficiency, or 
whether there are other factors involved in this. Furthermore, there is no clinical data on the 
controls in regards to activity levels and subsequent physical data, and so again it is hard to 
make any firm conclusions. That being said, it is very difficult to obtain control tissue that fits 
the exact criteria of a study and in regards to looking at mitochondrial respiratory chain 
deficiency using the quadruple immunofluorescent assay, the young controls met all 
requirements needed to qualify as suitable comparative controls, i.e. they had a good 
morphology and normal levels of respiratory chain proteins. If aged controls had been used for 
this particular assay, the results may only have been semi-quantitative due to potential 
respiratory chain deficiency in the aged individuals. 
3.5.5 Conclusions 
Although there are fundamental drawbacks in the design of this study, important conclusions 
can still be drawn from the findings. When comparing the participants to non-aged matched 
controls, it is evident that older adults who maintain high levels of physical activity have a 
mitochondrial capacity comparable to the younger control group. This reinforces the 








































































Chapter 4 : Development and optimisation of the use and 
analysis of imaging mass cytometry to investigate 













4.1.1 Current techniques to assess mitochondrial defects in skeletal muscle. 
4.1.1.1 COX/SDH histochemistry 
A simple way to assess mitochondrial dysfunction within skeletal muscle is to observe the 
activity of respiratory chain enzymes and this can be done using COX/SDH histochemistry. 
Complex IV, or cytochrome c oxidase (COX) is essential for the functioning of mitochondria 
and its synthesis relies heavily on the mitochondrial genome meaning that any mutation in 
mtDNA present at a high enough mutation load that  affects COX synthesis, will often lead to 
cells with COX deficiency. In contrast, complex II or succinate dehydrogenase (SDH), is solely 
encoded by the nuclear genome and therefore its activity is not usually compromised by 
dysfunctional mitochondria. The dual reaction of these two complexes has proven effective in 
locating cells with COX deficiency. The technique relies on the electron donor 3, 3’-
diaminobenzidine which will form a brown precipitate in cells with functioning COX. Cells 
with dysfunctional COX will not accumulate a brown precipitate thus allowing for the 
visualisation of SDH activity by the reduction of an electron acceptor nitroblue tetrazolium, to 
produce a blue colour (Ross, 2011, Old and Johnson, 1989, Sciacco and Bonilla, 1996). 
Although this technique has been able to detect mosaic COX deficiencies and identify COX-
positive, COX-intermediate and COX-negative fibres, it is both subjective and qualitative. 
Furthermore, it does not detect deficiencies in other complexes of the respiratory chain. 
4.1.1.2 Quadruple immunofluorescence 
Rocha et al. (2015) optimised a quadruple immunofluorescent assay to provide an objective and 
quantitative assessment of respiratory chain deficiency in skeletal muscle. As described in 
section 2.2.5 the technique analyses three mitochondrial proteins (NDUFB8, a subunit of 
complex I, MTCO1, a subunit of complex IV and VDAC1, a mitochondrial mass marker), as 
well as a cell membrane marker (laminin). Briefly, after fluorescent images are obtained, an in-
house analysis software is used to determine the optical densities of each channel corresponding 
to the four antibodies and z-scores are established for VDAC1, MTCO1 and NDUFB8. Fibres 
are classified into groups of NDUFB8 and MTCO1 levels based on their standard deviation 
(SD) limits and are classed as normal (z-score > -3SD), Intermediate(+) (z-scores between -
3SD and -4.5SD), Intermediate(-) (z-scores between -4.5SD and -6SD) and Negative (z-score 
< -6SD). Similarly, fibres are grouped and colour coded according to their VDAC1 levels (very 
low (<-3SD), low (between -3SD and -2SD), normal (between -2SD and +2SD), high (Between 
+2SD and +3SD) and very high (above +3SD)). This technique has become a valuable 
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diagnostic tool to identify patient-specific patterns of respiratory chain deficiency (Rocha et al., 
2015, Rocha et al., 2018, Ahmed et al., 2017).  
4.1.2 Challenges of current techniques  
Despite considerable progress being made in the understanding of the biochemical defect in 
individual muscle fibres as well as the improved investigation of respiratory chain deficiency 
through muscle biopsies, there are still limitations to the techniques that are currently in 
practise. The use of fluorophores as reporters in immunofluorescent techniques means that 
spectral overlap/bleed through of the wavelengths while imaging limits the number of 
parameters that can be measured simultaneously (Tsurui et al., 2000). Furthermore, the use of 
multiple secondary antibodies together is only possible if the primary species and isotype are 
different from one another, which again limits the number of parameters that can be measured 
in one experiment. Additionally, auto-fluorescence of the tissue can affect the detection and 
subsequent quantification of the markers. 
It is possible to make a greater number of measurements on one muscle section, however 
hardware cannot accommodate for making these measurements simultaneously, and so 
experimental protocols have to be adapted to allow for this. Sequential staining can be carried 
out whereby the section is imaged and subsequently washed and bleached before a new set of 
antibodies are added and the process is repeated. However, this strategy is time consuming and 
can affect the integrity of the tissue and so is not the most effective solution (Wahlby et al., 
2002). Alternatively serial sections can be used to look at a vast number of different proteins, 
however this method is time consuming, costly and requires a greater amount of tissue. 
Additionally there is evidence of segmental deficiency whereby the muscle exhibits short 
segments of deficiency as opposed to the same level of deficiency throughout the whole fibre 
(Murphy et al., 2012, Bua et al., 2006). This could impact results in that if a number of serial 
sections are used to measure a number of proteins, the segment of deficiency may be missed or 








4.1.3 Imaging mass cytometry 
Imaging mass cytometry (IMC) is a multiplexed ‘single cell omics’ technique that combines 
time of flight mass cytometry (CyTOF) and immunohistochemistry with a high resolution 
ablation system to enable the simultaneous imaging of up to 40 proteins (Giesen et al., 2014). 
In conventional mass cytometry, single cells are labelled with metal-conjugated antibodies, and 
following ionization, the quantities of the isotopes bound to each cell are analysed by time of 
flight (Bendall et al., 2012). IMC extends the capabilities of CyTOF by the introduction of a 
novel laser ablation device to the mass cytometer. In brief, the sample is labelled with antibodies 
that are tagged with rare-earth-metal isotopes and placed in a chamber where the tissue is 
ablated. Each ablated region is subsequently transported to the mass cytometer and levels of 
each labelled protein are quantified. Following data processing, spatially resolved images of 
the isotope signals are constructed and are comparable to that produced  by light microscopy at 
20X magnification (Chang et al., 2017) (Figure 4.1).  
 












The advantages of IMC are vast. The use of metals permits a much greater number of 
measurements to be made simultaneously without much concern about channel overlap (see 
section 4.5.2 for more detail about channel crosstalk). This can be enhanced further by a well-
designed panel. Additionally, as the antibodies are conjugated to rare-earth metals that are not 
found in biological tissues, the level of background signal and unspecific binding is very low 
when compared to conventional imaging techniques.  
Previously, IMC has predominantly been used throughout various oncological and 
immunological studies. Giesen et al. (2014) were one of the first groups to apply this technique 
to their research and using human breast cancer samples alongside 32 protein markers, were 
able to delineate cell subpopulations and cell-cell interactions to highlight tumour 
heterogeneity. Following on from this IMC has proven effective in studies involving pancreatic 
tissue (Wang et al., 2019), lymph tissue (Singh et al., 2017), and organs such as the kidney, 
liver, small intestine and skin (Chang et al., 2016). Although IMC has been used previously 
with FFPE tissue, the use of IMC on frozen tissue, and in particular on sections of skeletal 
muscle, is novel. 
4.2 Aims  
To overcome the limitations of other techniques that look at respiratory chain deficiency in 
skeletal muscle, the aims of this chapter are as follows: 
• Optimise a list of antibodies that can be used with IMC to identify mitochondrial 
deficiencies within skeletal muscle. 
• Develop a workflow and software that successfully quantifies mitochondrial 


















4.3 Materials and Methods 
4.3.1 Patient cohort 
Archived frozen muscle samples derived from healthy controls or patients with clinically and 
genetically characterised mitochondrial disease of either mtDNA or nuclear genetic origin were 
assessed. Table 4.1 summarises all relevant clinical information for this chapter. Control tissue 
was acquired with prior informed consent from the distal region of the hamstring of patients 
undergoing anterior cruciate ligament surgery. All ethical approval can be found in section 
2.2.1. P01 was a post-mortem biopsy taken from a patient with an inherited variant in the POLG 
gene. 
Table 4.1: Patient information. Information on controls and patients detailing gender, age at biopsy, 
clinical information and genetic defect. 
Subjects Gender Age Clinical information Genetic defect 
Controls     
C01  Male 33y n.a n.a 
C02  Female 23y n.a n.a 
C03  Male 28y n.a n.a 












arPEO: autosomal recessive progressive external opthalmoplegia; n.a: not applicable 
4.3.2 Muscle biopsies and cryo-sectioning 
Serial sections (6µm and 10µm in thickness) were obtained from transversely orientated muscle 
blocks as described in section 2.2.3  
4.3.3 Immunohistochemistry and imaging 
Various immunofluorescent stains were used in order to test and optimise antibodies for 
subsequent inclusion to an IMC panel. Immunofluorescence and imaging was carried out as 
described in sections 2.2.5 and 2.2.6 following the protocol established by Rocha et al. (2015). 
The antibodies and concentrations used for each variation are described in Table 4.2. 
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Table 4.2: List of antibodies and dilutions used for immunofluorescence.  
Optimisation of a membrane marker: 
Primary antibodies/ dilutions used Secondary antibodies/ dilutions used 
Mouse IgG1 Dystrophin (1/50) Anti-mouse IgG1 Alexa Fluor 647nm (1/200) 
Immunofluorescence used in panel design and protein expression levels: 
Protein target/Primary antibodies (1/100) Secondary antibodies (1/200) 
Complex I: Mouse IgG1 NDUFB8  
Complex I: Mouse IgG2b NDUFA13  
Complex II Mouse IgG1 SDHA  
Complex III: Mouse IgG1 UQCRC2  
Complex IV: Mouse IgG2a MTCO1  
Complex IV: Mouse IgG2a COX4+4L2  
Complex V: Mouse IgG1 OSCP  
Mitochondrial mass: Mouse IgG2b VDAC1  
Mitochondrial mass: Mouse IgG TOMM20  





Immunofluorescence used in testing antibody binding efficiency: 
Protein target/ Primary antibodies (1/100) Secondary antibodies (1/200)  
Metal and non-metal: 
Complex I: Mouse IgG1 NDUFB8  
Complex I: Mouse IgG2b NDUFA13  
Complex II: Mouse IgG1 SDHA  
Complex III: Mouse IgG1 UqCRC2  
Complex IV: Mouse IgG2a MTCO1 
Complex IV: Mouse IgG2a COX4+4L2  
Complex V: Mouse IgG1 OSCP  
Mitochondrial mass: Mouse IgG2b VDAC1  
Mitochondrial mass: Mouse IgG TOMM20 





Immunofluorescence used in optimisation of a mitochondrial mass marker: 
Primary antibodies/ dilutions used Secondary antibodies/ dilutions used 
Mouse IgG TOMM20 (1/50) 
Mouse IgG2a TOMM22 (1/200, 1/100, 1/50) 
Mouse IgG2b TIMM23 (1/200, 1/100, 1/50) 
Anti-mouse IgG Alexa Fluor 488nm (1/200) 
Anti-mouse IgG2a Alexa Fluor 488nm (1/200) 
Anti-mouse IgG2b Alexa Fluor 488nm (1/200) 
Immunofluorescence used in comparing section thicknesses: 
Primary antibodies/ dilutions used Secondary antibodies/ dilutions used 
Mouse IgG1 NDUFB8 (1/100) 
Mouse IgG2a MTCO1 (1/100) 
Mouse IgG2b VDAC1 (1/100) 
Rabbit polyclonal IgG Laminin (1/50) 
Anti-mouse IgG Alexa Fluor 647nm (1/200) 
Anti-mouse IgG Alexa Fluor 488nm (1/200) 
Anti-mouse IgG Alexa Fluor 546nm (1/200) 







4.3.4 Metal conjugations 
Conjugation of the metal Lanthanides to the corresponding antibody was carried out using a 
standard MAXPAR® antibody labelling Kit (DVS Sciences). The kit includes all the reagents 
(R-Buffer, C-Buffer, L-Buffer, W-Buffer, MAXPAR® polymer, Lanthanide solution, Bond-
Breaker™TCEP solution, antibody stabilizer) and materials (3kDa filters, 30kDa filters) 
necessary for the protocol. The protocol comprises of three main steps - in the first instance, a 
MAXPAR® polymer is preloaded with the metal Lanthanide. Concurrently, steps are taken to 
partially reduce the antibody before the Lanthanide-loaded polymer is then conjugated to the 
antibody.  
To begin, the MAXPAR® polymer (which is moisture-sensitive) was removed from storage at   
-20°C and equilibrated to room temperature before opening to avoid moisture condensation. 
The polymer was resuspended with 95µl of L-buffer and mixed thoroughly by pipetting. 5µl of 
the assigned Lanthanide metal solution was added to the tube (final concentration of 2.5mM) 
and the solution was incubated for 40 minutes at 37°C. Next, the solution was transferred to a 
3kDa filter and 200µl of L-buffer was added. The mix was centrifuged at 12000g for 25 minutes 
at RT before 300µl of C-buffer was added to the filter and centrifuged again at 30 minutes.  
Beginning to partially reduce the antibody to allow exposure of the antibody binding site , using 
a 30kDa filter, 300µl of R-buffer was added to 100µl of protein free antibody and centrifuged 
at 12000g for 10 minutes at RT. Once the flow-through had been discarded, 100µl of tris(2-
carboxyethyl)phosphine TCEP solution (4mM of stock solution diluted in R-buffer) was added, 
mixed by pipetting and incubated at 37°C for 30 minutes. Subsequently the solution was washed 
twice by the addition of C-buffer (300µl) and 12000g centrifugation for 10 minutes at RT.  
To conjugate the antibody with the Lanthanide-loaded polymer, the polymer was re-suspended 
in 100µl of C-buffer and mixed with the partially reduced antibody in the 30kDa filter with a 
1.5hr incubation at 37°C. This was followed by 4 washes using 400µl of W-buffer with 12000g 
centrifugation for 5 minutes after each wash. 
After final washes, the metal conjugated antibody was recovered by rinsing the walls of the 
filter with 50µl of W-buffer, inverting the filter over to a new collection tube and centrifuging 
at 1000g for 2 minutes. This process was then repeated using a further 50µl of W-buffer. As a 
final step, the yield of the antibody was determined (see section 4.3.5) and 100µl of stabilizer 
(supplemented with 0.05% sodium azide) was added to the antibody before storage at 4°C. 
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4.3.5 Confirming conjugations had been successful 
Initially, the antibodies were tested on a nanodrop both before and after metal conjugation to 
test the level of protein present. Briefly, using the ProteinA280 setting, the instrument was 
blanked against water followed by the wash buffer used in the conjugation protocol before 1µl 
of each antibody was subsequently tested in turn. The instrument calculates the concentration 
using mg/ml. 
Following from this it was important to test whether the metal had bound to the antibody. 50µl 
of distilled PBS and one drop of ebiosciences ultra comp beads (Fluidigm) were added to a tube 
containing 1µl of antibody and incubated at RT for 30min. Next, 2mls of PBS was added and 
the solution was centrifuged at 1500g for 5min before the supernatant was discarded and the 
pellet was re-suspended. 250µl of Ir-intercalator (at a concentration of 125µm) was added and 
left to incubate for 30min at RT which allows the nuclear DNA to bind. To wash, 2mls of water 
was added and the solution was centrifuged at 1500g for 5 min before the supernatant was 
discarded as before. This was repeated three times. As a final step, eq beads (Fluidigm) were 
added and the samples were run individually on the CyTOF mass cytometer. A positive signal 
was indicative of a successful conjugation (See Figure 4.2 as an example of positive signal). 
 
Figure 4.2: Example FACS plot demonstrating a successful antibody/metal conjugation. A positive 
signal is shown by the blue circle and is indicative of a successful conjugation. 
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4.3.6 Imaging mass cytometry 
The tissue is first labelled with metal-conjugated antibodies. Sections were fixed in 4% PFA 
for 3 minutes and permeabilised in a methanol gradient (70% for 10 minutes, 95% for 10 
minutes, 100% for 20 minutes, 95% for 10 minutes, 70% for 10 minutes). Next, sections were 
blocked for endogenous protein before incubation with the metal-conjugated antibody panel 
overnight at 4°C. Following thorough washes, tissue was stained with Ir-intercalator for 30 
minutes at RT, washed in ddH2O and air dried. Tissue sections were analysed on the imaging 
mass cytometer. The Hyperion Tissue Imaging module was spatially aligned and coupled to the 
Helios mass cytometer prior to tuning the instrument at 20Hz laser frequency with a 
standardised tuning slide and protocol (Fluidigm). Resolution mass and optimal alignment was 
verified using the dual count of lutetium 175 and an acceptable signal cross talk at a 200Hz 
laser frequency was verified. Slide libraries were then generated using low resolution images 
to guide high resolution epiflourescent panoramas around selected regions of the tissue as 
guided by previous IF data. Region sizes to ablate (Regions of interest, ROIs) were set so to 
ablate sufficient numbers of fibres for downstream analyses based on a mean fibre density ~15 
fibres per mm2 from 10 independent analyses. Prior to ablation, the optimal ablation energy 
was empirically determined to ablate the full depth of the tissue. All ablations were performed 
according to a pre-generated mass template with a laser frequency of 200Hz.  After successful 
ablation, files were exported in their native “MCD” file format and processed to single layer 
tiffs (16-bit) using MCD viewer software (Fluidigm).  
The development of further analysis software used to analyse IMC data (Mitocyto and plotIMC) 
was a collaborative effort between myself and Dr Conor Lawless. While I was the biological 
input behind the design of the software, the coding was carried out by Dr Lawless. Further 


















4.4.1 Optimisation of muscle sections, antibodies and conjugations for 
imaging mass cytometry 
4.4.1.1 Optimisation of a muscle fibre membrane marker 
Availability of antibodies in a protein-free solution, that is, free of any bovine serum albumin 
(BSA) or carrier-proteins that are usually added to stabilise the antibody, was a pre-requisite of 
including them in the panel design.  IMC relies on the segmentation of single cells, and thus the 
use of a good membrane marker is essential. The typical muscle membrane marker used 
routinely within the research group is laminin, but unfortunately, this could not be obtained in 
a protein-free solution and an alternative marker had to be found. Dystrophin is a cytoplasmic 
protein that is a vital part of the dystrophin-associated protein complex (DPC) that connects the 
cytoskeleton of a muscle fibre to the surrounding extracellular matrix (Blake et al., 2002), and 
was therefore tested as a possible alternative to laminin. Immunofluorescence was undertaken 
to assess its suitability as a membrane marker (Figure 4.3) and results demonstrate a clear 
labelling of fibre boundaries in comparison to the no-primary control (NPC). 
 
Figure 4.3: Successful dystrophin staining. Successful immunofluorescent staining of (a) dystrophin 












4.4.1.2 Design of antibody panel  
The first step in designing the panel after a membrane marker had been determined, was to 
choose which further antibodies were the most appropriate for the question that was being 
addressed. Due to the fact that this technique would be used initially to assess respiratory chain 
deficiency in skeletal muscle, it was important that the panel include a number of mitochondrial 
markers targeting all complexes of the respiratory chain. The successful optimisation and use 
of NDUFB8 (complex I), MTCO1 (complex IV) and VDAC1 (mitochondrial mass) in 
quadruple immunofluorescence made them a good choice for inclusion in the IMC panel.  
Similarly, NDUFA13, another marker of complex I, SDHA (complex II), UQCRC2 (complex 
III), COX4+4L2 (complex IV) and OSCP (complex V) had been shown previously within our 
lab to work well in skeletal muscle (data not shown) and thus were included in the panel as 
further markers of the respiratory chain. Each marker was tested using immunofluorescence at 
a dilution of 1/100 to ensure that they worked well on skeletal muscle (Figure 4.4). Further to 
this it was decided that TOMM20 (an outer membrane protein) be carried forward as well.  
 
Figure 4.4: Testing antibodies on control muscle. Immunofluorescent staining of included antibodies. 












The next step was to assign each antibody to a rare-metal isotope for subsequent conjugation. 
Although the CyTOF instrument employs a detector capable of simultaneously detecting over 
90+ isotopes which can be separated by their time of flight, the ion optics in the instrument are 
tuned for optimal delivery of metals in the 153-176 Da range (Figure 4.5), therefore it was 
recommended by the manufacturer that isotopes within this range be chosen as antibody 
reporters, particularly those with low abundance targets. 
 
Figure 4.5: Mass response curve. Relative counts (y-axis) of each mass channel (x-axis) detected by 























To compliment this approach, each antibody in the panel was ranked based on their expression 
levels for the targeted protein and this was based on immunofluorescent labelling of control 
muscle tissue using the protein-free version of each antibody. In brief, following the protocol 
described in section 2.2.5, each muscle biopsy section was incubated with a different antibody 
in the panel at a concentration of 1/100, followed by incubation with Alexa-Fluor 488nm. To 
keep experimental conditions controlled and to ensure only one parameter was being changed, 
it was important that a general secondary antibody was used to account for the different 
antibody isotypes. Sections were imaged as described in section 2.2.6, and exposure times were 
kept consistent throughout so it was assumed that the higher the intensity of the 488 channel, 




Figure 4.6: Expression level of each antibody in the IMC panel. Graph displaying expression of each 
protein by measurement of the intensity of the 488 channel. Each antibody is displayed as a separate 
strip and each dot represents an individual fibre. Red bars show the mean intensity for the given 




The results demonstrated varying levels of expression between each of the epitopes, however 
it was difficult to determine whether TOMM20 truly had a low expression level or whether the 
immunofluorescence had not worked correctly for this antibody. The expression level of 
TOMM20 relative to three no-primary controls is displayed in Figure 4.7a and demonstrates a 
similar intensity to the NPCs with a mean of 101.2 compared to an average mean of 79.1 for 
the NPCs, indicating that the low expression  level is not a reliable result but potentially due to 
background noise. Based on this, it was decided to re-test TOMM20 at a higher concentration 
(1/50) and run it alongside two antibodies of different expression levels which were known to 
work optimally. The two antibodies chosen were NDUFB8 and MTCO1. Although the 
expression of TOMM20 was low (mean of 108.8) (Figure 4.7b), there is a notable difference 
compared to the NPC (mean 67.1), suggesting that at a higher concentration the antibody 
staining was successful.  
 
Figure 4.7: TOMM20 expression level. (a) Intensity of TOMM20 relative to NPCs and (b) Repeat of 
TOMM20 alongside two other mitochondrial markers. Expression levels between all antibodies and 




Using both the expression level data and the known properties of the metal isotopes, each 
antibody was assigned a metal tag (with guidance from Dr Roberto Spada, Fluidigm) (Table 
4.3).  
Table 4.3: Antibodies in IMC panel and corresponding metal lanthanides. 
 
 
4.4.1.3 Testing antibody binding efficiency after conjugation 
In order to assess whether the addition of the metal lanthanide had affected the binding 
efficiency of the antibody, immunofluorescent staining was undertaken on 10µm control 
muscle sections for both non-metal and metal-bound antibodies at a concentration of 1/100, and 
the intensity of each antibody for each condition was measured (Figure 4.8). There appears to 
be differences in protein expressions, with the metal-bound antibodies exhibiting a lower 
channel intensity. To account for this difference, it was decided that when using metal-bound 




Figure 4.8: Expression levels of metal and non-metal bound protein. Intensity of the 488 channel (y) 
for each metal and non-metal conjugated antibody targeting individual proteins (x). (a) SDHA, (b) 
NDUFB8, (c) OSCP, (d) COX4+4L2, (e) MTCO1, (f) VDAC1, (g) NDUFA13, (h) UqCRC2. Red bars 
show the mean intensity for the given antibody. 
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4.4.1.4 Optimisation of a new mass marker 
Something that became apparent whilst testing whether the conjugation process had affected 
the antibodies binding ability, was the unsuccessful staining of TOMM20 (Figure 4.9) both 
pre- and post-conjugation. Repeats of this staining verified that TOMM20 was not being 
detected in muscle and that the lack of staining was not due to an experimental error.  
 
Figure 4.9: TOMM20 staining pre- and post-conjugation. Unsuccessful staining of both (a) pre-
conjugated TOMM20 and (b) metal-conjugated TOMM20 on C03 compared to (c) NPC. Sections were 














The mitochondrial import receptor TOMM20 is a protein that is localised to the outer 
mitochondrial membrane, and is therefore used widely in research as a marker of mitochondrial 
mass. Although VDAC1 and SDHA are other mitochondrial mass markers that are already 
included in the panel, SDHA is part of the respiratory chain complex II and because respiratory 
chain protein expression is being measured, is not the most ideal option as a mass marker. With 
TOMM20 staining unsuccessfully in skeletal muscle and thus being ineffective as a mass 
marker, there was a need to find another, more suitable, replacement. Upon a relevant literature 
search it was decided that two more antibodies be tested as potential mass markers that could 
replace TOMM20 in the IMC panel – TOMM22 and TIMM23. TOMM22 is a mitochondrial 
import receptor and has been shown to share a common signal recognition pathway in 
mitochondrial protein import to that of TOMM20 (Yamano et al., 2008). In addition, TIMM23, 
a protein import component of the mitochondrial inner membrane was also chosen. Similar to 
previous immunofluorescent experiments, control muscle sections were labelled with either an 
anti-TOMM22 or anti-TIMM23 antibodies at three different working dilutions (1/50, 1/100 and 
1/200) followed by sequential incubation with the appropriate secondary antibody. 
TIMM23 was unsuccessful at all working concentrations, and showed no difference to the no-
primary control, with a high exposure time of 1s revealing very little signal throughout the 
fibres (data not shown). In contrast, TOMM22 labelling was specific at both 1/100 and 1/50 at 
an exposure time of 400ms (Figure 4.10). Moreover, the NPC was entirely devoid of non-
specific signal. Additionally, TOMM22 demonstrated a good correlation with two other 
established mitochondrial mass markers in the panel – VDAC1 and SDHA (Figure 4.11). 
Based on this it was decided that TOMM22 would replace TOMM20 as a mitochondrial mass 
marker in the IMC panel. Subsequently the antibody was conjugated to the 155Gd lanthanide 
and tested as described in sections 4.3.4 and 4.3.5. Although the conjugation was a success, the 
antibody concentration after conjugation was very low and so staining in muscle was again 




Figure 4.10: TOMM22 staining. Control section (C03) incubated with anti-TOMM22 at working 











4.4.1.5 Ensuring section thickness has no impact on staining  
According to the manufacturer, for IMC to work effectively, it is recommended that thinner 
sections be used (an optimal thickness of 6µm), which differs from typical immunofluorescent 
work which uses 10µm sections. To ensure that section thickness had no impact on staining, 
both 6µm and 10µm sections from two controls and a patient sample were tested using an 
immunofluorescent protocol similar to that described in section 2.2.5. The results demonstrate 
that section thickness had no impact on staining (Figure 4.12a and 4.12b), with similar 
respiratory chain profiles produced for both thicknesses (Figure 4.13a). Quantitatively, there 
was very little difference in the percentages of positive fibres between both section thicknesses, 
with a difference of 0.67%, 0.22% and 1.5% in complex I positive fibres between 6µm and 
10µm for C01, C02 and P01 respectively. Likewise for complex IV positive fibres, there was a 
difference of 0.45%, 0.12% and 2.86% between 6µm and 10µm sections for C01, C02 and P01. 
Furthermore, histograms displaying the distribution of VDAC1 (Figure 4.13b) showed very 
little differences between both section thicknesses for all cases investigated. 
 
Figure 4.12: Quadruple immunofluorescent images to compare different section thicknesses -6µm v 
10µm. Representative images of NDUFB8 (complex I) (purple), MTCO1 (complex IV) (green), VDAC1 
(mitochondrial mass) (red), and a merge of all channels from serial sections of C01 at 6µm (a) and 







Figure 4.13: Comparing different section thicknesses -6µm v 10µm. (a) Respiratory chain profiles 
produced from 6µm and 10µm sections for C01, C02 and P01 using standard immunofluorescent 
proteins. Each dot represents an individual muscle fibre. Fibres are colour coded according to 
mitochondrial mass; red: very high, orange: high, grey: normal, light blue: low and dark blue: very 
low. z-scores for NDUFB8 (complex I) and MTCO1 (complex IV) are indicated on the x and y axis 
respectively (Rocha et al., 2015). (b) VDAC1 histograms for each case. 
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4.4.2 Optimisation of staining and development of analysis for imaging 
mass cytometry 
4.4.2.1 Preliminary imaging mass cytometry staining 
Nine metal-conjugated antibodies that targeted eight mitochondrial proteins and a fibre cell 
membrane marker were used to label frozen skeletal muscle sections. In order to assess the 
feasibility of the newly optimised IMC technique on muscle, two controls (C01 and C02) and 
a mitochondrial patient (P01) were selected and stained with a protocol adapted from (but 
similar to) the established immunofluorescent protocol (See section 2.2.5). The selected patient 
was a POLG post-mortem case and was chosen based on its good morphology and because it 
had been previously shown to display respiratory chain deficiency using the quadruple 
immunofluorescent assay. In brief, sections were fixed, permeabilised and blocked for 
endogenous protein as per section 2.2.5, before incubation with the metal-conjugated antibody 
panel at three different working concentrations (1/200, 1/100 and 1/50) overnight at 4°C. 
Following thorough washes, tissue was stained with Ir-intercalator for 30min at RT and washed 
in ddH2O. Finally slides were air dried and placed in sealed slide mailers until required. In the 
interest of time, ROI’s of approximately 1mm2 were selected for detection on each slide. 
In the first instance, a small area of C01 (ROI around 500µm2) was run on the IMC at all three 
dilutions to assess which dilution generated the best results. The data was extracted from the 
IMC and uploaded to MCD viewer (Fluidigm) for visual (or qualitative) analysis. To make 
visualisation easier, reassembled grayscale images from each individual antibody channel were 
pseudo-coloured and the three working dilutions from C01 are presented in Figure 4.14. 
After visual inspection of the images, it was decided that a dilution of 1/50 generated the best 
results – with the antibodies with the lowest signal presenting with the clearest images at this 
dilution (Figure 4.14). Subsequently the rest of the samples were imaged at 1/50 only and 
demonstrated that the technique was feasible on skeletal muscle (Figure 4.15), and that there 
was a marked difference between the controls and the patient sample when channels were 
overlaid for NDUFB8, MTCO1 and VDAC1 (Figure 4.16). This was also true quantitatively 
with the patient presenting with 94.31% and 73.24% positive fibres for CI and CIV respectively 





Figure 4.14: IMC images from C01. Pseudo-coloured images of C01 at three different working 
concentrations: (a) 1/200, (b) 1/100 and (c) 1/50. Each panel displays a different channel containing 





Figure 4.15: IMC images at 1/50 dilution. Pseudo-coloured images for (a) C01, (b) C02 and (c) P01. 
Each panel displays a different channel containing the 9 different antibodies used and a DNA 





Figure 4.16: Merged IMC images for C01 and P01. Images were overlaid for NDUFB8 (complex I) 
(purple), MTCO1 (complex IV) (green), VDAC1 (mitochondrial mass) (red) and dystrophin (membrane 
marker) (white) in (a) C01 and (b) P01. An example deficient fibre is highlighted in the patient case by 






























4.4.2.2 Development of Mitocyto 
A problem that hindered the progression of IMC was the lack of an available analysis software. 
Analysis software that were previously used by other groups such as MiCAT (Schapiro et al., 
2017), were not commercially available at the time and other packages that were considered 
such as cell profiler, were difficult to adapt in order to accommodate for the type of analysis 
that was required for IMC in skeletal muscle. Because of this it was decided that a new software 
was needed in order to manage the data. The most important aspect of the software would be 
the ability to segment the image so that single cell analysis could be undertaken.  Enlisting the 
help of Dr Yuchun Ding, a Matlab code was written which attempted image segmentation 
(example in Figure 4.17), however it was apparent that the software did not easily segment all 
fibres of interest and often included areas that were not suitable for analysis, therefore an 
alternative analysis programme was developed.  
 
Figure 4.17: Matlab image segmentation. Example segmentation of P01 using a Matlab script. Each 
segmented region is numbered. Note blank areas of the image that have been picked up for segmentation 











Analysis software to accompany IMC must include a number of key features - the most 
prominent being a way to effectively segment the fibres for subsequent single cell analysis.  
Working alongside Dr Conor Lawless, a computational biologist, a python based software 
called Mitocyto was created and further refined for IMC 
(https://github.com/CnrLwlss/mitocyto). The design and refinement of Mitocyto was a 
collaborative effort while the actual coding of the software was carried out exclusively by Dr 
Conor Lawless. 
The concept behind Mitocyto is that a map of cell edges (an edgemap) is constructed and used 
to identify areas corresponding to individual cells. The edgemap can be constructed 
automatically, either directly from an image representing cell membranes (for example using 
the dystrophin channel), from a thresholded version of an image, or from a gradient map 
automatically constructed from a channel (or from an average of all available channels). The 
edgemap can also be drawn by manual tracing over individual channel images (or over an 
average of all available channels), using the mouse. Although using multiple channels is often 
less successful at segmentation compared to the use of the cell membrane channel, it is valuable 
when manually editing the edgemap to only include suitable fibres. Automatic construction of 
an edgemap can be improved by manual editing of areas where edge signal is weak. It was 
envisaged that the scenario where a first draft of the edgemap is constructed automatically, 
followed by manual update, would be the most common workflow. This scenario is based on 
past experience where occasionally the quality of the membrane markers have faltered meaning 
that manual intervention has been necessary. 
The edgemap is then used to identify distinct areas in the source images (also called contours) 
corresponding to individual cells. This works by identifying areas in the edgemap which are 
completely enclosed by an edge, and filtering these by size (areamin=500, areamax=17500), 
circularity (circmin=0.0, circmax=100.0), aspect ratio (ratiomin=0.0, ratiomax=10.0) and 
convexity (convexmin=0.75, convexmax=1.0) to ensure that the area morphologies are such 
that they are likely, individual, transverse fibres sections. For each cell area and for each 
available channel, average intensities are constructed, tabulated and written to an output file 
(.csv format).  
An example of the initial segmentation outcome is displayed in Figure 4.18a. Although the 
software was successful in automatically segmenting the majority of fibres, a method to delete 
contours where errors were induced was necessary. Therefore, Mitocyto was updated to allow 
for manual deletion of contours. This could be achieved by either removal of the whole contour 
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(Figure 4.18b) which creates a white mask over the unwanted area, or by partial removal of 
the fibre edge. Following from this, it was recognised that due to the lack of transparency of the 
contours, it was difficult to determine whether selected fibres were suitable for subsequent 
analysis. Therefore the software was again updated to include transparent contours which 
allowed the fibres to be displayed (Figure 4.18c). Further to this another update permitted the 
transparent contour map to be viewed on any channel/view, including the merged gradient map 
of all available channels. A feature that the software was lacking was the merging of multiple 
output files so that all cases could be read as one single file for subsequent analysis. As before, 
this was solved with a new update of Mitocyto allowing the merging of multiple output files 




Figure 4.18: Development of Mitocyto with addition of further factors. (a) Initial automatic segmentation of muscle fibres. (b) Update to include manual 
deletion of fibres and (c) a further update to include transparent contours. 
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4.4.2.3 Development of plotIMC 
After the development of Mitocyto permitting successful segmentation of individual muscle 
fibres, there was a need to develop a tool that could deal with the increased complexity of the 
multi-dimensional data generated by IMC.  Again working alongside Dr Conor Lawless, 
plotIMC was built - a novel, interactive web-tool using the R package shiny. Similar to before, 
the design and any further alterations to plotIMC was a collaborative effort, whilst the actual 
coding of the tool was carried out solely by Dr Conor Lawless.  The web-tool has three views, 
and by default, displays data as 2Dmito plots which are 2D scatter plots comparing the mean 
signal intensity observed for one protein marker on the y-axis with a marker for mitochondrial 
mass (VDAC1) on the x-axis (example patient in Figure 4.19). In order to account for 
mitochondrial mass, using the 1m function in R, a linear regression model is generated between 
values observed for the chosen protein marker and VDAC1 in all controls and the 95% 
predictive interval around the regression is displayed. It was decided to classify fibres as being 
affected by the mutation a patient harbours, if they lie outside the 95% predictive interval for 




Figure 4.19: PlotIMC 2Dmito plot view showing expression of each antibody against a surrogate for 
mitochondrial mass. Example patient (P01) visualised in PlotIMC using the default 2Dmito plot view. 
One single-cell IMC measurement from the patient is represented by a coloured point in each panel. 
Control observations are in grey.  Each plot represents an antibody observed during the IMC run. Points 
representing patient fibres are coloured for the ratio value (protein/VDAC1) of that fibre. Regression 
through the control data is drawn as a solid grey line and the 95% predictive interval for control fibres 
lies between the dashed grey lines. Total number of fibres above and below the confidence interval are 










In order to quantitatively assess the data, a table is included which summarises the proportion 
of fibres above, below or within the 95th percentile predictive interval for each channel 
identified (See example Table 4.4). Further to this, due to the nature of respiratory chain 
deficiencies, it was important to understand the relationship between the levels of different 
proteins in the different channels and so an additional table is included which summarises the 
proportion of fibres whose categories overlap pairwise for all proteins examined (see example 
Table 4.5) 
Table 4.4: Example table from PlotIMC displaying 95th percentile predictive interval. Example table 
from P01 with a POLG mutation. 
 

















As secondary views, plotIMC also presents data in two further stripchart views. Mean intensity 
displays the raw mean intensity for the proteins observed in each fibre during image analysis 
(example patient in Figure 4.20a), whilst theta displays the angle (degrees, anticlockwise) 
made between coordinates representing each fibre, the origin and the x-axis in 2Dmito plot 
(Figure 4.20b). For stripchart views, patient fibres can be coloured according to the expression 
of the proteins selected in a ‘colour fibres by channel’ drop down menu with red fibres having 
the lowest expression and blue fibres expressing the protein highly. Both examples in Figure 
4.20 are coloured according to levels of NDUFB8. 
 
Figure 4.20: Secondary data views on PlotIMC displaying mean intensity and theta views. (a) Mean 
intensity view on plotIMC and (b) theta view, worked out by calculating the angle (degrees, 
anticlockwise) made between coordinates representing each fibre, the origin and the x-axis in 2Dmito 
plot.  One single-cell IMC measurement from the patient (P01) is represented by a coloured point in 
each panel.  Control observations are in grey. Each plot represents an antibody observed during the 




It was also important, due to the large multi-dimensional datasets produced by IMC, that 
PlotIMC included a feature which allowed the user to independently highlight the most relevant 
features. The ability of PlotIMC to select fibres of interest permits the user to not only assess 
the link between individual fibres, but also, due to the different views available, observe a 
number of different measurements in relation to the selected fibres. The selection of fibres in 
one plot causes circles to be drawn around the position of those fibres in all channels throughout 
all plots (example in Figure 4.21). Quantitative data for these selected fibres is also generated. 
 
Figure 4.21: Example of selected fibres on PlotIMC. One single-cell IMC measurement from the 
patient (P01) is represented by a coloured point in each panel.  Control observations are in grey.  Each 
plot represents an antibody observed during the IMC run. Data presented using plotIMC theta (VDAC1) 
view. Points representing patient fibres are coloured for the ratio value (NDUFB8/VDAC1) for that 






Due to the use of multiple antibodies for some targets, it was thought useful if PlotIMC 
displayed a correlation matrix that showed Pearson’s correlation coefficients between channels 
(example in Figure 4.22). This correlation changes depending what view is displayed, and also 
adjusts when a subset of fibres are selected to include the correlations associated with those 
fibres only.  
 
Figure 4.22: Example correlation matrix generated using PlotIMC. Pearson’s correlation coefficients 
between expression levels of each pair of proteins for all fibres from the selected patient (P01) using the 
theta view. Points representing patient fibres are coloured for the ratio value (NDUFB8/VDAC1) for 











As a final element, two further tables are displayed that summarise expression levels for each 
protein for both the selected patient and another for all the controls (see example Table 4.6). 
The summaries display descriptive statistics including the minimum, median, mean and max 
expression levels of each protein as well as different percentiles (2.5%, 5%, 25%, 75%, 95% 
and 97.5%) and the standard deviation.  
Table 4.6: Example output from plotIMC displaying a summary of descriptive statistics. Descriptive 








The chapter describes the optimisation of a novel use for imaging mass cytometry and 
subsequent bespoke analysis. Exceeding previous techniques, it enables accurate quantification 
of OXPHOS proteins spanning all five of the respiratory chain complexes (NDUBF8, 
NDUFA13, SDHA, UqCRC2, MTCO1, COX4+4L2, OSCP) as well as a mitochondrial mass 
marker (VDAC1), simultaneously in individual muscle fibres using 6µm sections. The use of 
dystrophin and subsequent development of Mitocyto to segment individual fibres enables 
automatic quantification of proteins with little need for manual intervention. Interacting with 
and visualising large multi-dimensional datasets can be challenging, but by the development 
and interactive nature of plotIMC, this challenge has been overcome and many different aspects 
of IMC data can now be examined simultaneously.   
4.5.1 Advantages of imaging mass cytometry 
Many studies have assessed mitochondrial dysfunction by quantifying the abundance of 
respiratory chain proteins, and in particular complexes I and IV (Rocha et al., 2015, Rocha et 
al., 2018, Ahmed et al., 2017). The application of IMC to skeletal muscle accurately quantifies 
the abundance of eight mitochondrial markers including proteins from all five complexes of the 
respiratory chain in individual muscle fibres without the need for serial sectioning. This is a 
huge advantage in that much less of the limited and valuable tissue is required – and this will 
only become more evident as more antibodies are added to the panel. Furthermore, the removal 
of serial sectioning eliminates the issue of any discrepancies created because of segmental 
deficiency (Bua et al., 2006, Murphy et al., 2012). A number of characteristics make IMC 
advantageous over other imaging techniques. There is no sample autofluorescence and due to 
the use of rare earth metals, there is very little background signal. Furthermore, in contrast to 
IHC, there is no need for an amplification step. With regards to sample preparation, the protocol 
for IMC is very similar to that of IHC which will subsequently enable rapid implementation of 
the new technique into muscle-based experiments. The automated capacity of IMC and 
subsequent analysis will minimise user subjectivity and also experiment completion time – 
something which will become much more apparent with a larger panel of antibodies. In order 
to validate the expression of respiratory chain deficiency using this approach I have compared 
the amount of deficiency using both the 95% predictive interval (used in IMC) and z-scores 





4.5.2 Limitations of imaging mass cytometry  
Although there are many advantages to IMC, the technique does not come without its 
limitations. To start, a large amount of antibody is lost during the conjugation process with low 
recovery rates post-conjugation. This not only has costing implications, but also affects the 
binding ability of the antibody, which subsequently means that higher concentrations have to 
be used in order for the antibody to work effectively (Han et al., 2018). The recovery rate of the 
antibody varies quite heavily both between antibodies and between conjugations, and similar 
to this study, other research groups have also struggled with finding the cause of this.  
As a result of the conjugations, there were a number of antibodies that had to be removed from 
this study due to insufficient staining - one of which being the mass marker TOMM20. As a 
future way to counteract this limitation, higher concentrations could be used post conjugation. 
Alternatively, after each conjugation, the antibody could be titrated to ensure the optimal 
concentration was being used each time.  
Another potential limitation of IMC is in the panel design. Although a much greater number of 
targets can be assessed simultaneously compared to IHC, panels have to be carefully thought 
out to ensure that there is no cross talk of signal between each target (Chevrier et al., 2018). 
Cross talk or spill over in IMC is generally minimal in comparison to fluorescence-based 
techniques, however the spill over effect still exists between different detection channels and 
can be due to a number of different factors including isotope purity, oxide formation (M+16) 
and abundance sensitivity (M±1).  The percentage overlap of all metal tags in all channels has 
been quantified by Fluidigm, and the subsequent matrix is displayed in Figure 4.23. Whilst this 
is not a problem for this study currently, as the number of targets included in the panel increases, 




Figure 4.23: Matrix displaying percentage crosstalk for metal tags. The signal overlap is indicated: blue boxes ≥ 0.5%, clear boxes ≤ 0.5%. Mass Channels 
are in columns and Mass Tag probes are in rows. For Mass Tags: Colour indicates probes that contribute ≥ 0.5% crosstalk into no channels (green), one or 
two channels (yellow), or more than two channels (orange). For Mass Channels: Colour indicates channels receiving ≥ 0.5% crosstalk from no probes (green), 
one or two channels (yellow), or more than two channels (orange). Images adapted from Fluidigm with extra information courtesy of FCCF Newcastle. 
116 
 
4.5.3 Potential applications 
The use of IMC in skeletal muscle has a great potential in future experiments. The ability to 
simultaneously measure up to 40 proteins means that a great number of targets can be assessed 
with complete certainty that measurements are made from the same muscle fibre. It is 
anticipated that IMC be used to not only assess mitochondrial respiratory chain deficiency in 
skeletal muscle of patients with various mitochondrial diseases, but with the addition of more 
targets, to assess the consequence of respiratory chain deficiency on downstream signalling 
pathways within the cell. This assessment of signalling can be coupled to genetic analysis to 
investigate the effect of heteroplasmy on the cell. 
Imaging mass cytometry can also be used in conjunction with other technologies. RNAscope is 
an in situ hybridization assay for detection of target RNA within intact cells (Wang et al., 2012). 
Generally, RNAscope employs the use of fluorescent probes however there is potential to 
couple this with IMC and replace the fluorescent markers with heavy metals. Again, this would 



































Chapter 5 : Understanding multi-dimensional respiratory 
chain deficiency phenotypes in single skeletal muscle fibres 

























Mitochondrial diseases are a heterogeneous group of disorders that are characterised by defects 
in oxidative phosphorylation (OXPHOS) and although they can present in any tissue, they 
predominantly affect the most energy demanding tissues such as the brain and skeletal muscle 
(Gorman et al., 2016). Mitochondrial diseases can either be caused by mutations in 
mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) genes. 
Both mitochondrial and nuclear genetic variants can lead to either isolated respiratory chain 
deficiencies (affecting one complex of the respiratory chain) or combined deficiency (affecting 
multiple complexes). With complex I being the largest of the respiratory chain complexes, it is 
not surprising that deficiency in this complex is the most common biochemical phenotype in 
patients with mitochondrial disease (Janssen et al., 2006). Isolated complex I deficiencies are 
the most common OXPHOS defects accounting for up to a third of all OXPHOS disorders 
(Loeffen et al., 2000), followed by isolated complex IV deficiencies (Diaz, 2010), and less 
commonly in complexes II, III and V. Isolated deficiencies can be attributed to mutations in 
structural subunits (of mtDNA or nuclear origin) or in nuclear-encoded assembly factors 
necessary for the formation of a complex. Not surprisingly, patients with isolated deficiency 
present biochemically with a severe loss of subunit immunoreactivity in the affected complex 
(Ahmed et al., 2017).   
Combined deficiencies are generally caused by either single, large-scale mtDNA deletions or 
point mutations in mt-encoded tRNAs or rRNAs (Chinnery et al., 2000) as well as mutations in 
nuclear genes. Single, large-scale mtDNA deletions account for around 16% of all adult 
mtDNA mutations (Gorman et al., 2015) and are associated with a number of clinical 
phenotypes including CPEO, Pearson’s syndrome and Kearns-Sayre syndrome. The 
biochemical phenotype of the patients will not only depend on the size and location of the 
deletion but also how many genes are knocked out, and the associations these have to specific 
complexes. Rocha et al. (2018) have grouped single, large-scale mtDNA deletions into three 
classes with very distinct patterns of respiratory chain deficiency, determined by the size and 
location of the mtDNA deletion. In their study, in all patients from class I, the deletions 
consistently removed five to six tRNA genes, four to five complex I genes and one complex IV 
gene, and patients were shown to have equal downregulation of both complex I and complex 
IV. In class II, deletions removed three to four tRNA genes and three to four complex I genes 
while all complex IV genes were preserved which explains why these patients had a more 
pronounced loss of complex I than complex IV. In class III, the deletions removed six to eight 
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tRNA genes, two to four complex I genes, two complex V genes and all complex IV genes. The 
loss of all complex IV genes in class III can explain why these patients had a more severe loss 
of complex IV than complex I (Rocha et al., 2018).  
The m.3243A>G MT-TL1 point mutation is thought to affect 1 in 12,800 adults and is the most 
prevalent point mutation of mtDNA (Gorman et al., 2015). Biochemically, studies identify 
reduced activities of both complex I and complex IV in muscle biopsies of patients with 
m.3243A>G, with a much more severely affected complex I than complex IV (Rocha et al., 
2015, Mariotti et al., 1995). The effect of the m.3243A>G mutation on both complex II 
(encoded by nuclear DNA) and complexes III and V (encoded by mtDNA), is less clear and 
although a number of studies demonstrate a decrease in these complexes in response to the 
mutation (Jiang et al., 2015, Sasarman et al., 2008), this is often investigated using cell lines 
and not directly in patient muscle. Mutations in other mitochondrial-encoded tRNAs present 
biochemically with much greater heterogeneity than m.3243A>G mutations and, although 
reduced levels of complex I and complex IV are generally observed, the pattern of this 
deficiency varies between different mutations (Rocha et al., 2015). Furthermore, the levels of 
deficiency will also depend on the amounts of the associated amino acid within each of the mt-
encoded complex I and IV proteins. The heterogeneity of these mutations means that the 
resultant biochemical defects vary considerably and there has been no group of studies that 
show a very clear pattern of deficiency with regards to the other respiratory chain complexes. 
Current techniques used to investigate mitochondrial diseases rely on histochemical and 
immunofluorescent methods which have allowed measurements of biochemical deficiency at 
both single cell and sub-cellular resolution (Old and Johnson, 1989, Rocha et al., 2015, Vincent 
et al., 2018). Although these methods have been used to uncover patient-specific patterns of 
respiratory chain deficiency, the limitation of immunofluorescence (IF) and conventional 
immunohistochemistry is the small number of proteins that can be assessed at a single cell level 
on one tissue section due to the possible bleed through of channels. Furthermore, the use of 
secondary antibodies together on one section is only possible if the primary species differ and 
because of this, the number of proteins that can be measured simultaneously is limited to four.  
To overcome the limitations of other techniques, imaging mass cytometry can be used to 
effectively quantify mitochondrial dysfunction in skeletal muscle and to study the relationship 





5.2 Aims of the study 
The aims of this chapter were as follows: 
• To validate the use of IMC in skeletal muscle by comparing results to the established 
immunofluorescent assay 
• To use IMC to look at multi-dimensional respiratory chain phenotypes in patients with 

















5.3.1 Patient cohort 
Skeletal muscle samples were taken from the vastus lateralis of patients with clinically and 
genetically-characterised mitochondrial diseases of either mtDNA or nuclear genetic origin. 
For the initial cohort, patients were grouped based on the type of mutation: single, large-scale 
mtDNA deletion (n=2), m.3243A>G MT-TL1 (n=3), mutations in other, less common 
mitochondrial-encoded tRNAs (m.10010T>C MT-TG (n=1), m.14709T>C MT-TE (n=1) and 
m.5543T>C MT-TW (n=1)) and pathogenic nDNA variants in complex I (CI) assembly factors 
(n=2). Additional patients were later included; pathogenic nDNA variants in complex II (CII) 
assembly factors (n=2), pathogenic nDNA variants in complex IV (CIV) assembly factors (n=2) 
and pathogenic nDNA variants in complex V (CV) assembly factors (n=2). 
 Ethical approval for use of mitochondrial disease patient tissue was granted by the Newcastle 
and North Tyneside Local Research Ethics Committee (reference 16NE/0267). Control tissue 
was acquired from the distal part of the hamstring muscle from individuals undergoing anterior 
cruciate ligament surgery following approval by the Newcastle and North Tyneside Local 
Research Ethics Committee (reference 12/NE/0394). Information about all patients and control 
cases presented in this chapter are displayed in Tables 5.1 and 5.2. 
5.3.2 Antibodies and panel design 
A panel was designed to include antibodies that specifically targeted a number of mitochondrial 
proteins as well as a fibre membrane marker. Of the eight mitochondrial antibodies included, 
seven targeted proteins involved in complexes I-V (CI-CV) of the mitochondrial oxidative 
phosphorylation machinery and one targeted a mitochondrial outer membrane protein which 
acted as a surrogate for mitochondrial mass. As described in section 4.4.1.2, before conjugation, 
each antibody was ranked based on its expression levels for the targeted protein and based on 
these results, was subsequently paired with a metal using the protocol described in section 4.3.4. 







Table 5.1: Patient information. Information on patients and controls detailing gender, age at biopsy, 
clinical information and genetic defect. 
Subjects Gender Age Clinical information Genetic defect Heteroplasmy level 







Exercise intolerance, unable to 
perform sustained aerobic exercise 












Exercise intolerance, muscle 















CPEO and bilateral ptosis 
Deletion size: 4372bp 
Breakpoints: 8929-13301 










Deletion size: 7498bp 
Breakpoints: 7130-14628 
mtDNA deletion level: 28% 
28% 
Point mutations in mitochondrial-encoded tRNA leucine (MT-TL1) (taken from the vastus lateralis) 
 P05 F 25yrs Exercise intolerance, ptosis m.3243A>G MT-TL1 
mutation 
66% 
P06 F 47yrs Modest exercise intolerance m.3243A>G MT-TL1 
mutation 
34% 
 P07 M 53yrs CPEO m.3243A>G MT-TL1 
mutation 
74% 
Point mutations in other mitochondrial-encoded tRNAs (taken from the vastus lateralis)  
 P08 M 33yrs Mitochondrial myopathy m.10010T>C MT-TG 
mutation 
89% 
 P09 F 35yrs Mild weakness m.14709T>C MT-TE 
mutation 
76% 





Healthy controls (taken from the tibialis anterior)  
C01 M 20yrs Taken during anterior cruciate 
ligament surgery 
  
C02 M 24yrs  Taken during anterior cruciate 
ligament surgery 
  
C03 F 23yrs  Taken during anterior cruciate 
ligament surgery 
  
 CK; Creatine kinase, CPEO; Chronic progressive external ophthalmoplegia, MILS; Maternally inherited Leigh syndrome, n/a; 




Table 5.2: Patient information. Information on patients and controls detailing gender, age at biopsy, 
clinical information and genetic defect. 
Subjects Gender Age  Clinical information Genetic defect 
Nuclear-encoded mutations affecting complex II (taken from the vastus lateralis) 
P11 M 3yrs Cardiomyopathy, hypotonia, myopathy CII SDHB 
P12 M 1 day Cardiomyopathy CII SDHD 
Nuclear encoded mutations affecting complex IV (taken from the vastus lateralis) 
P13 M 6 months NARP/MILS, cardiomyopathy, 
hypotonia, myopathy 
CIV SCO2 
P14 F 15 months Encephalopathy, hypotonia CIV SURF1 
Nuclear encoded mutations affecting complex V (taken from the vastus lateralis) 
P15 F 5 months Cardiomyopathy CV TMEM70 
P16 n/a 4 months Congenital lactic acidosis CV TMEM70 
Healthy controls (taken from the tibialis anterior) 
C03 F 23yrs  Taken during anterior cruciate ligament 
surgery 
 
C04 M 22yrs Taken during anterior cruciate ligament 
surgery 
 
C05 F 23yrs Taken during anterior cruciate ligament 
surgery 
 
C06 M 4yrs Taken for diagnostic investigation but 
no mitochondrial dysfunction present 
 











Table 5.3: List of primary and secondary antibodies. Detail on antibody host, dilution and supplier is 
provided. 
Antibodies Host and isotype Dilution Company 
Protein target/ Primary 
antibodies 
      
Membrane marker: Laminin  Rabbit 1:50 Sigma-Aldrich (L9393) 
Membrane marker: Dystrophin  Mouse 1:50 EMD Millipore (Mab 1645) 
Complex I: NDUFB8  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (110242) 
Complex I: NDUFA13  Mouse IgG2b 1:50 (IMC) 1:100 (IF) Abcam (110240) 
Complex II: SDHA  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (14715) 
Complex III: UqCRC2  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (14745) 
Complex IV: MTCO1  Mouse IgG2a 1:50 (IMC) 1:100 (IF) Abcam (14705) 
Complex IV: COX4+4L2  Mouse IgG2a 1:50 (IMC) 1:100 (IF) Abcam (110261) 
Complex V: OSCP  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (110276) 
Mass marker: VDAC1 Mouse IgG2b 1:50 (IMC) 1:100 (IF) Abcam (14734) 
 
Secondary antibodies       
Anti-rabbit Alexa Fluor 405nm Goat 1:100 Life Technologies (A31556) 
Anti-IgG2a Alexa Fluor 488nm Goat 1:200 Life Technologies (A21131) 
Anti-IgG2b Alexa Fluor 546nm Goat 1:200 Life Technologies (A21143) 
Anti-IgG1 biotin Goat 1:200 Life Technologies (A10519) 
Streptavidin Alexa Fluor 647nm Goat 1:100 Life Technologies (S32357) 
Anti-IgG1 Alexa Fluor 647nm Goat 1:200 Life Technologies 
(AA21240) 
Anti-mouse IgG Alexa Fluor 
488nm 
Goat 1:200 Life Technologies (A11001) 
125 
 
5.3.3 Muscle biopsy and cryo-sectioning 
6µm serial sections were obtained from transversely orientated muscle blocks as described in 
section 2.2.3. 
5.3.4 Preparation of samples for immunofluorescence  
Sections were prepared for immunofluorescence as described in section 2.2.5. Since many of 
the antibodies had the same isotypes, serial sections were incubated with five different 
combinations of primary antibodies to account for any overlap (see Table 5.4). Each antibody 
was diluted at 1:50. Following overnight incubation and subsequent washes, the sections were 
incubated with secondary antibodies diluted to a working concentration. 
Table 5.4: Immunofluorescent antibody combinations. Combinations of metal-conjugated antibodies 
used in quadruple immunofluorescence.  
Combination 1 Combination 2 Combination 3 Combination 4 Combination 5 
Laminin  Laminin Laminin  Laminin  Laminin  
NDUFB8  NDUFB8  SDHA  OSCP  UQCRC2 
MTCO1  COX4+4L2  MTCO1 MTCO1  MTCO1  
VDAC1 VDAC1 NDUFA13  VDAC1 VDAC1 
 
5.3.5 Imaging and analysis of samples prepared for immunofluorescence 
Samples were imaged using the Zeiss Axio Imager M1 as described in section 2.2.6 and images 
were segmented using an in-house Quadruple Immunoanalyser Software as previously 
described (Ahmed et al., 2017). In brief the software segments muscle fibres based on 
membrane labelling and extracts average fluorescent intensities for each single cell. 
5.3.6 Preparation of samples for imaging mass cytometry 
The protocol used for preparing the samples for IMC (see section 4.3.6) was adapted from the 
quadruple IHC protocol (Rocha et al., 2015). In brief, tissues were removed from -80°C storage 
and left to air dry for one hour before being fixed with 4% paraformaldehyde (Sigma) for 3 
minutes. Next sections were permeabilised by dehydration and rehydration in a methanol 
gradient as follows: 70% for 10 minutes, 95% for 10 minutes, 100% for 20 minutes, 95% for 
10 minutes, 70% for 10 minutes. Following washes, sections were blocked for any endogenous 
126 
 
protein by incubation with 10% normal goat serum (NGS) for one hour at RT before overnight 
incubation with the metal-conjugated antibody panel (all antibodies were used after a 1/50 
dilution in 10% NGS) at 4°C. Following thorough washes in TBST, sections were stained with 
an Ir intercalator for 30 minutes at RT, washed quickly with ddH2O for 5 minutes and air dried 
ready for use on the IMC.  
5.3.7 Imaging mass cytometry  
ROIs were selected for each muscle section and each patient was run in turn on the IMC. In 
every case, the ROI covered as much of the tissue section as possible so that fibres could be 
matched to their immunofluorescent equivalent on a serial section. The technical set up of the 
instrument is described in section 4.3.6. After successful ablation files were exported in their 
native “MCD” file format and processed to single layer TIFFs (16-bit) using MCD viewer 
software (Fluidigm). 
5.3.8 Analysis of imaging mass cytometry data 
The data generated from the imaging mass cytometer was initially opened in MCD viewer 
(Fluidigm) and subsequently exported as TIFF files for further analysis. Each image had a 
resolution of 1 pixel per 1μm2, which is determined by the size of the laser spot. As described 
in detail in the previous chapter, images were segmented using the custom-made image analysis 
software Mitocyto (mitocyto: https://github.com/CnrLwlss/mitocyto). Image segmentation was 
automatically generated using the dystrophin channel or from a map of the mean of all channels. 
Segmentation was further refined manually when signal was too weak for identification of cell 
membranes. Following segmentation, average signal intensity for each channel and each cell 
was reported in an output file for further analysis.  
Any further analysis was carried out using the plotIMC web-tool which is described in detail in 






5.4 Results  
5.4.1 Successful imaging of patient cohort 
A cross sectional muscle section from 10 patients with various clinically and genetically-
characterised mitochondrial diseases of either mtDNA or nuclear genetic origin (single, large-
scale mtDNA deletion (n=2), m.3243A>G MT-TL1 (n=3), mutations in other, less common 
mitochondrial-encoded tRNAs (m.10010T>C MT-TG (n=1), m.14709T>C MT-TE (n=1) and 
m.5543T>C MT-TW (n=1)) and pathogenic nDNA variants in complex I (CI) assembly factors 
(n=2)) were run on the imaging mass cytometer alongside three control cases. The subsequent 
TIFF files from a representative control and patient from each patient group are displayed in 
Figure 5.1. Although all nine proteins are measured, due to the lack of colours available for the 
overlay, the images show a merge of the four channels commonly used in immunofluorescence 
(NDUFB8, MTCO1, VDAC1 and a membrane marker) and successfully demonstrates the 
technique is feasible on human skeletal muscle.  
 
Figure 5.1: Example patient from each patient group imaged using IMC. (a) C03, (b) P07 with a 
m.3243A>G point mutation in MT-TL1, (c) P04 with a 7498bp single, large-scale deletion from regions 
7130-14628, (d) P09 with a m.14709T>C point mutation in other mt-encoded tRNA (MT-TE), (e) P02 
with a nuclear-encoded ACAD9 mutation affecting complex I. Image displays merged channels for four 




5.4.2 Validation of imaging mass cytometry  
Because IMC has not been used to investigate skeletal muscle previously, it was pivotal that 
the results generated by IMC were validated against the established quadruple IHC. To assess 
whether quantification of changes in mitochondrial protein expressions were comparable 
between IHC and IMC, serial sections were stained with the same cocktail of antibodies and 
analysed using the two techniques (example area of a patient section in Figure 5.2).  Visually, 
both methods appeared to produce reproducible staining patterns (Figure 5.2). 
 
Figure 5.2: Comparison of images generated by IHC and IMC. Intensities scaled for each individual 
channel to fill bit-depth range for display and then merged. (a) IHC and (b) IMC carried out on serial 
sections of skeletal muscle tissue from P04 using antibodies recognising the indicated markers and an 




In order to quantify the protein expression using these two techniques, the mean ratio of each 
protein over mitochondrial mass was calculated for each control and patient and each protein 
after IHC and IMC. To do this, each patient was analysed in the typical way for both IHC and 
IMC, with care taken to ensure the exact same fibres were selected for each. Subsequently the 
data was generated for both techniques and compared using a Pearson’s correlation and 
demonstrated a strong correlation between IMC data that was log transformed and IHC data 
with a correlation coefficient of 0.85 (See Figure 5.3). 
 
Figure 5.3: Pearson’s correlation of IHC versus IMC. Points represent mean protein level for each 
antibody target in each patient or healthy control, CI = nuclear-encoded mutation causing a defect in 
complex I, control = healthy control, deletion = single, large-scale mtDNA deletion, MT-TL1 = point 




5.4.3 Reproducibility of imaging mass cytometry  
It was essential to test whether the data that was generated by IMC was reproducible. To 
investigate this, three repeats were examined. The first replicate was carried out with one batch 
of reagents and conjugations, and the further two replicates were carried out with a different 
batch of reagents and conjugations to the first, but identical to one another. Data generated from 
the two replicates that used the same batch of conjugations showed excellent reproducibility 
with a correlation coefficient of 0.98 (Figure 5.4c). Comparing the first replicate to the further 
replicates that used a different batch of conjugations was less reproducible but still 
demonstrated positive correlations of 0.87 (between replicate one and replicate two) (Figure 




Figure 5.4: Correlation plots to determine the reproducibility of IMC experiments. Scatterplots comparing theta measures of protein expression between two 
replicate IMC experiments.  Pearson’s correlation coefficient reported on top of each panel.  Each dot represents the mean theta of one antibody from each 
control and each patient. Controls are depicted by grey dots and patients are depicted by pink dots. (a) Initial experiment (replicate 1) and replicate 2, (b) 
Replicate 1 and replicate 3, (c) Replicate 2 and replicate 3. Reagents were kept the same between replicate 2 and replicate 3 but different antibody conjugations 
were used between replicate 1 and both the repeats (replicates 2 and 3).
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5.4.4 Visualising biochemical phenotypes of mitochondrial patients using 
IMC 
After confirming that IMC results were reproducible and consistent with those obtained using 
immunofluorescence, the data could then be analysed in more depth. To deal with the increased 
complexity and multi-dimensional nature of the IMC data, several different approaches were 
investigated.  
Data generated from the IMC is similar to the data that is generated in flow cytometry and so 
clustering analysis (a standard cytometry methodology) was attempted. Dr Conor Lawless 
carried out k-means global clustering on the full IMC dataset but with little success. k-means 
identified fibres from patients with nuclear-encoded CI variants (Figure 5.5 cluster 4),  but 
was unable to identify any other patient groups with mtDNA mutations. It was suspected that 
this was because of different mutations loads in individual fibres causing a mosaic pattern of 
deficiency rather than the easily classifiable OXPHOS states that are seen with nuclear 
mutations.   
 






Because of this, plotIMC was used for all further data exploration. For detail on the 
development of plotIMC see chapter 4. In brief, plotIMC uses two related approaches to 
analyse data and account for mitochondrial mass. The first approach is visual inspection of 
2Dmito plots which are scatterplots comparing cell-average IMC measurements for each 
antibody target observed during the IMC run with a surrogate for mitochondrial mass 
(VDAC1). The second approach is to examine the angle (theta) that each fibre in a 2Dmito plot 
makes with the origin (0,0) and the x-axis. Theta represents the level of expression relative to 
mitochondrial mass. In both views, each point represents a single fibre – grey points represent 
fibres from the controls and the patient points can be colour coded according to the expression 
of the proteins selected in the ‘colour fibres by channel’ drop down menu. 
5.4.5 Patients with nuclear-encoded complex I variants  
P01 and P02 presented with nuclear-encoded mutations in assembly factors TMEM126B and 
ACAD9 respectively. Assessing their biochemical phenotype using the theta view in plotIMC 
demonstrated that both patients had much lower levels of complex I proteins compared to the 
controls (Figure 5.6). Quantitatively, 100% of fibres fall below the 95% predictive interval for 
both NDUFB8 and NDUFA13. Interestingly both patients exhibit an upregulation of proteins 
involved in the other complexes (CII-CV) in response to CI deficiency when compared to 
controls. 98.5%, 97.9%, 84.9% and 99.1% of fibres lie above the 95% predictive interval for 
SDHA, UqCRC2, MTCO1 and OCSP respectively for P01 (Figure 5.7) and 70.2%, 71%, 
88.9% and 61.5% of fibres lie above the 95% predictive interval for SDHA, UqCRC2, MTCO1 
and OCSP respectively for P02 (Figure 5.8).  Furthermore, there was a very strong correlation 







Figure 5.6: Biochemical profile of patients with nuclear-encoded CI variants causing isolated CI 
deficiency. Data presented using plotIMC theta (VDAC1) view.  (a) P01 with a mutation in TMEM126B 
and (b) P02 with a mutation in ACAD9. One single-cell IMC measurement from the patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Each plot represents 
an antibody observed during the IMC run. Points representing patient fibres are coloured for the 
NDUFB8 value for that fibre. Images from each patient showing NDUFB8 (purple) and dystrophin 





Figure 5.7: 2Dmito plot from P01 with a TMEM126B mutation affecting complex I. 2Dmito plots 
from P01 comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) 
UqCRC2, (e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each 
patient is represented by a coloured point in each panel.  Control observations are in grey.  Points 
representing patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the 
control data is drawn as a solid grey line and the 95% predictive interval for control fibres lies between 
the dashed grey lines. Total number of fibres above and below the control predictive interval are written 




Figure 5.8: 2Dmito plot from P02 with a ACAD9 mutation affecting complex I. 2Dmito plots from 
P01 comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) 
UqCRC2, (e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each 
patient is represented by a coloured point in each panel.  Control observations are in grey.  Points 
representing patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the 
control data is drawn as a solid grey line and the 95% predictive interval for control fibres lies between 
the dashed grey lines. Total number of fibres above and below the control predictive interval are written 
above each panel. 
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5.4.6 Patients with single, large-scale mtDNA mutations 
P03 and P04 had heteroplasmic single, large-scale mtDNA deletions removing regions m.8929-
13301 and m.7130-14628, respectively (Figure 5.9). P03 had an mtDNA deletion level of 28% 
and P04 had an mtDNA deletion level of 53%. 
 
Figure 5.9: Location of single, large-scale mtDNA deletions for P03 and P04. Location and size of 
the mtDNA deletion from individual patients: P03 deletion size 4372bp, breakpoints: m.8929-13301, 
mtDNA deletion level: 28% and P04; deletion size 7498bp, breakpoints: m.7130-14628, mtDNA 
deletion level: 53%. The mtDNA is colour-coded by gene-type: CI genes; orange, CIII genes; red, CIV 











P03 has the smallest deletion removing four CI genes, one CIV gene and five tRNAs and shows 
very little deficiency (Figure 5.10), with only 4.6% of fibres falling below the 95% predictive 
interval for NDUFB8 (Figure 5.10 panel b) which is lower for NDUFA13 (2.4%) (Figure 5.10 
panel a) and MTCO1 (2.7%) (Figure 5.10 panel f).  
 
Figure 5.10: 2Dmito plot from P03 with a single, large-scale mtDNA deletion removing regions 
m.8929-13301. 2Dmito plots from P03 comparing OXPHOS targets against VDAC1: (a) NDUFA13, 
(b) NDUFB8, (c) SDHA, (d) UqCRC2, (e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell 
IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta NDUFB8 for that 
fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive interval 
for control fibres lies between the dashed grey lines. Total number of fibres above and below the control 
predictive interval are written above each panel. 
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P04 (Figure 5.11) has a larger deletion removing four CI genes, two CIV genes, two CV genes 
and seven tRNAs. P04 has a more obvious subpopulation of deficient fibres (Figure 5.12) with 
a greater percentage (28.3% and 5.5%) of fibres falling below the 95% predictive interval for 
NDUFB8 and NDUFA13 respectively and similar to P03, a lower proportion of fibres are 
deficient for CIV (5.6% and 6.8% respectively for COX4+4L2 and MTCO1). Interestingly, 
discrepancies were observed between the two complex I markers, with NDUFB8 appearing to 
be more affected than NDUFA13 in both patients. This is highlighted in P04 with 5.1 times 
more fibres falling below the 95% predictive interval for NDUFB8 compared to NDUFA13. 
Furthermore, looking at P04 using the ‘colour fibres by channel’ tool it appeared as if there was 
an upregulation of complex II in response to CI and IV deficiency. This was confirmed by 
selecting fibres with an upregulation in CII (theta > 80° for SDHA). Selecting these fibres 
revealed that the fibres presenting with a theta of above 80° for SDHA were the same fibres 
demonstrating the most deficiency in CI and IV (theta <40° for NDUFB8 and MTCO1). 
Although a slight upregulation of CIII and CV was observed in P04, there is no clear trend in 
these complexes in response to deficiency.  
 
Figure 5.11: Theta plot of P04 with a single, large-scale deletion removing regions m.7130-14628. 
Data presented using plotIMC theta (VDAC1) view. P04 harbouring a deletion affecting breakpoints 
m.7130-14628. One single-cell IMC measurement from the patient is represented by a coloured point 
in each panel.  Control observations are in grey.  Each plot represents an antibody observed during the 




Figure 5.12: 2Dmito plot from P04 with a single, large-scale mtDNA deletion removing regions 
m.7130-14628. 2Dmito plots from P04 comparing OXPHOS targets against VDAC1: (a) NDUFA13, 
(b) NDUFB8, (c) SDHA, (d) UqCRC2, (e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell 
IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta NDUFB8 for that 
fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive interval 
for control fibres lies between the dashed grey lines. Total number of fibres above and below the control 
predictive interval are written above each panel. 
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5.4.7 Patients with point mutations in mt-encoded tRNA Leucine (MT-TL1) 
P05, P06 and P07 had the common m.3243A>G MT-TL1 mtDNA point mutation affecting the 
mitochondrial-encoded tRNA Leucine. Theta plots for each patient are presented in Figure 5.13 
and show that each patient within the group have a very similar biochemical profile. 
 
 
Figure 5.13: Biochemical profile of patients with an m.3243A>G point mutation in MT-TL1. Data 
presented using plotIMC theta (VDAC1) view. (a) P05, (b) P06 and (c) P07. One single-cell IMC 
measurement from the patient is represented by a coloured point in each panel.  Control observations 
are in grey.  Each plot represents an antibody observed during the IMC run. Points representing patient 





The 2Dmito plots showing the 95% confidence intervals for P05, P06 and P07 can be found in 
Figure 5.14, Figure 5.15 and Figure 5.16 respectively. All patients have a stronger 
downregulation of complex I than complex IV, with 29.8%, 23.1% and 70.1% of fibres falling 
below the 95% predictive interval for NDUFB8 compared 14.3%, 9.5% and 19.8% of fibres for 
MTCO1 in P05, P06 and P07 respectively. Like the previous patient group, NDUFA13 and 
NDUFB8 appear unequally affected with a greater proportion of fibres falling below the 95% 
predictive interval for NDUFB8 compared to NDUFA13.  
Using the ‘colour fibres by channel’ tool to investigate the response of complex II to complex 
I deficiency demonstrates that in P05 and P06, the most deficient fibres in CI (theta <40° for 
NDUFB8) are the fibres with the highest levels of SDHA (theta >80°). Although P07 has 68.6% 
of fibres above the 95% predicative interval for SDHA, this is not correlated to complex I 
deficiency. Likewise, all patients present with an upregulation of complex III (43.8%, 55.4% 
and 66.7% for UQCRC2 for P05, P06 and P07) and complex V (17.9%, 11.5% and 41.9% for 




Figure 5.14: 2Dmito plot from P05 with an m.3243A>G mutation in MT-TL1. 2Dmito plots from P05 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 





Figure 5.15: 2Dmito plot from P06 with an m.3243A>G mutation in MT-TL1. 2Dmito plots from P06 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 





Figure 5.16: 2Dmito plot from P07 with an m.3243A>G mutation in MT-TL1. 2Dmito plots from P07 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 




5.4.8 Patients with point mutations in other mt-encoded tRNAs  
P08, P09 and P10 all had mutations in other mitochondrial tRNA variants (Figure 5.17); P08 
with a point mutation in MT-TG (Figure 5.18a), P09 with a point mutation in MT-TE (Figure 
5.18b) and P10 with a point mutation in MT-TW (Figure 5.18c). All three variants can affect 
the expression of the mitochondrial-encoded subunits of CI, CIII, CIV and CV, however the 
effect they have on each of these complexes will differ and will depend on the relative positions 
during OXPHOS complex assembly of the mtDNA encoded subunits. 
 
Figure 5.17: Location of tRNA variants for P08, P09 and P10. Location of P08 with a mutation 
affecting MT-TG (tRNAGly), P09 with a mutation affecting MT-TE (tRNAGlu) and P10 with mutation in 
MT-TW (tRNATrp). The mtDNA is colour-coded by gene-type: CI genes; orange, CIII genes; red, CIV 




Figure 5.18: Biochemical profile of patients with a point mutation in other mt-encoded tRNAs. Data 
presented using plotIMC theta (VDAC1) view. (a) P08 with a point mutation in mitochondrial-encoded 
tRNAGly (MT-TG), (b) P09 with a point mutation in mitochondrial-encoded tRNAGlu (MT-TE) and (c) 
P10 with a point mutation in mitochondrial-encoded tRNATrp (MT-TW). One single-cell IMC 
measurement from the patient is represented by a coloured point in each panel.  Control observations 
are in grey.  Each plot represents an antibody observed during the IMC run. Points representing patient 







The 2Dmito plots showing the 95% confidence intervals for P08, P09 and P10 can be found in 
Figure 5.19, Figure 5.20 and Figure 5.21 respectively. All patients showed a downregulation 
of both CI and CIV with 89.2%, 48.2% and 88.3% of fibres lying below the 95% predictive 
interval for NDUFB8 and 89.3%, 35.1% and 85.9% of fibres lying below the 95% predictive 
interval for MTCO1, in P08, P09 and P10 respectively. Additionally, there is a significant 
downregulation of CIII in all patients with 55.8%, 30.1% and 60% of fibres lying below the 
95% predictive interval for UqCRC2 in P08, P09 and P10 respectively. Only P08 and P10 have 
a significant upregulation in CII with 89.5% and 58.1% of fibres above the 95% predictive 
interval for SDHA. Furthermore P08 demonstrates an increase in CV with 90.8% of fibres 
above the 95% predictive interval for OSCP, and this increase appears to be correlated to 
deficiency with upregulated fibres (theta >80°) being the most deficient (theta <30°) 
(highlighted in Figure 5.18a using the ‘colour fibres by channel’ tool). Unlike the other patient 
groups with mtDNA mutations, in these patients, NDUFB8 and NDUFA13 are equally affected 

















Figure 5.19: 2Dmito plot from P08 with an m.10010T>C mutation in MT-TG. 2Dmito plots from P08 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 





Figure 5.20: 2Dmito plot from P09 with an m.14709T>C mutation in MT-TE. 2Dmito plots from P09 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 





Figure 5.21: 2Dmito plot from P10 with an m.5543T>C mutation in MT-TW. 2Dmito plots from P10 
comparing OXPHOS targets against VDAC1: (a) NDUFA13, (b) NDUFB8, (c) SDHA, (d) UqCRC2, 
(e) COX4+4L2, (f) MTCO1, (g) OSCP. Individual single-cell IMC measurements from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Points representing 
patient fibres are coloured for by theta NDUFB8 for that fibre. Regression through the control data is 
drawn as a solid grey line and the 95% predictive interval for control fibres lies between the dashed 




5.4.9 Genetic thresholds at which OXPHOS deficiency occurs 
It is known that in patients with mitochondrial disease, a threshold effect occurs whereby a 
threshold proportion of mtDNA mutation must be achieved before fibres become deficient 
(reviewed in (Rossignol et al., 2003)), but further to this, it is suspected that this threshold varies 
for each complex. In line with the idea of a threshold effect, Figure 5.22 shows the 2Dmito 
plots for NDUFB8 in all patients with a combined deficiency and demonstrates that the fibres 
are split into two groups for CI - one group in which the relationship between CI signal and 
VDAC1 signal resembles control patients, and another group where the signal resembles 
patients with a nuclear-encoded CI mutation (v-shaped data in Figure 5.22). 
 
Figure 5.22: NDUFB8 levels in patients with combined deficiency. (a) P03, (b) P04, (c) P05, (d) P06, 
(e) P07, (f) P08, (g) P09 and (h) P10. Individual single-cell IMC measurement from each patient is 
represented by a coloured point in each panel.  Control observations are in grey.  Data presented using 
plotIMC 2Dmito plot view. Points representing patient fibres are coloured for theta NDUFB8 levels for 
that fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive 
interval for control fibres lies between the dashed grey lines. Total number of fibres above and below 
the control predictive interval are written above each panel. 
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 This pattern also occurs for MTCO1 but with a smaller proportion of CIV-deficient fibres. In 
order to explore this quantitatively, categories of deficient fibres were assessed (Table 5.5) and 
highlights that most CIV-deficient fibres are also CI-deficient, suggestive of a higher threshold 
for CIV. A similar pattern can be seen between CIII and CIV where most CIII-deficient fibres 
are also deficient for CIV. 
Table 5.5: Relationship of complexes in all patients and controls. The percentage and number of fibres 
falling below the 95% predictive interval for NDUFB8 (complex I), MTCO1 (complex IV) and UqCRC2 
(complex III) for all patients and controls. Further to this the table displays the percentage of fibres that 





5.4.10 Patients with isolated complex deficiency  
IMC has the capacity to look at multiple targets simultaneously and, although all five complexes 
were investigated in the initial cohort of patients, it was decided to further run patients with 
isolated deficiencies to ensure that IMC was detecting deficiencies in other, less commonly 
affected complexes. Six patients with isolated deficiency (isolated deficiency in CII (n=2), 
isolated deficiency in CIV (n=2) and isolated deficiency in CV (n=2)) were run alongside 
controls (n=4) and because the patients were all paediatric cases, it was decided that one of the 
controls chosen was also paediatric.  
As these are isolated cases it is expected that the levels of the protein involved in the affected 
complex will be lower. Patients with an isolated defect in CII, CIV and CV were investigated 
relative to controls and the expression of each antibody targeting the relevant affected complex 
in each case was examined. Figures 5.23 to 5.25 display the patients from each group of 
isolated deficiencies as well as all controls examined (isolated complex II deficiency (Figure 
5.23), isolated complex IV deficiency (Figure 5.24) and isolated complex V deficiency (Figure 
5.25)). Results show that visually, there was a marked decrease in protein levels in each of the 
patients with isolated deficiencies in comparison to the controls (highlighted by the weaker 
















Figure 5.23: IMC staining for SDHA in patients with isolated complex II deficiency and controls. 
SDHA expression from (a) C03 (b) C04, (c) C05, (d) C06, (e) P11 with a defect in SDHB causing 





Figure 5.24: IMC staining for MTCO1 in patients with isolated complex IV deficiency and controls. 
MTCO1 expression from (a) C03 (b) C04, (c) C05, (d) C06, (e) P13 with a defect in SCO2 causing 





Figure 5.25: IMC staining for OSCP in patients with isolated complex V deficiency and controls. 
OSCP expression from (a) C03 (b) C04, (c) C05, (d) C06, (e) P15 with a defect in TMEM70 causing 




Unfortunately, due to the nature of paediatric samples and because the fibres were so small, 
Mitocyto was initially unable to segment individual fibres from these cases. Although the 
software is currently being adapted to work with paediatric tissue, this was not an option at the 
time and so these patients had to be analysed in a different way. Because it is assumed that 
nuclear gene mutations affect all cells in a tissue in a similar way, to quantitatively analyse 
these cases, the mean expression of each antibody was taken from the section as a whole and 
not from individual fibres. 
Before analysis was carried out on these samples, and to confirm the assumption that nuclear 
mutations affect all cells in a tissue in a similar way, three different regions of one control 
(Figure 5.26a) and one patient (Figure 5.26b) were sampled and the mean expression of each 
antibody was taken for each region. Results show that mean expressions did not differ very 
much between each region and thus analysing the section as a whole would not affect the results.  
 
Figure 5.26: Mean expression of each antibody in three different regions of the muscle biopsy. Three 
different regions were selected from (a) C06 and (b) P11 and the mean expression of each antibody in 










P11 and P12 have mutations affecting complex II and presented with nuclear-encoded 
mutations in SDHB and SDHD respectively. Assessing the biochemical phenotype 
demonstrated that both patients had much lower levels of SDHA compared to the controls 
(Figure 5.27a) with fold decreases of 13.3 and 5.4 between the controls and P11 and P12 
respectively. Similar to the isolated complex I patients there is an upregulation of proteins 
involved in the other complexes (CI, CIII, CIV and CV) in response to CII deficiency (Figure 
5.27b). Fold increases of 1.1, 1.2, 1.1 and 1.2 are seen in P11 for NDUFB8, UqCRC2, MTCO1 
and OSCP respectively. Generally more pronounced upregulation is seen in P12 with fold 
increases of 1.1, 1.3, 1.2 and 3.6 for NDUFB8, UqCRC2, COX4+4L2 and OSCP respectively. 
P13 and P14 have mutations affecting complex IV and presented with nuclear-encoded 
mutations in SCO2 and SURF1 respectively. Both patients show a downregulation in proteins 
associated with CIV (MTCO1 and COX4+4L2) (Figure 5.27c), with fold decreases of 2.2 and 
5.5 in MTCO1 and 2.7 and 7.6 in COX4+4L2 for P13 and P14 respectively. Similar to other 
isolated deficiencies, an upregulation is seen in proteins associated with other unaffected 
complexes (Figure 5.27d). Interestingly P13 has an upregulation of all of the unaffected 
complexes, with fold increases of 1.1, 1.1, 1.5 and 1.5 for NDUFB8 (CI), SDHA (CII), 
UqCRC2 (CIII) and OSCP (CV) respectively whilst P14 only presents with an upregulation of 
complex III (a fold increase of 1.1 in UqCRC2) 
P15 and P16 have mutations affecting complex V with a nuclear-encoded mutation in TMEM70. 
Both patients present with a severe loss of the CV protein OSCP in comparison to the controls 
(Figure 5.27e) (fold decreases of 15.5 and 17.4 in P15 and P16 respectively). An upregulation 
of the unaffected CIII is also observed by an increase in UqCRC2 in both patients above the 
controls (fold increases of 1.1 and 1.3 for P15 and P16 respectively). Furthermore P15 also 
presents with an upregulation in CIV, seen by an increase in COX4+4L2 (Figure 5.27f). 
One interesting observation is that for all the patients with isolated complex deficiencies, similar 
to other patients in this chapter, there are differences in expression levels between both of the 
CI antibodies NDUFB8 and NDUFA13 as well as both of the CIV antibodies MTCO1 and 






Figure 5.27: Antibody expression in patients with isolated deficiencies. The mean expression of (a) 
SDHA (CII) in controls and patients with isolated complex II deficiency (P11 and P12), (b) all 
antibodies measured in controls and patients with isolated complex II deficiency (P11 and P12), (c) 
MTCO1 and COX4+4L2 (CIV) in controls and patients with isolated complex IV deficiency (P13 and 
P14), (d) all antibodies measured in controls and patients with isolated complex IV deficiency (P13 and 
P14), (e) OSCP (CV) in controls and patients with isolated complex V deficiency (P15 and P16) and (f) 
all antibodies measured in controls and patients with isolated complex V deficiency (P15 and P16). 
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5.4.11 Comparing imaging mass cytometry analysis to z-scores 
For data analysed using plotIMC, a fibre was defined as deficient if it falls below the 95% 
predictive interval for the controls, however this is not how deficiency has previously been 
described. Rocha et al. (2015) assessed z-scores as a measure of deficiency and classified fibres 
into four different groups dependant on these z-scores (Positive, int(+), int(-) and negative (see 
section 2.2.8 for detail)). A schematic of how z-scores and the 95% confidence interval is 
calculated is shown in Figure 5.28. 
 
Figure 5.28: z-score v 95% confidence interval. (a) Classification of deficiency based on z-score 
calculations; positive (z-score > -3SD), intermediate (+) (z-score between -3SD and -4.5SD), 
intermediate (-) (z-score between -4.5SD and -6SD) and negative (z-score < -6SD). (b) Classification 
of deficiency based on 95% confidence intervals. Solid black line indicates the mean of the controls 
while dashed lines indicates the upper and lower 95% confidence intervals. A fibre is classed as deficient 
if it lies outside the lower 95% confidence interval and is classified as upregulated if it lies outside the 




 Because of this, it was important to check how comparable the methods were by looking at 
how the level of deficiency varied in the patients when using both the 95% confidence interval 
and z-scores as a measure (Table 5.6). When investigating the z-scores, two groups were 
examined; deficient fibres, which were classed as fibres falling into any of the deficient 
categories (int(+), int(-) and negative), and negative fibres, which were any fibres falling 
exclusively into to the negative category (z-score < -6). Because the software that generates the 
z-scores uses a marker of mitochondrial mass to normalise the data, VDAC1 could not be 
analysed.  
The investigation into how the level of deficiency varied in the patients when using both the 
95% confidence interval and z-scores highlighted that the percentage of fibres classed as 
deficient did vary between the two methods and generally, the 95% confidence interval 
classifies a greater proportion of fibres as deficient compared to the z-scores. This is highlighted 
in Table 5.6, with higher percentage displayed in the red rows compared to both the other 
groups.   
However, the results demonstrate that when exploring the percentage of deficient fibres using 
the 95% confidence intervals compared to all the deficient categories using the z-score 
calculations (int(+), int(-) and negative), outcomes were similar. For example P01 has 100% 
NDUFB8 deficiency using the 95% interval and similarly 99.4% NDUFB8 deficiency when 
grouping all deficient z-score categories. This similarity was lost when exploring the 95% 
interval and any fibres falling exclusively into to the negative category – with the negative 
category producing much lower percentages (65.4% NDUFB8 deficiency in P01).  
From this we can conclude that the results generated from the IMC using the 95% confidence 
intervals as a cut-off for deficiency were comparable to the z-scores when the all the negative 
categories (int(+), int(-) and negative) are grouped together. This is further supported by a 
Pearson’s correlation of 0.98 between the two (Figure 5.29). 
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Table 5.6: z-scores vs 95% confidence interval. IMC data from all patients for all proteins analysed using two different methods. Table displays the percentage 
of fibres below the 95% confidence interval for each protein in each case as well as z-score data (percentage of fibres falling into deficient category (any fibre 





Figure 5.29:   Correlation of deficient fibres categorised by z-scores or 95% confidence interval. Each 
dot represents the percentage of fibres deficient for each protein measured in each patient using either 














The advent of IMC means that many proteins can be targeted simultaneously which will further 
the understanding of respiratory chain defects in skeletal muscle and the downstream effects 
they may cause. This technique is a major improvement on immunofluorescent techniques; I 
have studied the expression of nine proteins simultaneously in thousands of single skeletal 
muscle fibres sampled from 10 patients with mitochondrial disease. Furthermore, the bespoke 
analysis created for use with IMC moves away from arbitrary z-score classifications that are 
used in IF and which fail to allow for the possibility of upregulation or overexpression of 
proteins compared to controls. 
I  demonstrated that the technique was highly reproducible between both repeat runs when using 
the same reagents (correlation of 0.98) but was less so between the repeats when different 
reagents were used (correlations of 0.87), and it is hypothesised that this difference is due to 
differences in antibody batches. As a result of the conjugation process, antibody is lost, and the 
recovery rate of each antibody will differ with each conjugation. Because of their limited 
supply, each antibody had to be re-conjugated between the initial run and the subsequent repeat 
runs and thus the recovery rates will have differed. It is assumed that it is this difference in 
antibody recovery that led to the lower correlations between the initial and repeat runs as when 
the same antibody batches were used between the repeats, the correlation was strong. This 
observation will guide future experiments in ensuring there are sufficient antibodies stored for 
a number of linked experiments. Alternatively, each antibody could be titrated to the same 
working concentration to ensure the amount of antibody is consistent between experiments 
using different conjugation batches.  
The quality of the experiment is due, in part, to the quality of the antibodies that are used and 
therefore a crucial part in the development of this technique was the design of an antibody panel 
to run on the IMC. Since the technique would be used initially to assess respiratory chain 
deficiency in skeletal muscle it was important that the panel include a number of mitochondrial 
markers that targeted all five complexes of the respiratory chain as well as a good fibre 
membrane marker that would allow effective segmentation of individual cells. However all 
studies are limited by the antibodies that are available, and this study was no different. A 
determining factor in the inclusion of certain antibodies was whether they were available in a 
protein-free solution and as such, suitable antibodies may have been unavailable for use on 
IMC. Furthermore, as a result of the low recovery rate of some antibodies post-conjugation, a 
number of antibodies could not be included in the panel due to insufficient staining (see section 
166 
 
4.5.2). Both CI antibodies chosen (NDUFB8 and NDUFA13) target nuclear-encoded accessory 
subunits of CI and it has been revealed throughout this chapter that they detect differing levels 
of CI deficiency in a number of patients. Schematically shown in Figure 1.6, NDUFA13 is 
involved earlier in CI assembly upon the combining of Q and ND1-modules whilst NDUFB8 
is involved much later on in the process in the formation of the ND5-module (Guerrero-Castillo 
et al., 2017). What is unusual, is that the correlations between NDUFB8 and NDUFA13 vary 
between different patient groups; similar expressions of NDUFA13 and NDUFB8 are seen in 
fibres from CI patients (P01 and P02) and patients with mutations in other tRNA variants (P08, 
P09 and P10), whereas in fibres from the single, large-scale mtDNA deletion (P03 and P04) 
and MT-TL1 patients (P05, P06 and P07), NDUFA13 is expressed at higher levels than 
NDUFB8. Stroud et al. (2016) have previously demonstrated a stronger correlation of subunit 
stability within modules of CI than between modules, and this may explain the differences that 
are observed in this study. For m.3243A>G MT-TL1 patients, the only mtDNA encoded subunit 
that is incorporated into ND5-module other than NDUFB8 is ND5. The ND5 subunit requires 
104 Leucine tRNAs compared to, 12 Tryptophan, 9 Glutamic acid and 26 Glycine tRNAs 
meaning that the m.3243A>G MT-TL1 will have a much more substantial effect on this subunit 
than the other tRNA variants. Furthermore, because there are fewer (63) Leucine tRNAs 
required for ND1 (which is the only mtDNA encoded subunit in the ND1-module alongside 
NDUFA13) compared to ND5, it is hypothesised that m.3243A>G should have a greater impact 
on NDUFB8 stability than NDUFA13. In the single, large-scale mtDNA deletion patients, 
whilst multiple mtDNA encoded CI subunits and tRNAs are deleted, both patients have a 
deletion removing ND5 which will affect stability of the ND5-module containing NDUFB8, 
but neither affects ND1 which means the ND1-module containing NDUFA13 with be relatively 
more stable. Differences in expression were also observed between the two antibodies targeting 
CIV proteins (MTCO1 and COX4+4L2). MTCO1 is encoded by mtDNA while COX4 is 
nuclear-encoded and thus it not surprising that these antibodies behave different from one 
another – with COX4+4L2 revealing less deficiency than MTCO1 (Rahman et al., 2000). 
Unfortunately for both CIII and CV there are no good commercially available mitochondrial-
encoded subunit specific antibodies. The antibodies used target the nuclear-encoded proteins of 
CIII and CV (the core protein UqCRC2 and the structural protein OSCP respectively), both of 
which seem to be stable in the absence of mitochondrial encoded subunits and this may explain 
why in this study, and in previous studies using western blotting, both CIII and CV appear to 
be less affected in patients with mtDNA disease (Metodiev et al., 2016). Ideally, it is envisaged 
that future panels include antibodies that target both mtDNA-encoded and nuclear-encoded 
subunits of each complex so that potential discrepancies can be investigated.  
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What is encouraging about the technique is that the results generated in this chapter confirm 
biochemical phenotypes that have been previously reported.  Here, it is shown that using 
plotIMC, patients with nuclear-encoded CI assembly defects have 100% of fibres deficient for 
CI, consistent with previous findings (Ahmed et al., 2017, Alston et al., 2016). Although 
Mitocyto and plotIMC were not used to analyse the IMC data from patients with other isolated 
complex deficiencies (CII, CIV and CV), results still demonstrate a downregulation of proteins 
associated with the affected complex and further present with an upregulation in the non-
affected complexes in response to deficiency. P15 and P16 have isolated complex V deficiency 
due to a TMEM70 mutation and show a compensatory upregulation of CIII and IV which is 
consistent with previous findings (Havlickova Karbanova et al., 2012). Similarly P13 and P14 
with mutations affecting complex IV demonstrate an upregulation in CI, CIII and CV which is 
also consistent with previous data (Kovarova et al., 2012).  
A study by Rocha et al. (2018) found that patients with single, large-scale mtDNA deletions 
could be split into different classifications based on the size and location of the deletion and 
that these classes had distinct patterns of CI and CIV deficiency. In their work, a class I deletion 
caused equal levels of CI and CIV deficiency while a class II deletion caused greater deficiency 
in CI than CIV. In the study, P03 was defined as a class I deletion thus it is expected that fibres 
would have well correlated levels of CI and CIV deficiency which is consistent with the IMC 
data for this patient. Similarly, P04 was defined as a class II deletion, and so it would be 
expected that this patient would present with a proportion of fibres with only CI deficiency and 
a proportion of fibres with both CI and CIV deficiency and this observation is consistent with 
the IMC data also. It is demonstrated in this study that CI is more severely affected than CIV 
in patients with the m.3243A>G mutation, consistent with other research into these patients 
(Rocha et al., 2015).  
With regards to the patients with mutations in other mitochondrial-encoded tRNAs, although 
there have been no previous studies assessing the levels of individual complex proteins in 
individual muscle fibres, muscle homogenates showed CIV deficiency in patients with mt-
tRNA defects similar to those in this tRNA patient group (MT-TW (Anitori et al., 2005, 
Taivassalo et al., 2001), MT-TG (Bidooki et al., 1997) and MT-TE (Hao et al., 1995)). 
The direct effect that the tRNA mutation has on the deficiency of specific complexes will 
depend on which mtDNA subunits are most affected (based on the frequency at which that 
tRNA is required for a subunit). Here, it is interesting that the relative proportion of fibres 
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deficient for a particular complex seems to reflect the relative importance of the tRNA that is 
mutated in each complex.  
The whole idea that OXPHOS complexes can present a biochemical threshold effect, whereby 
a threshold proportion of mtDNA mutation must be achieved before fibres become deficient, 
has been described previously (reviewed by Rossignol et al. (2003)). Expanding on this, Rocha 
et al. (2018) found that the threshold required for the expression of a respiratory chain 
deficiency is different for complex I and complex IV – with a higher threshold needed for CIV. 
It appears as if this is paralleled in this study with most CIV-deficient fibres also deficient in 
CI in patients with mutations in mt-encoded tRNAs. A pattern is observed whereby fibres have 
highest levels of CI deficiency, followed by CIV then CIII. Furthermore, it is shown that a large 
proportion of CIV-deficient fibres are also deficient for CI and the same occurring between CIV 
and CIII. Although this is suggestive of a threshold mechanism, this is only one of a number of 
patterns observed in the data and without genetic analysis to assess the heteroplasmy of the 
individual fibres where this effect is occurring, firm conclusions cannot be drawn. That said, it 
would be interesting in the future to look at individual fibres at the genetic level so that the idea 
of a threshold effect can be investigated more thoroughly. 
Through examining further patients with isolated deficiencies, it was revealed that Mitocyto 
was not designed to segment fibres from paediatric cases and thus these images could not be 
analysed at a single cell level. Instead, the mean expression of each antibody was taken from 
the section as a whole, but reassuringly it was found that the expression of the antibodies 
targeting the relevant affected complex in each case was decreased below the controls.   Similar 
to the other patients, differences in expression were observed between the two antibodies 
targeting CIV proteins (MTCO1 and COX4+4L2), with less deficiency in COX4+4L2 than 
MTCO1. MTCO1 is mtDNA-encoded and is one of the initial subunits incorporated into CIV, 
around which the rest of the subunit is built.  Although COX4 associates with MTCO1 very 
early in complex assembly, it is nuclear-encoded and thus it not surprising that these antibodies 
behave different from one another. Furthermore, the COX4+4L2 antibody also targets both the 
COX4 and 4L2 isoforms which may explain why levels of COX4 are approximately double 
that of MTCO1.  
It has been clearly demonstrated that in patients with isolated complex deficiencies as well as 
patients with combined deficiencies, in fibres that are deficient in one or more OXPHOS 
complexes, there is a compensatory increase in OXPHOS complexes that are not directly 
affected by a mutation. Although previous studies report this in patients with isolated 
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deficiencies (CIV (Kovarova et al., 2012) and CV (Havlickova Karbanova et al., 2012)), the 
experiments are often carried out on cell lines, not in muscle tissue which is more clinically 
relevant, and not at a single cell level like is reported here.   
In the first instance, future work will look to optimise further antibodies for inclusion into the 
IMC panel. These will include antibodies that target mtDNA-encoded subunits of each 
respiratory chain complex in hope that these can be used alongside nuclear-encoded subunits 
to investigate respiratory chain deficiency more thoroughly in mitochondrial disease patients. 
Looking at these antibodies in patients with mutations such as a single, large-scale deletion will 
allow the determination of how the mutation is affecting each complex directly and if the size 
and location of the deletion impacts this. Furthermore, the investigation of nuclear-encoded 
proteins alongside the mtDNA-encoded proteins will advance the understanding of the 
importance of assembly factors to the overall functioning of a complex.  
Antibodies targeting a number of proteins involved in various signalling pathways will also be 
included to future panels. Signalling pathways to be explored will include biogenesis, 
mitophagy, glycolysis, protein synthesis and apoptosis and the investigation of these pathways 
will open up the opportunity to assess the downstream effect of respiratory chain deficiency on 
the cell.  It is known that deletions accumulate during ageing (Cortopassi and Arnheim, 1990) 
and thus it would be interesting to investigate both respiratory chain and signalling differences 
that are seen in “normal” ageing, compared to a patient with mitochondrial disease. Furthermore 
genetically assessing the heteroplasmy levels of these samples and how this correlates to 
changes in both respiratory chain deficiency and signalling could also be a direction of future 



































Chapter 6 : Optimisation of new antibodies targeting 
mtDNA-encoded proteins for use with 
























6.1.1 Advent of imaging mass cytometry 
Imaging mass cytometry utilises rare earth metals as reporters on antibodies instead of using 
conventional fluorophores (Giesen et al., 2014). This eliminates the complications behind 
spectral overlap that has previously resulted in a very limited number of parameters being 
investigated at one time and with the expansion of IMC, it is now possible to examine up to 
40+ parameters simultaneously (Chevrier et al., 2018). 
6.1.2 Limitations of validated antibodies and current imaging mass 
cytometry panel  
Every study is limited by the antibodies that are available. The OXPHOS system is comprised 
of five complexes – four of which are encoded, in part, by the mitochondrial genome. Therefore 
it would be ideal to have access to antibodies that target these mtDNA-encoded subunits for 
each complex, however to date, there have been no good working antibodies targeting these 
subunits for CI, CIII or CV and thus antibodies that target the nuclear-encoded subunits of these 
complexes have had to suffice.  
Two proteins commonly investigated when assessing CI deficiency are the accessory subunits 
NDUFB8 and NDUFA13. During assembly of the complex, NDUFA13 comes at the early 
stages of CI assembly where it is involved in the formation of the P-module while NDUFB8, 
although still part of the P-module, comes much later on in complex assembly. The findings 
from chapter 5 show that in a number of patients, different patterns of deficiency were seen 
between the two CI antibodies NDUFB8 and NDUFA13. By carrying out proteomic analysis 
on human knockout cell lines,  Stroud et al. (2016) had previously demonstrated that accessory 
subunits are associated into modules, and that there is a stronger correlation of subunit stability 
within a particular module rather than between different modules. Because of the variation 
observed between different accessory subunits, it is important to investigate mtDNA-encoded 
subunits in patients with mtDNA variants, and so alternative antibodies were suggested. ND2 
and ND4 are both mtDNA-encoded core subunits of complex I which are incorporated during 
the assembly of the membrane arm, specifically during the formation of the PP-b/PD-a 
intermediate (Guerrero-Castillo et al., 2017).  
A frequently used target to investigate CIII is the nuclear-encoded core protein UqCRC2 which 
is shown to be involved in the dimerization of the complex (reviewed by Signes and Fernandez-
Vizarra (2018)). Although it is demonstrated that CIII is less affected in mitochondrial disease 
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than the other complexes (reviewed by Fernández-Vizarra and Zeviani (2015)), it is still 
important to examine the changes seen in response to deficiency. CYB is the only mtDNA-
encoded subunit of CIII and is synthesised at the very start of assembly, therefore it is an ideal 
protein to assess CIII deficiency.  
CIV is the only complex for which there is a working, commercially-available antibody 
targeting an mtDNA-encoded subunit. MTCO1 is the largest catalytic subunit of CIV and is the 
“seed” around which the other subunits assemble. COX4 is nuclear-encoded and incorporates 
at the very early stages of complex assembly (Nijtmans et al., 1998). The results shown in 
chapter 5 highlighted the differences between these two proteins, with MTCO1 proving more 
affected than COX4 in disease.  
Similar to CIII, CV is less commonly affected in disease and it has been shown that in 
mitochondria lacking mtDNA (Rho0 cells), the complex can still assemble (Wittig et al., 2010). 
The reason for this may be that there are only two subunits encoded by the mitochondrial 
genome – ATP6 and ATP8, both of which are involved in the F0 sector of CV and are added at 
the later stages of the assembly process. Although a search was performed to find suitable 
antibodies that targeted these two subunits, no options appeared to work in skeletal muscle and 
so nuclear-encoded proteins such as OSCP (which is also involved in F0 sector) have been used 
to investigate deficiency instead.  
I wanted to not only test antibodies that targeted mtDNA-encoded proteins, but also to further 
investigate OXPHOS deficiency. One of the most commonly investigated groups of 
mitochondrial patients are those that present with single, large-scale mtDNA deletions. Work 
from Rocha et al. (2018) previously classified these patients into three classes based on the size 
and location of the mtDNA deletion. These classes were also shown to have distinct patterns of 
CI and CIV deficiency. More detail on these classes can be found in section 5.1. 
6.2 Aims 
The aim of this chapter was to optimise a set of new antibodies that target mtDNA-encoded 








6.3.1 Patient cohort 
Nine patients with single, large-scale mtDNA deletions (n=9) and one patient with multiple 
mtDNA deletions due to a nuclear-encoded POLG mutation were assessed alongside healthy 
controls. P01 was a post-mortem biopsy taken from a patient who had the defect in the gene 
POLG, whilst P02-P10 had a single, large-scale mtDNA deletion. Control tissue was acquired 
with prior informed consent from the distal part of the hamstring of patients undergoing anterior 
cruciate ligament surgery. Table 6.1 summarises all relevant clinical information for this 
chapter. All ethical approval can be found in section 2.2.1. 
6.3.2 Antibodies  
A full list of the antibodies used in this chapter are shown in Table 6.2 and Table 6.3. 
6.3.3 Muscle biopsy and cryosectioning  
Serial sections (6µm for IMC and 10µm for IF) were obtained from transversely orientated 
frozen muscle blocks as described in section 2.2.3.  
6.3.4 Preparation and imaging of samples for immunofluorescence 
Sections were prepared for immunofluorescence using the same protocol as described in section 
2.2.5 and imaged as described in section 2.2.6, following the protocol established by Rocha et 
al. (2015).   
6.3.5 Preparation and imaging of samples for imaging mass cytometry 
Sections were prepared for IMC using the protocol described in section 4.3.6.  The data 
generated from the imaging mass cytometer was initially opened in MCD viewer (Fluidigm) 
and subsequently exported as TIFF files for further analysis. Segmentation was performed on 
Mitocyto and analysis was carried out using the custom-built programme plotIMC as described 






Table 6.1: Patient information. Information on controls and patients detailing age, gender, clinical 
information and genetic defect. 
Subjects Gender Age Clinical information Genetic defect 
Controls     
C01  Female 23y n.a n.a 
C02  Male 22y n.a n.a 
C03  Female 23y n.a n.a 
Patient     




P02  Female 21y CPEO,myopathy, cerebellar ataxia, short stature (KSS) 
Deletion size: 4978bp 
Breakpoints: 8482-13460 
mtDNA deletion level: 87% 
P03  Female 43y CPEO, myopathy 
Deletion size: 4978bp 
Breakpoints: 8482-13460 
mtDNA deletion level: 73% 
P04  Female 48y CPEO, myopathy 
Deletion size: 4241bp 
Breakpoints: 9498-13739 
mtDNA deletion level: 39% 
P05  Female 26y CPEO, myopathy 
Deletion size: 4851bp 
Breakpoints: 10747-15598 
mtDNA deletion level: 71% 
P06  Female 26y CPEO, myopathy, deafness, diabetes 
Deletion size: 4641bp 
Breakpoints: 10946-15587 
mtDNA deletion level: 83% 
P07  Female 40y 
CPEO, myopathy, bulbar 
weakness, muscle atrophy, 
pigmentary retinopathy 
Deletion size: 2308bp 
Breakpoints: 12113-14421 
mtDNA deletion level: 90% 
P08  Female 28y CPEO, myopathy 
Deletion size: 7648bp 
Breakpoints: 6341-13989 
mtDNA deletion level: 33% 
P09  Male 31-34y CPEO, myopathy 
Deletion size: 7144bp 
Breakpoints: 5772-12916 
mtDNA deletion level: 36% 
P10  Male 59y CPEO, myopathy 
Deletion size: 5219bp 
Breakpoints: 6002-11221 
mtDNA deletion level: 15% 





Table 6.2: List of primary antibodies. Detail on antibody host, dilution and supplier is provided. 
Antibodies Host and isotype Dilution Company 
Protein target/ Primary 
antibodies 
      
Complex I: ND2  IgG2a 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Complex I: ND4  IgG2a 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Complex III: CYB  IgG2b 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Complex IV: MTCO1  IgG2a 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Complex V: ATP6  IgG2b 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Complex V: ATP8  IgG2b 1:100 Bespoke, courtesy of Dr 
Mike Marusich, University 
of Oregon 
Membrane marker: Laminin  Rabbit 1:50 Sigma-Aldrich (L9393) 
Membrane marker: Dystrophin  Mouse 1:50 EMD Millipore (Mab 
1645) 
Complex I: NDUFB8  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (110242) 
Complex I: NDUFA13  Mouse IgG2b 1:50 (IMC) 1:100 (IF) Abcam (110240) 
Complex II: SDHA Mouse IgG1 1:50 (IMC) Abcam (14715) 
Complex III: UqCRC2  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (14745) 
Complex IV: MTCO1  Mouse IgG2a 1:50 (IMC) 1:100 (IF) Abcam (14705) 
Complex IV: COX4+4L2 Mouse IgG2a 1:50 (IMC) 1:100 (IF) Abcam (110261) 
Complex V: OSCP  Mouse IgG1 1:50 (IMC) 1:100 (IF) Abcam (110276) 
Complex V: ATPB  Mouse IgG1 1:50 (IMC) Abcam (14730) 






Table 6.3: List of secondary antibodies. Detail on antibody host, dilution and supplier is provided. 
Antibodies Host Dilution Company 
Secondary antibodies    
Anti-rabbit Alexa Fluor 405nm Goat 1:100 Life Technologies (A31556) 
Anti-IgG2a Alexa Fluor 488nm Goat 1:200 Life Technologies (A21131) 
Anti-IgG2b Alexa Fluor 546nm Goat 1:200 Life Technologies (A21143) 
Anti-IgG1 biotin Goat 1:200 Life Technologies (A10519) 
Streptavidin Alexa Fluor 647nm Goat 1:100 Life Technologies (S32357) 
Anti-IgG1 Alexa Fluor 647nm Goat 1:200 Life Technologies (AA21240) 


















6.4.1 Testing new antibodies on control skeletal muscle tissue 
In the first instance, to assess whether the antibodies that target mtDNA-encoded proteins would 
be successful in labelling skeletal muscle tissue, each antibody was tested on control tissue at 
three different dilutions (1/200, 1/100 and 1/50) using the standard immunofluorescent protocol 
as described in section 2.2.5 (Figure 6.1). Exposure times were set based on there being no 
signal for each NPC. ND2 (Figure 6.1a), ND4 (Figure 6.1b), CYB (Figure 6.1c) and ATP8 
(Figure 6.1f) labelled specifically at all concentrations. MTCO1 (Figure 6.1d) and ATP6 
(Figure 6.1e) demonstrated very weak staining at a concentration of 1/200, but improved at 





Figure 6.1: Immunofluorescent staining on a control section using new antibodies targeting mtDNA-
encoded proteins. (a) ND2, (b) ND4, (c) CYB, (d) MTCO1, (e) ATP6 and (f) ATP8. All antibodies were 
used at three working concentrations (1/200, 1/100 and 1/50) and exposure times were set so that there 
was a lack of signal in the corresponding NPC. Scale bars: 50µm. 
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6.4.2 Testing new antibodies on patient skeletal muscle tissue  
After staining was successful on control muscle tissue, each antibody was further tested on post-
mortem skeletal muscle sections from a POLG patient at a dilution of 1/100. Each section was 
incubated with the antibody of interest and another known mitochondrial antibody for 
comparison (either MTCO1 or VDAC1 depending on the subtype of the new antibody). Table 
6.4 displays antibodies used in this experiment. The results are displayed in Figure 6.2 and 
demonstrate that all antibodies labelled the patient tissue successfully at 1/100; each antibody 
gave a good signal, the staining was specific and punctate, and each antibody produced labelling 
patterns expected of a patient with multiple mtDNA deletions.  
Table 6.4: Testing new antibodies using quadruple immunofluorescence. Each section was incubated 
with a new antibody that targeted mtDNA-encoded proteins and an old antibody targeting a nuclear-
encoded proteins for comparison. Each new antibody of interest is highlighted. Note that both an 
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Figure 6.2: Immunofluorescent staining of a patient section using new antibodies that target mtDNA-
encoded proteins. (a) ND2, (b) ND4, (c) CYB, (d) MTCO1, (e) ATP6 and (f) ATP8. All antibodies were 
used at a working concentration of 1/100 and incubated with another established mitochondrial 





6.4.3 Comparing established OXPHOS antibodies to new antibodies 
targeting mtDNA-encoded subunits 
Although it had now been established that the antibodies worked well in skeletal muscle, an 
important next step was to test them alongside recognised antibodies targeting the same 
respiratory chain complexes that are routinely used in the laboratory. Sections from a control 
and a patient case were incubated with each new antibody and a paired validated antibody 
targeting the same respiratory chain complex, at a dilution of 1/100 (Table 6.5) following the 
standard immunofluorescent protocol as described in section 2.2.5. It needs to be noted that 
because sections 1 and 2 included the NDUFB8 antibody, biotinylation was performed on these 
sections following the normal immunofluorescent protocol. Where there was an overlap in 
isotypes (for example the two MTCO1 antibodies), the antibody was used on serial sections so 
that comparisons could still be made. The sections were subsequently imaged as described in 
section 2.2.6 and exposure times were set based on there being no signal for each NPC. 
Table 6.5: Comparing antibodies that target mtDNA-encoded proteins with antibodies that target 
nuclear-encoded proteins against the same complex. Combination of antibodies used and subtype. 
Section 1 Section 2 Section 3 Section 4 Section 5 
ND2 (IgG2a) ND4 (IgG2a) Old MTCO1 (IgG2a) New MTCO1 (IgG2a) Old MTCO1 (IgG2a) 
VDAC1 (IgG2b) VDAC1 (IgG2b) CYB (IgG2b) ATP6 (IgG2b) ATP6 (IgG2b) 
NDUFB8 (IgG1) NDUFB8 (IgG1) UqCRC2 (IgG1) OSCP (IgG1) OSCP (IgG1) 
Laminin (rabbit) Laminin (rabbit) Laminin (rabbit) Laminin (rabbit) Laminin (rabbit) 
 
Results from the patient case (P01) are displayed in Figure 6.3 and demonstrate that labelling 
of the new antibodies targeting mtDNA-encoded proteins produced similar staining patterns to 
the old antibodies targeting the same complex when exposure times were kept constant. CYB 
and ATP8 were successful at targeting CIII and CV respectively, and worked better than the 
other antibodies for these complexes (UqCRC2 and OSCP respectively) (Figure 6.3c and 6.3f). 
The new MTCO1 antibody was not as strong as the old MTCO1 antibody in labelling CIV 
(Figure 6.3d), and this was the same for the CV antibody ATP6 when compared to OSCP 
(Figure 6.3e). ND2 and ND4 were successful in labelling CI (Figure 6.3a and 6.3b) and were 
equivalent to that of biotinylated NDUFB8 even without biotinylation.  
After imaging, individual fibres were segmented using the software described in section 2.2.7, 
and the expression level of each protein for each fibre was plotted. The expression levels from 
each new antibody were plotted against the old antibody and correlation coefficients were 
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assessed (Figure 6.4). Both CI antibodies ND2 and ND4 had a good correlations with NDUFB8 
(R²=0.91 and 0.84 respectively) (Figure 6.4a and 6.4b). Although still a positive correlation, 
CYB and ATP8 had a weaker relationship to their corresponding antibodies (R²=0.72 for CYB 
and R²=0.77 for ATP8) (Figure 6.4c and 6.4e). There was also a weak correlation between 
ATP6 and OSCP (R²=0.45) (Figure 6.4d). Assessment of the images revealed that the 
antibodies showing the lowest correlations (CYB, ATP6 and ATP8) were the same antibodies 
that showed the most variation in staining compared to their paired antibody and therefore it 
explains why the correlations are not as strong. Although both the validated and new MTCO1 
had the same subtype and were assessed on serial sections, correlations could not be acquired 




Figure 6.3: Immunofluorescent staining of P01 comparing new antibodies targeting mtDNA-encoded 
proteins with antibodies targeting nuclear-encoded proteins against the same complex. (a) ND2, (b) 
ND4, (c) CYB, (d) MTCO1, (e) ATP6 and (f) ATP8. All antibodies were used at a dilution of 1/100 and 
incubated with another antibody targeting the same respiratory chain target. Exposure times were set 




Figure 6.4: Antibody correlations. Correlations and subsequent R² values of new antibodies compared 
to a validated antibody targeting the same complex. (a) ND2 and NDUFB8 of complex I, (b) ND4 and 
NDUFB8 of complex I, (c) CYB and UqCRC2 of complex III, (d) ATP6 and OSCP of complex V and (e) 
ATP8 and OSCP of complex V. Each dot represents an individual fibre. Staining and analysis carried 
out on serial sections from P01 with a POLG mutation. 
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6.4.4 Expression of antibodies targeting mtDNA-encoded subunits for 
subsequent metal conjugation. 
Similar to the work undertaken in section 4.4.1.2, each new antibody that was included in the 
IMC panel were ranked based on their expression levels for the targeted protein. As previous, 
this was performed immunofluorescently on control muscle tissue. Following the protocol 
described in 2.2.5, each section was incubated with a different antibody at a concentration of 
1/100 followed by incubation with Alexa-Fluor 488nm. Sections were imaged as described in 
section 2.2.6 and exposure times were kept constant throughout. It was assumed the higher the 
intensity of the 488 channel, the higher the expression of the protein (Figure 6.5). As a 
comparison, two proteins from the previous panel that had different expression levels 
(NDUFA13 and MTCO1) were also included. 
 
Figure 6.5: Intensity of new antibodies that target mtDNA-encoded proteins. A graph displaying 
intensities of each antibody by measurement of the intensity of the 488nm channel. Each antibody is 
displayed as a separate strip and each dot represents an individual fibre. Red bars show the mean 
intensity for the given antibody. 
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Using the expression level data, each antibody was ranked so that an appropriate metal could 
be assigned. As there was already a CIV antibody in the panel (old MTCO1) as well as another 
CV antibody in the panel that worked better (ATP8), it was decided that MTCO1 and ATP6 
would not be included due to their weak staining pre-conjugation.  
The rankings of each new antibody alongside two validated antibodies already included in the 
panel are shown in Table 6.6.  
Table 6.6: Antibody rankings in muscle.  








The idea was to pair these new antibodies to corresponding metals in a way that essentially 
allows for three mitochondrial panels to be run – the previously established mitochondrial panel 
alone, a panel including the new antibodies that target mtDNA-encoded proteins, and a merge 
of the two that will include antibodies that target both a nuclear-encoded and mtDNA-encoded 
proteins in each complex. In order for this to be implemented successfully, careful panel design 
was needed to ensure that low abundance antibodies were tagged with metals that fell within 
the optimal detection range (153-176Da), but ensuring that no channel cross talk occurred. 
Figure 6.6 displays all antibodies that are being used with IMC currently alongside the new 
antibodies in question; green indicating the previously used antibodies and red indicating the 
new antibodies targeting mtDNA-encoded proteins. The panel used in this run is displayed in 
Table 6.7 and includes all the working new antibodies alongside the old ones where possible. 
Once the antibodies were paired to their respective metals, conjugations and subsequent testing 





Figure 6.6: Metal pairings. Antibodies and their corresponding metals. Antibodies are colour-coded; 
previously used antibodies (green) and new antibodies targeting mtDNA-encoded (red). Graph shows 
the optimum delivery of metals between the 153 and 176 Da range. 






6.4.5 Running the new antibodies with imaging mass cytometry 
A single transverse muscle section from nine patients with a single, large-scale mtDNA deletion 
were run on the imaging mass cytometer alongside three control cases. Each antibody was 
diluted 1/50. Each antibody from a representative control (Figure 6.7) and patient (Figure 6.8) 
is displayed and demonstrates successful staining of both the established antibodies as well as 
the antibodies that target mtDNA-encoded proteins.  
 
Figure 6.7: IMC images from C03. Pseudo-coloured images of C03. Each panel displays a different 






Figure 6.8: IMC images from P04. Pseudo-coloured images of P04. Each panel displays a different 





6.4.6 PlotIMC profiles from patients with single, large scale mtDNA 
deletions 
After confirming that the new antibodies worked well with both IF and IMC, the data could 
then be analysed in more depth. Once the images were segmented using the Mitocyto tool, 
plotIMC was used for all further analysis. At this point, it became apparent that the morphology 
of P08 was poor and because of this, P08 was removed from any subsequent analysis. 
 
Figure 6.9: Location of single, large-scale mtDNA deletions for P02, P03 and P04. Location and size 
of the mtDNA deletion from individual patients: P02 deletion size 4978bp, breakpoints: m.8482-13460, 
P03 deletion size 4978bp, breakpoints: m.8482-13460 and P04; deletion size 4241bp, breakpoints: 
m.9498-13739. The mtDNA is colour-coded by gene-type: CI genes; orange, CIII genes; red, CIV genes; 










Based on the work by Rocha et al. (2018), P02-P04 in this study were defined as class I deletions 
which removed regions m.8482-13460, m.8482-13460 and m.9498-13739 respectively in P02, 
P03 and P04 (Figure 6.9). Deletion levels varied between each patient; P02 had a deletion level 
of 87%, P03 had a deletion level of 73% and P04 has a deletion level of 39%. 
Typical of a class I deletion, P02 has an equal level of CI and CIV deficiency with 93.2% and 
93.5% of fibres below the 95% predictive interval for ND4 and MTCO1 respectively (Figure 
6.10 panels b + f). These high levels of deficiency are expected given the 87% deletion level 
in P02. While only ND4 is deleted, a strong correlation is seen between the two CI antibodies 
(0.95 between ND2 and ND4). There are also good correlations between the two CIII antibodies 
(0.98 between CYB and UqCRC2), and the two CIV antibodies (0.99 between MTCO1 and 
COX4+4L2). Although CYB is not deleted in this patient, a CIII deficiency is observed; 22.9% 
and 26.5% of fibres are below the 95% predictive interval for UqCRC2 and CYB respectively 
(Figure 6.10 panels d + e). This is to be expected given the contribution of the deleted tRNAs 
to complex III (discussed further in the discussion). The mtDNA deletion in P02 removes both 
CV genes, and this is reflected by a CV deficiency where 54.1% of fibres fall below the 95% 
predictive interval for ATP8 (Figure 6.10 panel i). This is less obvious using ATPB where 
only 10.4% of fibres are classed as deficient (Figure 10 panel h). Assessing the 2Dmito plot 
for SDHA, there appears to be a change in patient fibres compared to controls; patient fibres 
are shifted to the right of the controls – indicative of increased VDAC1. Because of this shift, 
although SDHA levels are similar between patients and controls, 10.4% of fibres fall below the 






Figure 6.10: 2Dmito plot from P02 with a single, large-scale mtDNA deletion removing regions 
m.8482-13460. 2Dmito plots from P02 comparing OXPHOS targets against VDAC1: (a) ND2, (b) ND4, 
(c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual single-
cell IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for that fibre. 
Regression through the control data is drawn as a solid grey line and the 95% predictive interval for 
control fibres lies between the dashed grey lines. Total number of fibres above and below the control 







Although previously identified as a class I deletion, P03 presents with higher levels of CIV 
deficiency (51.7% of fibres below the 95% predictive interval for MTCO1 (Figure 6.11 panel 
f)) compared to CI (31.5% of fibres below the 95% confidence interval for ND4 (Figure 6.11 
panel b)). Although only ND4 is deleted, there is a good correlation between the two CI 
antibodies ND2 and ND4 (0.96), the two CIII antibodies CYB and UqCRC2 (0.94), and the 
two CIV antibodies MTCO1 and COX4+4L2 (0.98), as previously seen. Similar to P02, 
although CYB is not deleted in this patient, a CIII deficiency is observed (19.9% and 11.1% of 
fibres below the 95% predictive interval for UqCRC2 and CYB respectively (Figure 6.11 
panels d and e)). Furthermore, as a result of both CV genes being deleted, a downregulation 
of CV is demonstrated by 42.3% of fibres below the 95% predictive interval for ATP8 (Figure 
6.11 panel i). This is less obvious using ATPB (Figure 6.11 panel h) where only 0.3% of fibres 
are classed as deficient. Looking at the 2Dmito plot for SDHA, there is a population of fibres 
that have an upregulation in CII above controls; 4.6% of fibres lie above the 95% predictive 




Figure 6.11: 2Dmito plot from P03 with a single, large-scale mtDNA deletion removing regions 
m.8482-13460. 2Dmito plots from P03 comparing OXPHOS targets against VDAC1: (a) ND2, (b) ND4, 
(c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual single-
cell IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for that fibre. 
Regression through the control data is drawn as a solid grey line and the 95% predictive interval for 
control fibres lies between the dashed grey lines. Total number of fibres above and below the control 







P04 follows a more typical biochemical phenotype of a class I deletion; with equal amounts of 
CI and CIV deficiency; 29.2% and 22.0% of fibres below the 95% predictive interval for ND4 
and MTCO1 respectively (Figure 6.12 panels b and f). Again, there is a strong correlation 
between the two CI antibodies ND2 and ND4 (0.96) even though only ND4 is deleted. There 
are also strong correlations between the two CIII antibodies CYB and UqCRC2 (0.97) as well 
as the two CIV antibodies MTCO1 and COX4+4L2 (0.99). Low levels of deficiency are seen 
for both CIII (7.6% and 8.4% of fibres below the predictive interval for UqCRC2 and CYB 
respectively (Figure 6.12 panels d and e)) and CV (5.8% of fibres below the 95% predictive 
interval for ATP8 (Figure 6.12 panels i)) – however these are expected given the size and level 
of the mtDNA deletion. Similar to P01, the 2Dmito plot for SDHA is shifted right for patient 
fibres compared to controls which implies that there is an increase in VDAC1. Although it 
appears that patient fibres have increased levels of SDHA relative to controls (demonstrated by 
an upwards shift in a number of fibres), because of the right shift in VDAC1, 6.2% of fibres 
fall below the 95% predicative interval (Figure 6.12 panel c). The lower levels of deficiency 







Figure 6.12: 2Dmito plot from P04 with a single, large-scale mtDNA deletion removing regions 
m.9498-13739. 2Dmito plots from P04 comparing OXPHOS targets against VDAC1: (a) ND2, (b) ND4, 
(c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual single-
cell IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for that fibre. 
Regression through the control data is drawn as a solid grey line and the 95% predictive interval for 
control fibres lies between the dashed grey lines. Total number of fibres above and below the control 







Figure 6.13: Location of single, large-scale mtDNA deletions for P05, P06 and P07. Location and 
size of the mtDNA deletion from individual patients: P05 deletion size 4851bp, breakpoints: m.10747-
15598, P06 deletion size 4641bp, breakpoints: m.10946-15587 and P07; deletion size 2308bp, 
breakpoints: m.12113-14421. The mtDNA is colour-coded by gene-type: CI genes; orange, CIII genes; 
red, CIV genes; green, CV genes; blue and tRNA genes (dark blue). 
As shown in the work by Rocha et al. (2018), P05-P07 are defined as class II deletions which 
removed regions m.10747-15598, m.10946-15587 and m.12113-14421 in P05, P06 and P07 
respectively (Figure 6.13). All patients presented with high deletion levels of 71%, 83% and 
90% in P05, P06 and P07 respectively.   
As a class II deletion, it is expected that there is a higher level of CI deficiency in comparison 
to CIV. This is well exemplified in P05; 65.1% of fibres are below the 95% predictive interval 
for ND4 (Figure 6.14 panel b) compared to 33.8% for MTCO1 (Figure 6.14 panel f). 
Consistent with previous patients, although only ND4 is deleted, there is strong correlation 
between the two CI antibodies ND2 and ND4 (0.97). The two CIII antibodies CYB and 
UqCRC2 (0.98), and the two CIV antibodies MTCO1 and COX4+4L2 (0.98) also have strong 
correlations. A high level of CIII deficiency is observed with 56.9% of fibres below the 95% 
predictive interval for CYB (Figure 6.14 panel e). This is slightly lower than UqCRC2 where 
63.8% of fibres fall below the predictive interval (Figure 6.14 panel d). This is unexpected 
given that the mtDNA deletion in P05 removes CYB and thus it is anticipated that a CIII 
deficiency is displayed – with CYB presenting higher levels than UqCRC2. The mtDNA 
deletion does not affect any CV genes and this is reflected by the low levels of CV deficiency 
199 
 
observed; only 8.3% of fibres fall below the 95% predictive interval for ATP8, which is thought 
to be a result of the deletion of tRNAs that are important for the translation of ATP8 (Figure 
6.14 panel i). Although only a small percentage of fibres, a change is seen in CII relative to the 
control population, with 1.5% of fibres above and 1.7% of fibres below the 95% predictive 
intervals respectively (Figure 6.14 panel c). 
 
Figure 6.14: 2Dmito plot from P05 with a single, large-scale mtDNA deletion removing regions 
m.10747-15598. 2Dmito plots from P05 comparing OXPHOS targets against VDAC1: (a) ND2, (b) 
ND4, (c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual 
single-cell IMC measurements from each patient is represented by a coloured point in each panel.  
Control observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for 
that fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive 
interval for control fibres lies between the dashed grey lines. Total number of fibres above and below 
the control predictive interval are written above each panel. 
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P06 shows the typical biochemical phenotype of a class II deletion; 61.4% of fibres fall below 
the 95% predictive interval for ND4 (Figure 6.15 panel b) compared to 36.1% for MTCO1 
(Figure 6.15 panel f). The mtDNA deletion removes CYB and thus a CIII deficiency is 
observed (51.9% of fibres are below the 95% predicative interval for CYB (Figure 6.15 panel 
e)). This is marginally lower using UqCRC2 as a marker (48.7%) (Figure 6.15 panel d), which 
is expected given that UqCRC2 is nuclear-encoded. Although both CV genes are preserved, a 
complex V deficiency is observed using the mitochondrial marker ATP8 (17.9% of fibres fall 
below the 95% predictive interval (Figure 6.15 panel i)) but not when using ATPB (Figure 
6.15 panel h). Looking at the 2Dmito plot for SDHA, there is an upwards shift in patient fibres 
compared to controls; 5.1% of fibres lie above the 95% predictive interval for SDHA, indicative 
of CII upregulation (Figure 6.15 panel c). There is a good correlation between the two 
antibodies targeting CI (correlation of 0.97 between ND2 and ND4), CIII (correlation of 0.99 






Figure 6.15: 2Dmito plot from P06 with a single, large-scale mtDNA deletion removing regions 
m.10946-15587. 2Dmito plots from P06 comparing OXPHOS targets against VDAC1: (a) ND2, (b) 
ND4, (c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual 
single-cell IMC measurements from each patient is represented by a coloured point in each panel.  
Control observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for 
that fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive 
interval for control fibres lies between the dashed grey lines. Total number of fibres above and below 







Similar to P05 and P06, P07 has a larger proportion of fibres deficient for CI than CIV (96.4% 
of fibres below the 95% predictive interval for ND4 compared to 58.2% for MTCO1 (Figure 
6.16 panels b and f)). Although CYB is preserved, a large CIII deficiency is observed; 39.7% 
and 47% of fibres are below the 95% predictive interval for UqCRC2 and CYB respectively 
(Figure 6.16 panels d and e). There are low levels of CV deficiency (7.8% and 12.5% of fibres 
lie below the 95% predictive interval for ATPB and ATP8 respectively (Figure 6.16 panels h 
and i)) which is expected given that both ATP6 and ATP8 genes are preserved. VDAC1 is 
increased in patient fibres compared to controls and this is demonstrated by a right shift in the 
2Dmito plot. Because of this, although a large proportion of patient fibres have an increased 
SDHA expression level above the controls (demonstrated by an upwards shift in Figure 6.16 
panel c, 12.7% of fibres fall below the 95% predictive interval for SDHA. The correlations 
between antibodies targeting the same complexes are strong (0.92 between ND2 and ND4 (CI), 





Figure 6.16: 2Dmito plot from P07 with a single, large-scale mtDNA deletion removing regions 
m.12113-14421. 2Dmito plots from P07 comparing OXPHOS targets against VDAC1: (a) ND2, (b) 
ND4, (c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual 
single-cell IMC measurements from each patient is represented by a coloured point in each panel.  
Control observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for 
that fibre. Regression through the control data is drawn as a solid grey line and the 95% predictive 
interval for control fibres lies between the dashed grey lines. Total number of fibres above and below 








Figure 6.17: Location of single, large-scale mtDNA deletions for P09 and P10. Location and size of 
the mtDNA deletion from individual patients: P09 deletion size 7144bp, breakpoints: m.5772-12916 and 
P10; deletion size 5219bp, breakpoints: m.6002-11221. The mtDNA is colour-coded by gene-type: CI 
genes; orange, CIII genes; red, CIV genes; green, CV genes; blue and tRNA genes (dark blue). 
Based on the work by Rocha et al. (2018), P09 and P10 are defined as class III deletions which 
removed regions m.5772-12916 and m.6002-11221 in P09 and P10 respectively (Figure 6.17). 
Both patients have low deletion levels of 36% and 15% in P09 and P10 respectively.  
Typical of a class III deletion, P09 (Figure 6.18) has higher levels of CIV deficiency than CI; 
31.4% of fibres are below the 95% predictive interval for ND4 (Figure 6.18 panel b) compared 
to 38.1% for MTCO1 (Figure 6.18 panel f). There is a strong correlation (0.97) between the 
two CI antibodies, with both ND2 and ND4 showing equal levels of deficiency despite only 
ND4 being deleted. There are also good correlations between both CIII antibodies CYB and 
UqCRC2 (1.0) and both CIV antibodies MTCO1 and COX4+4L2 (0.99). CYB is preserved in 
this deletion, so it is not surprising that only low levels of CIII deficiency is seen (9.4% and 
5.4% of fibres below the 95% predictive interval for UqCRC2 and CYB respectively (Figure 
6.18 panels d + e). Although there is some CV deficiency (22.4% of fibres below the 95% 
predictive interval for ATP8 (Figure 6.18 panel i)), this is lower than what is expected given 
that the mtDNA deletion removes both CV genes. However this result may reflect the mtDNA 
deletion level of the patient, with P09 presenting with a low mtDNA deletion level of 36%. A 
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total of 20.6% of fibres fall below the 95% predictive interval for SDHA (Figure 6.18 panel 
c), however, as demonstrated in P01, P04 and P07, this may be a result of patient fibres having 
higher levels of VDAC1 compared to controls (shown by a shift right in Figure 6.18 panel c). 
 
Figure 6.18: 2Dmito plot from P09 with a single, large-scale mtDNA deletion removing regions: 
m.5772-12916. 2Dmito plots from P09 comparing OXPHOS targets against VDAC1: (a) ND2, (b) ND4, 
(c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual single-
cell IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for that fibre. 
Regression through the control data is drawn as a solid grey line and the 95% predictive interval for 
control fibres lies between the dashed grey lines. Total number of fibres above and below the control 




Consistent with P09, P10 (Figure 6.19) has a larger proportion of fibres deficient for CIV than 
CI (62.1% of fibres fall below the 95% predictive interval for MTCO1 compared to 54.7% for 
ND4 (Figures 6.19 panels b and f)). Although there are good correlations between the two CI 
antibodies (0.98), higher levels of deficiency are seen with ND4 (54.7%) compared to ND2 
(36.7%). This is also the case for both CIV antibodies with COX4+4L2 displaying a higher 
level of deficiency than MTCO1 (76% and 62.1% respectively) despite a very strong correlation 
(0.99). Although CYB is not deleted, CIII deficiency is observed, however there is great 
variability between the two CIII antibodies; UqCRC2 indicates 66.6% of fibres fall below the 
95% predictive interval (Figure 6.19 panel d) and this is much lower using CYB (32.2% of 
fibres fall below the 95% predictive interval (Figure 6.19 panel e)). This is not reflected in the 
correlation matrix, with a strong correlation between the two (0.99). There are high levels of 
CV deficiency which is expected given both CV genes are removed; 53.9% of fibres fall below 
the 95% predictive interval for ATP8 (Figures 6.19 panel i). 11.2% of fibres fall below the 




Figure 6.19: 2Dmito plot from P10 with a single, large-scale mtDNA deletion removing regions: 
m.6002-11221. 2Dmito plots from P10 comparing OXPHOS targets against VDAC1: (a) ND2, (b) ND4, 
(c) SDHA, (d) UqCRC2, (e) CYB, (f) MTCO1, (g) COX4+4L2, (h) ATPB, (i) ATP8. Individual single-
cell IMC measurements from each patient is represented by a coloured point in each panel.  Control 
observations are in grey.  Points representing patient fibres are coloured for by theta ND2 for that fibre. 
Regression through the control data is drawn as a solid grey line and the 95% predictive interval for 
control fibres lies between the dashed grey lines. Total number of fibres above and below the control 






The aim of this chapter was to optimise six antibodies that targeted mtDNA-encoded proteins 
for use with both IF and IMC, and the results presented throughout demonstrate that this aim 
was met. Four out of the six antibodies were successful with both immunofluorescence and 
IMC, and were comparable with other antibodies that target the same respiratory chain 
complexes. Both ND2 and ND4 were better at successfully labelling CI than biotinylated 
NDUFB8. Additionally, CYB and ATP8 stained better than both their nuclear-encoded 
counterparts (UqCRC2 and OSCP respectively). 
The advantages of plotIMC as an analysis tool means that protein levels from all five OXPHOS 
complexes are examined in thousands of cell simultaneously. It is reassuring to note that 
generally, with the exception of P03, the pattern of CI and CIV deficiency seen in these patients 
parallels what is expected given their class of deletion (as determined by Rocha et al. (2018)). 
Furthermore, deficiency in the less commonly studied complexes (CIII and CV), fit what is 
expected given the size and location of each deletion.  
Interestingly, six out of the eight patients (P02, P03, P04, P07, P09 and P10) present with a 
down regulation in complex III, despite the relevant deletions having no effect on the CYB 
gene. It is hypothesised that this CIII deficiency may be driven by the removal of tRNAs that 
are essential for the translation of CYB. Table 6.8 displays each tRNA and their relative 
involvement with each of the 13 mitochondrial genes. Of the 380 amino acids that are needed 
for CYB to function, P02-P04 have deletions that consistently removes 9% of these (35 tRNAs; 
L, S, H R and G), P07 has a deletion that removes 28.4% of these (108 tRNAs; E, L, S and H), 
P09 has a deletion that removes 59.7% of these (227 tRNAs; L, S, H, R, G, K, D, S, Y, C, N 
and W) and P10 has a deletion that removes 20.8% of these (79 tRNAs; R, G, K, D and S). This 
suggests that although the CYB gene is preserved, the elimination of a number of tRNAs 
important for the translation of CYB means that CIII is not completely functional, hence why 
a deficiency is detected. Furthermore, the percentage of deficiency that is detected will depend 








Table 6.8: tRNAs required for the translation of each mitochondrial gene. Each column displays the 
number of each different tRNA that is needed for the translation of each mitochondrial gene (displayed 
in each row). The overall number of tRNAs needed for the translation of each gene is also displayed in 
brackets. Data sourced from Smith and Robinson (2016). 
 
Although well correlated, the level of deficiency detected by the two CIII antibodies UqCRC2 
and CYB differs. CYB is encoded by the mtDNA whist UqCRC2 is a nuclear protein, therefore 
it is expected that if there are differences in the level of deficiency, because the mtDNA 
deletions will most likely affect mtDNA-encoded genes to a greater extent than nuclear genes, 
a higher level of deficiency will be detected using CYB compared to UqCRC2. Unusually, this 
appears to vary between patients; P02, P04, P06, P07 show higher levels of CIII deficiency 
using CYB compared to UqCRC2, whilst P03, P05, P09 and P10 show higher levels of CIII 
deficiency using UqCRC2 compared to CYB. It is unclear as to why this occurs and further 
investigation will need to be carried out to determine the cause of this. 
The results demonstrate a very good correlation between the two CI antibodies ND2 and ND4, 
despite ND4 being the only subunit of the two that is deleted in the majority of patients. 
Although Stroud et al. (2016) suggests that subunits within the same assembly intermediate 
modules will impact one another, ND2 and ND4 are part of different assembly intermediate 
modules and thus does not explain why such a good correlation is seen. However, it may be 
that the ND4 deletion is having some influence on ND2 expression due to the interaction of the 
modules. In support of this observation, previous studies have demonstrated that other complex 
I subunits (including ND2) are strongly reduced in cells lacking ND4 (Hofhaus and Attardi, 
1993, Hofhaus and Attardi, 1995).  
Most intriguingly, a lower level of SDHA relative to VDAC1 was seen in a number of these 
patients, compared to the controls. Although there is limited research into CII, this result 
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contradicts previous work that suggests that CII is either typically unaffected by impaired 
mtDNA, or increased as a result of mitochondrial biogenesis (Edgar et al., 2009, Ross et al., 
2010). This increase was also demonstrated in the work described in chapter 5.  
In this cohort of patients with single, large-scale deletions, there are a number of fibres that fall 
below the 95% predictive interval for SDHA. Whilst fibres falling below this interval are 
normally classed as deficient, it is hypothesised that for SDHA this may not be true deficiency, 
but a result of how the data is statistically analysed. To calculate the 95% predictive intervals, 
a crude linear regression is assumed and the model does not take into account that the data may 
be different shapes; this will affect how many fibres fall above, below or within the predicative 
interval and thus will affect what is classed as SDHA deficient. This is supported by looking 
more closely at the 2Dmito plots. Fibres deficient in other complexes arrange in a “v-shaped” 
manner, one group in which the relationship between the antibody signal and VDAC1 signal 
resembles a control patient, and another group where the signal is much lower (see section 
5.4.9). This is not the case for SDHA deficient fibres, which follow the line of the controls but 
fall just below the 95% predictive interval. Furthermore, the patients with SDHA deficiency 
tend to be the same patients that have a shift in the level of VDAC1 higher than the control 
population – indicative of increased mitochondrial mass or ragged red fibres. This shift suggests 
that the SDHA deficiency may not be “real” but may be a product of disconnect between SDHA 
and VDAC1 expression – with VDAC1 expression increasing disproportionally to SDHA. 
Moreover, the analysis used with plotIMC is designed in such a way that all proteins are 
corrected for mitochondrial mass by normalising to the VDAC1 channel. This means that 
although there may be ragged red fibres present (a common occurrence in patients with single, 
large-scale deletions (Pitceathly et al., 2012)), these will not be detected quantitatively and thus 
may also be a reason for the disconnect between SDHA and VDAC1. If the 95% predictive 
intervals are ignored and the raw shape of the data is examined, selecting CI and CIV deficient 
fibres reveals the highest levels of SDHA. This is not entirely consistent between patients, but 
is expected given the variation in the size and location of the different deletions – more 
consistent with previous work.  
The advantages of IMC means that a great number of proteins can be examined simultaneously.  
The addition of antibodies targeting mtDNA-encoded proteins together with the panel of 
antibodies that target nuclear proteins only strengthens this advantage and allows a number of 
different research avenues to be explored.  
The analysis carried out in conjunction with plotIMC has proven effective in detecting both 
upregulation and downregulation of respiratory chain proteins. However, throughout this 
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chapter there has been evidence indicating that this analysis may present some limitations 
moving forward. The way in which the 95% predictive intervals are calculated means that any 
data which does not follow a crude linear regression could be affected; impacting the level of 
deficiency by influencing how many fibres lie above, below or within the interval. Future work 
may look to solve this by deducing an alternative model that classifies dysfunction in ways that 
are not solely based on a linear regression. 
The work carried out in Chapter 5 revealed that in patients with combined deficiencies, 
OXPHOS complexes could present a biochemical threshold effect, whereby a threshold 
proportion of mtDNA mutation must be achieved before fibres become deficient. Furthermore, 
it was found that this threshold differed for each complex. In line with this work, it would be 
interesting to carry out mtDNA threshold analysis in this cohort of single, large-scale mtDNA 
patients. This would involve carrying out genetic analysis alongside IMC to determine the 


































































































Mitochondrial diseases are a group of heterogeneous genetic disorders that are characterised by 
defects in oxidative phosphorylation and can be attributed to mutations in either mitochondrial 
(mtDNA) or nuclear DNA (Gorman et al., 2016). The skeletal muscle is one of the most energy 
demanding tissues in the body and because of this, it is not surprising that respiratory chain 
deficiency in skeletal muscle is often a consequence of mitochondrial disease. Due to the 
heteroplasmic nature of mtDNA, respiratory chain deficiency arises in a mosaic pattern and 
these levels of deficiency in individual fibres can now be accurately quantified (Rocha et al., 
2015). However, due to limitations of current techniques, it is still challenging to 
simultaneously investigate the OXPHOS deficiency of all complexes. As such, this research 
was aimed to develop a technique that overcomes this limitation and successfully quantifies 
mitochondrial dysfunction of all complexes simultaneously in human skeletal muscle.  
7.1 Main findings 
7.1.1 Mitochondrial function is maintained in active 85 year old adults  
Previously, research looking into mitochondrial dysfunction in older individuals has 
demonstrated increased levels of respiratory chain deficiency with advancing age (reviewed by 
Larsson (2010)). Furthermore, it has been shown that physical activity can increase the 
oxidative capacity of the muscle (reviewed by Rogers and Evans (1993)), and can attenuate any 
age related symptoms. However, there are very few studies that have looked at very old 
participants, and often, relevant studies typically have a mean age below 85 years (Spendiff et 
al., 2016, Rygiel et al., 2017). The most interesting finding from work presented in Chapter 3 
is that active individuals in their 85th year of life and who engage in regular physical activity, 
have levels of respiratory chain deficiency comparable to young healthy controls.  
7.1.2 Imaging mass cytometry can be used to successfully assess OXPHOS 
deficiency in single skeletal muscle fibres and is comparable to other 
techniques.  
Imaging mass cytometry is a technique that has been adapted to accurately quantify a number 
of different proteins simultaneously within skeletal muscle. Furthermore, the development of 
subsequent novel analysis has permitted the interactive investigation of these proteins on a 
single cell level and offers the opportunity to answer key mechanistic questions such as: which 
complex(es) is/are affected by particular nuclear and mtDNA mutations?; what is the 
relationship between each of the individual complexes?; is there a change in the unaffected 
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complex(es) in response to respiratory chain deficiency?; is deficiency the same in all fibres or 
do individual fibres respond differently? 
Regarding the validity of IMC, this work has shown that the technique is comparable to the 
established quadruple immunofluorescent assay and demonstrates that the biochemical profiles 
from patients with varying mitochondrial mutations are similar between the two methods. 
Furthermore, the reproducibility of the technique is strong - particularly between the same 
batches of conjugated antibody.  
7.1.3 IMC can deduce different OXPHOS phenotypes in different patient 
groups. 
Through the use of IMC, this work has shown that patients with different nuclear and mtDNA 
variants present with different OXPHOS deficiency phenotypes that are reflective of their 
respective mutations. Furthermore, for the first time, patients with CI deficiency present with 
an upregulation of proteins involved in unaffected respiratory chain complexes and in most 
cases, this upregulation correlates with the level of deficiency. Although this occurs in CII-CV, 
this is demonstrated most strongly in CII by an increase in SDHA. It could be that this is a 
compensatory response to deficiency and is seen more strongly in CII as this complex acts as 
the only second entry point for electrons entering the electron transport chain when CI is not 
available. 
7.1.4 Successful identification and optimisation of antibodies targeting 
mtDNA-encoded OXPHOS subunits. 
Previously, there have been limited antibodies that target mtDNA-encoded subunits of the 
OXPHOS protein complexes efficiently and thus deficiency has been studied primarily using 
antibodies that target the nuclear-encoded subunits of each complex. This work has now 
identified and optimised working antibodies targeting these mtDNA-encoded subunits and has 
shown that they are successful in labelling skeletal muscle using both immunofluorescence and 
imaging mass cytometry.  
7.1.5 The biochemical profiles of single, large-scale mtDNA deletion 
patients correlate well with the size and location of the respective 
deletions. 
Through IMC, proteins involved in all five complexes of the respiratory chain can now be 
examined. The work presented in Chapter 6 investigated a cohort of patients with single, large-
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scale mtDNA deletions, using antibodies that targeted both nuclear and mtDNA-encoded 
proteins. It was revealed that the deficiency observed in these patients matched their respective 
mtDNA deletions and correlated well with what genes were affected. Furthermore, complex III 
deficiency was detected in patients where the deletion did not encompass CYB. It is 
hypothesised that this is caused by the removal of tRNAs that are essential for the translation 
of CYB, and thus highlights the importance of tRNA involvement for the functioning of each 
complex. 
7.2 Advantages of imaging mass cytometry 
The main focus of this thesis has been to develop and optimise the use of IMC to examine 
proteins within skeletal muscle. There are a number of characteristics that makes IMC 
advantageous over other imaging techniques. Because the antibodies are conjugated to heavy 
metal isotopes that do not suffer from the same degree of signal overlap as fluorochromes, IMC 
allows simultaneous multiplex assessment of many more protein targets than is possible with 
immunofluorescent techniques in a single tissue section.  This not only preserves valuable 
samples by reducing the amount of tissue that is required, but also eliminates the need for serial 
sections - removing any potential for discrepancies between sections and the potential for 
“batch effects”. The removal of fluorochromes also eliminates any sample autofluorescence 
and fluorescent background signal. Moreover, the automated capacity of IMC means that user 
subjectivity is minimised and the efficiency of each experiment is improved -with experiments 
being completed more quickly.  
Alongside Dr Conor Lawless, I have designed and implemented novel analysis tools which 
permits the analysis of many targets simultaneously at a single fibre level. Mitocyto enables 
successful automatic single fibre segmentation. This means that analysis is more standard 
between users and also much quicker than other available software. Furthermore, the tool 
permits manual intervention when needed, thus ensuring only fibres that should be included are 
further analysed. Additionally, the interactive nature of the plotIMC means that users can 
manually select fibres of interest from each patient and examine the protein levels of those 
fibres across all of the different channels - allowing thousands of measurements to be extracted 
at one time. 
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7.3 Disadvantages of imaging mass cytometry  
IMC is not without its limitations and throughout its development, a number of problems have 
arisen. Unlike conventional immunohistochemistry, antibodies that are compatible with IMC 
are not readily available and often, bespoke antibodies are required, which is both time 
consuming and expensive. However, with the expansion of IMC as an imaging technique, it is 
envisaged that biotechnology companies will produce more IMC-ready antibodies which will 
be more easily accessible and eliminate the need for customised ordering. Furthermore, it has 
been found that the conjugations of the metal lanthanides have an impact on the antibodies, 
with large amounts being lost during the process. This not only has costing implications, but 
also means that higher concentrations need to be used in order for the antibody to work 
correctly. 
Whilst a much greater number of targets can be assessed simultaneously, there are still 
limitations surrounding IMC panel design. Although there is no fluorescent signal overlap 
between fluorochromes, there is the potential for cross talk between the different metal 
channels. Therefore, it is crucial that panels are carefully considered to minimise this risk, and 
it may be that a smaller number of proteins can be assessed in one section than was initially 
thought possible. 
The protocol for frozen tissue preparation required for IMC is comparable to the preparation 
used for immunofluorescence, in that it is both quick and easy to undertake. However, as it is 
envisaged that this technique will be used in other tissue types including Formalin-Fixed 
Paraffin-Embedded (FFPE) tissue, as well as in cell work, the protocol will require alterations 
to accommodate these changes. Furthermore, a number of antibodies that will be included in 
future panels (for example antibodies that target phosphorylated targets) will need an alternative 
staining preparation compared to the current panel, therefore serial sections will need to be used 
to ensure all targeted antibodies can be used.  
The development of Mitocyto and plotIMC have surpassed previous analyses software and have 
permitted the interactive assessment of many proteins simultaneously. However, throughout 
this thesis it has come to light that these analysis programmes also present some disadvantages. 
Mitocyto was built to allow automatic segmentation of individual muscle fibres, and although 
a larger proportion of fibres are segmented automatically using this compared to other software, 
there is still the occasional need for manual intervention. Furthermore, Mitocyto failed to 
segment smaller fibres from paediatric cases and thus the software will have to undergo a 
number of modification to allow for this.  
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The classification of deficiency is calculated from plotIMC using 95% predictive intervals. 
These intervals are based on the data having a crude linear regression and the model does not 
take into account that this may not always be the case. Because of this, the classification of 
fibres above, below or within the interval may be affected, thus having an effect on what is 
classed as deficient.    
7.4 Future work 
Although respiratory deficiency is well characterised in skeletal muscle, there is very little 
investigation into the downstream effect of this deficiency at a single cell level. It is known that 
a principle feature of mitochondrial disease is an impairment in OXPHOS, which is thought to 
induce an adaptive stress response to trigger a number of signalling pathways. The development 
of IMC has provided the opportunity to assess many proteins simultaneously and therefore it is 
envisaged that IMC be used to look at the consequence of deficiency on various downstream 
signalling pathways that are involved in mitochondrial biology. These pathways include 
glycolysis, biogenesis, mitophagy and protein synthesis, which have been reported to have a 
response to mitochondrial dysfunction (Hansson et al., 2004, Wu et al., 2015). Identifying 
suitable targets for each pathway of interest is a fundamental first step and similar to the work 
carried out in this thesis, antibodies targeting each protein must be available in a protein free 
solution and work successfully with immunofluorescence before a metal can be assigned, and 
the antibody can be conjugated for use with IMC.  
There is a hypothesis that different thresholds of deficiency occur for different complexes, and 
although work carried out in chapter 5 supports this suggestion, this cannot be confirmed 
without further analysis. Therefore future work will involve carrying out genetic analysis on 
single fibres with different levels of deficiency to assess the heteroplasmy level and whether 
this correlates to the level of deficiency that is observed. 
Imaging mass cytometry gives opportunity for further development and refinements. Although 
Mitocyto is effective at segmenting single fibres from adult cases, it was unsuccessful at 
segmenting smaller fibres from paediatric cases. This may be a result of poorer image resolution 
with smaller fibres and thus it is more difficult to use the dystrophin image as fibre boundary 
marker as the labelling is not as clear and precise. Therefore tailoring Mitocyto to these needs 
will overcome this current limitation. Furthermore, it would be useful to look at alternative 
statistical models or an adaptation of the current statistical model to move away from classifying 
deficiency solely based on a regressions. 
219 
 
Although this thesis has focussed on investigating skeletal muscle, IMC can be applied to a vast 
number of research areas both in isolation and in conjunction with other technologies. There is 
the potential to adapt IMC to explore other tissues such as the bone - in patients with 
osteoporosis, and the brain, where it can be used to look at mitochondrial dysfunction in 
Parkinson’s disease or potentially to look at the link between the mitochondria and immune 
cells in patients with Multiple Sclerosis.  
In pharmaceutical research, high-content screening is crucial and with IMC opening up the 
possibility of examining 40+ parameters simultaneously, it is the ideal technique to use in the 
early stages of compound discovery where extensive cell-based screening for a number of 
different biomarkers is required. Bouzekri et al. (2019) have carried out a proof of concept study 
to investigate this and have demonstrated that IMC can be successfully used in the field of cell-
based screening. Currently, a number of different trials are being carried out into mitochondrial 
therapeutics and it is envisaged that IMC could assist this process.  
7.5 Final conclusion  
This work has resolved many of the limitations that were found with previous methods to 
investigate mitochondrial function in human skeletal muscle through the optimisation and 
validation of a novel technique. The use of the IMC assay has provided greater insights into the 
biochemical profiles of patients with a range of mitochondrial disorders and has opened up the 





















Chapter 8 : References 
ACIN-PEREZ, R. & ENRIQUEZ, J. A. 2014. The function of the respiratory supercomplexes: The 
plasticity model. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1837, 444-450. 
AHMED, S. T., ALSTON, C. L., HOPTON, S., HE, L., HARGREAVES, I. P., FALKOUS, G., 
OLÁHOVÁ, M., MCFARLAND, R., TURNBULL, D. M., ROCHA, M. C. & TAYLOR, R. 
W. 2017. Using a quantitative quadruple immunofluorescent assay to diagnose isolated 
mitochondrial Complex I deficiency. Scientific Reports, 7, 15676. 
ALBRING, M., GRIFFITH, J. & ATTARDI, G. 1977. Association of a protein structure of probable 
membrane derivation with HeLa cell mitochondrial DNA near its origin of replication. 
Proceedings of the National Academy of Sciences of the United States of America, 74, 1348-
1352. 
ALESSANDRO, R., BERNARD, T., FELICE, L., EDWIN, V. & CHARLES, H. 2005. Structural 
differences in two biochemically defined populations of cardiac mitochondria. American 
Journal of Physiology-Heart and Circulatory Physiology, 289, H868-H872. 
ALLEN, D. L., ROY, R. R. & EDGERTON, V. R. 1999. Myonuclear domains in muscle adaptation and 
disease. Muscle Nerve, 22, 1350-60. 
ALSTON, CHARLOTTE L., COMPTON, ALISON G., FORMOSA, LUKE E., STRECKER, V., 
OLÁHOVÁ, M., HAACK, TOBIAS B., SMET, J., STOUFFS, K., DIAKUMIS, P., CIARA, 
E., CASSIMAN, D., ROMAIN, N., YARHAM, JOHN W., HE, L., DE PAEPE, B., 
VANLANDER, ARNAUD V., SENECA, S., FEICHTINGER, RENÉ G., PŁOSKI, R., 
ROKICKI, D., PRONICKA, E., HALLER, RONALD G., VAN HOVE, JOHAN L. K., 
BAHLO, M., MAYR, JOHANNES A., VAN COSTER, R., PROKISCH, H., WITTIG, I., 
RYAN, MICHAEL T., THORBURN, DAVID R. & TAYLOR, ROBERT W. 2016. Biallelic 
Mutations in TMEM126B Cause Severe Complex I Deficiency with a Variable Clinical 
Phenotype. The American Journal of Human Genetics, 99, 217-227. 
ALWAY, S. E., MYERS, M. J. & MOHAMED, J. S. 2014. Regulation of Satellite Cell Function in 
Sarcopenia. Frontiers in Aging Neuroscience, 6, 246. 
AMATI-BONNEAU, P., VALENTINO, M. L., REYNIER, P., GALLARDO, M. E., BORNSTEIN, B., 
BOISSIERE, A., CAMPOS, Y., RIVERA, H., DE LA ALEJA, J. G., CARROCCIA, R., 
IOMMARINI, L., LABAUGE, P., FIGARELLA-BRANGER, D., MARCORELLES, P., 
FURBY, A., BEAUVAIS, K., LETOURNEL, F., LIGUORI, R., LA MORGIA, C., 
MONTAGNA, P., LIGUORI, M., ZANNA, C., RUGOLO, M., COSSARIZZA, A., 
WISSINGER, B., VERNY, C., SCHWARZENBACHER, R., MARTIN, M. A., ARENAS, J., 
AYUSO, C., GARESSE, R., LENAERS, G., BONNEAU, D. & CARELLI, V. 2008. OPA1 
mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain, 
131, 338-51. 
ANDERSON, S., BANKIER, A. T., BARRELL, B. G., DE BRUIJN, M. H. L., COULSON, A. R., 
DROUIN, J., EPERON, I. C., NIERLICH, D. P., ROE, B. A., SANGER, F., SCHREIER, P. H., 
SMITH, A. J. H., STADEN, R. & YOUNG, I. G. 1981. Sequence and organization of the human 
mitochondrial genome. Nature, 290, 457. 
ANITORI, R., MANNING, K., QUAN, F., WELEBER, R. G., BUIST, N. R., SHOUBRIDGE, E. A. & 
KENNAWAY, N. G. 2005. Contrasting phenotypes in three patients with novel mutations in 
mitochondrial tRNA genes. Mol Genet Metab, 84, 176-88. 
BAUER, M. F., HOFMANN, S., NEUPERT, W. & BRUNNER, M. 2000. Protein translocation into 
mitochondria: the role of TIM complexes. Trends Cell Biol, 10, 25-31. 
BEINERT, H., HOLM, R. H. & MÜNCK, E. 1997. Iron-Sulfur Clusters: Nature's Modular, 
Multipurpose Structures. Science, 277, 653-659. 
BELLANTI, F., ROMANO, A. D., LO BUGLIO, A., CASTRIOTTA, V., GUGLIELMI, G., GRECO, 
A., SERVIDDIO, G. & VENDEMIALE, G. 2018. Oxidative stress is increased in sarcopenia 
and associated with cardiovascular disease risk in sarcopenic obesity. Maturitas, 109, 6-12. 
BENDALL, S. C., NOLAN, G. P., ROEDERER, M. & CHATTOPADHYAY, P. K. 2012. A deep 
profiler's guide to cytometry. Trends in Immunology, 33, 323-332. 
BENDER, A., KRISHNAN, K. J., MORRIS, C. M., TAYLOR, G. A., REEVE, A. K., PERRY, R. H., 
JAROS, E., HERSHESON, J. S., BETTS, J., KLOPSTOCK, T., TAYLOR, R. W. & 
221 
 
TURNBULL, D. M. 2006. High levels of mitochondrial DNA deletions in substantia nigra 
neurons in aging and Parkinson disease. Nat Genet, 38, 515-7. 
BÉNIT, P., LEBON, S. & RUSTIN, P. 2009. Respiratory-chain diseases related to complex III 
deficiency. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1793, 181-185. 
BEREGI, E. & REGIUS, O. 1987. Comparative morphological study of age related mitochondrial 
changes of the lymphocytes and skeletal muscle cells. Acta morphologica Hungarica, 35, 219-
224. 
BEREITER-HAHN, J. & VÖTH, M. 1994. Dynamics of mitochondria in living cells: Shape changes, 
dislocations, fusion, and fission of mitochondria. Microscopy Research and Technique, 27, 198-
219. 
BERG, J. M., TYMOCZKO, J. L., GATTO, G. J. & STRYER, L. 2015a. Biochemistry 8th edition. 
Glycolysis and gluconeogenesis. 
BERG, J. M., TYMOCZKO, J. L., GATTO, G. J. & STRYER, L. 2015b. Biochemistry 8th edition. The 
Citric Acid Cycle. 495-522. 
BERG, J. M., TYMOCZKO, J. L., GATTO, G. J. & STRYER, L. 2015c. Biochemistry 8th edition. 
Oxidative phosphorylation. 523-563. 
BHARGAVA, K. & SPREMULLI, L. L. 2005. Role of the N- and C-terminal extensions on the activity 
of mammalian mitochondrial translational initiation factor 3. Nucleic Acids Research, 33, 7011-
7018. 
BIDOOKI, S. K., JOHNSON, M. A., CHRZANOWSKA-LIGHTOWLERS, Z., BINDOFF, L. A. & 
LIGHTOWLERS, R. N. 1997. Intracellular mitochondrial triplasmy in a patient with two 
heteroplasmic base changes. Am J Hum Genet, 60, 1430-8. 
BLAKE, D. J., WEIR, A., NEWEY, S. E. & DAVIES, K. E. 2002. Function and Genetics of Dystrophin 
and Dystrophin-Related Proteins in Muscle. Physiological Reviews, 82, 291-329. 
BLEAZARD, W., MCCAFFERY, J. M., KING, E. J., BALE, S., MOZDY, A., TIEU, Q., NUNNARI, 
J. & SHAW, J. M. 1999. The dynamin-related GTPase Dnm1 regulates mitochondrial fission 
in yeast. Nat Cell Biol, 1, 298-304. 
BLUMENTHAL, J. A., EMERY, C. F., MADDEN, D. J., GEORGE, L. K., COLEMAN, R. E., 
RIDDLE, M. W., MCKEE, D. C., REASONER, J. & WILLIAMS, R. S. 1989. Cardiovascular 
and Behavioral Effects of Aerobic Exercise Training in Healthy Older Men and Women. 
Journal of Gerontology, 44, M147-M157. 
BOURGERON, T., RUSTIN, P., CHRETIEN, D., BIRCH-MACHIN, M., BOURGEOIS, M., 
VIEGAS-PEQUIGNOT, E., MUNNICH, A. & ROTIG, A. 1995. Mutation of a nuclear 
succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet, 
11, 144-9. 
BOUZEKRI, A., ESCH, A. & ORNATSKY, O. 2019. Multidimensional profiling of drug-treated cells 
by Imaging Mass Cytometry. bioRxiv, 549592. 
BOWEN, T. S., SCHULER, G. & ADAMS, V. 2015. Skeletal muscle wasting in cachexia and 
sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia 
Muscle, 6, 197-207. 
BOWLING, A., BOND, M., JENKINSON, C. & LAMPING, D. L. 1999. Short Form 36 (SF-36) Health 
Survey questionnaire: which normative data should be used? Comparisons between the norms 
provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford 
Healthy Life Survey. J Public Health Med, 21, 255-70. 
BRACK, A. S., BILDSOE, H. & HUGHES, S. M. 2005. Evidence that satellite cell decrement 
contributes to preferential decline in nuclear number from large fibres during murine age-related 
muscle atrophy. J Cell Sci, 118, 4813-21. 
BRIERLEY, E. J., JOHNSON, M. A., LIGHTOWLERS, R. N., JAMES, O. F. & TURNBULL, D. M. 
1998. Role of mitochondrial DNA mutations in human aging: implications for the central 
nervous system and muscle. Ann Neurol, 43, 217-23. 
BROWN, D. T., SAMUELS, D. C., MICHAEL, E. M., TURNBULL, D. M. & CHINNERY, P. F. 2001. 
Random genetic drift determines the level of mutant mtDNA in human primary oocytes. 
American journal of human genetics, 68, 533-536. 
BROWN, T. A., CECCONI, C., TKACHUK, A. N., BUSTAMANTE, C. & CLAYTON, D. A. 2005. 
Replication of mitochondrial DNA occurs by strand displacement with alternative light-strand 
origins, not via a strand-coupled mechanism. Genes & Development, 19, 2466-2476. 
222 
 
BUA, E., JOHNSON, J., HERBST, A., DELONG, B., MCKENZIE, D., SALAMAT, S. & AIKEN, J. 
M. 2006. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental 
levels in aged human skeletal muscle fibers. American journal of human genetics, 79, 469-480. 
BULLER, A. J., ECCLES, J. C. & ECCLES, R. M. 1960. Interactions between motoneurones and 
muscles in respect of the characteristic speeds of their responses. The Journal of physiology, 
150, 417-439. 
BURMAN, J. L., PICKLES, S., WANG, C., SEKINE, S., VARGAS, J. N. S., ZHANG, Z., YOULE, A. 
M., NEZICH, C. L., WU, X., HAMMER, J. A. & YOULE, R. J. 2017. Mitochondrial fission 
facilitates the selective mitophagy of protein aggregates. The Journal of Cell Biology, 216, 
3231-3247. 
BURZYNSKA, A. Z., CHADDOCK-HEYMAN, L., VOSS, M. W., WONG, C. N., GOTHE, N. P., 
OLSON, E. A., KNECHT, A., LEWIS, A., MONTI, J. M., COOKE, G. E., WOJCICKI, T. R., 
FANNING, J., CHUNG, H. D., AWICK, E., MCAULEY, E. & KRAMER, A. F. 2014. Physical 
activity and cardiorespiratory fitness are beneficial for white matter in low-fit older adults. PloS 
one, 9, e107413-e107413. 
CAI, Y. C., BULLARD, J., L THOMPSON, N. & SPREMULLI, L. 2000a. Interaction of Mitochondrial 
Elongation Factor Tu with Aminoacyl-tRNA and Elongation Factor Ts. 
CAI, Y. C., BULLARD, J. M., THOMPSON, N. L. & SPREMULLI, L. L. 2000b. Interaction of 
mitochondrial elongation factor Tu with aminoacyl-tRNA and elongation factor Ts. J Biol 
Chem, 275, 20308-14. 
CALVO, S. E., CLAUSER, K. R. & MOOTHA, V. K. 2016. MitoCarta2.0: an updated inventory of 
mammalian mitochondrial proteins. Nucleic acids research, 44, D1251-D1257. 
CAMMACK, R. 1992. Iron—Sulfur Clusters in Enzymes: Themes and Variations. In: CAMMACK, R. 
(ed.) Advances in Inorganic Chemistry. Academic Press. 
CAMPBELL, G., KRISHNAN, K. J., DESCHAUER, M., TAYLOR, R. W. & TURNBULL, D. M. 
2014. Dissecting the mechanisms underlying the accumulation of mitochondrial DNA deletions 
in human skeletal muscle. Human molecular genetics, 23, 4612-4620. 
CARROLL, J., FEARNLEY, I. M., SKEHEL, J. M., SHANNON, R. J., HIRST, J. & WALKER, J. E. 
2006. Bovine complex I is a complex of 45 different subunits. J Biol Chem, 281, 32724-7. 
CAVALIER-SMITH, T. 1987. The Origin of Eukaryote and Archaebacterial Cells. Annals of the New 
York Academy of Sciences, 503, 17-54. 
CECCHINI, G. 2003. Function and Structure of Complex II of the Respiratory Chain. Annual Review 
of Biochemistry, 72, 77-109. 
CHANG, Q., ORNATSKY, O. I., SIDDIQUI, I., LOBODA, A., BARANOV, V. I. & HEDLEY, D. W. 
2017. Imaging Mass Cytometry. Cytometry Part A, 91, 160-169. 
CHANG, Q., ORNATSKY, O. I., SIDDIQUI, I., STRAUS, R., BARANOV, V. I. & HEDLEY, D. W. 
2016. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive 
collagen binding in tumor and normal tissues. Scientific Reports, 6, 36641. 
CHEN, H. & CHAN, D. C. 2009. Mitochondrial dynamics–fusion, fission, movement, and mitophagy–
in neurodegenerative diseases. Human Molecular Genetics, 18, R169-R176. 
CHEN, H., VERMULST, M., WANG, Y. E., CHOMYN, A., PROLLA, T. A., MCCAFFERY, J. M. & 
CHAN, D. C. 2010. Mitochondrial fusion is required for mtDNA stability in skeletal muscle 
and tolerance of mtDNA mutations. Cell, 141, 280-9. 
CHEVRIER, S., CROWELL, H. L., ZANOTELLI, V. R. T., ENGLER, S., ROBINSON, M. D. & 
BODENMILLER, B. 2018. Compensation of Signal Spillover in Suspension and Imaging Mass 
Cytometry. Cell systems, 6, 612-620.e5. 
CHINNERY, P. F., JOHNSON, M. A., WARDELL, T. M., SINGH-KLER, R., HAYES, C., BROWN, 
D. T., TAYLOR, R. W., BINDOFF, L. A. & TURNBULL, D. M. 2000. The epidemiology of 
pathogenic mitochondrial DNA mutations. Ann Neurol, 48, 188-93. 
CHUMLEA, W. C., CESARI, M., EVANS, W. J., FERRUCCI, L., FIELDING, R. A., PAHOR, M., 
STUDENSKI, S. & VELLAS, B. 2011. International working group on Sarcopenia. The journal 
of nutrition, health & aging, 15, 450-455. 
CLAYPOOL, S. M. 2009. Cardiolipin, a critical determinant of mitochondrial carrier protein assembly 
and function. Biochimica et biophysica acta, 1788, 2059-2068. 
CLAYTON, D. A. 1982. Replication of animal mitochondrial DNA. Cell, 28, 693-705. 
COATES, S. 2018. Overview of the UK population: November 2018. 
223 
 
COGSWELL, A. M., STEVENS, R. J. & HOOD, D. A. 1993. Properties of skeletal muscle 
mitochondria isolated from subsarcolemmal and intermyofibrillar regions. American Journal of 
Physiology-Cell Physiology, 264, C383-C389. 
CONLEY, K. E., AMARA, C. E., BAJPEYI, S., COSTFORD, S. R., MURRAY, K., JUBRIAS, S. A., 
ARAKAKI, L., MARCINEK, D. J. & SMITH, S. R. 2013. Higher Mitochondrial Respiration 
and Uncoupling with Reduced Electron Transport Chain Content in Vivo in Muscle of 
Sedentary Versus Active Subjects. The Journal of Clinical Endocrinology and Metabolism, 98, 
129-136. 
COOPER, J. M., MANN, V. M. & SCHAPIRA, A. H. 1992. Analyses of mitochondrial respiratory 
chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. J 
Neurol Sci, 113, 91-8. 
COOPER, R., BANN, D., WLOCH, E. G., ADAMS, J. E. & KUH, D. 2015. "Skeletal muscle function 
deficit" in a nationally representative British birth cohort in early old age. J Gerontol A Biol Sci 
Med Sci, 70, 604-7. 
COOPER, R., HARDY, R., AIHIE SAYER, A., BEN-SHLOMO, Y., BIRNIE, K., COOPER, C., 
CRAIG, L., DEARY, I. J., DEMAKAKOS, P., GALLACHER, J., MCNEILL, G., MARTIN, 
R. M., STARR, J. M., STEPTOE, A., KUH, D. & ON BEHALF OF THE, H. S. T. 2011. Age 
and Gender Differences in Physical Capability Levels from Mid-Life Onwards: The 
Harmonisation and Meta-Analysis of Data from Eight UK Cohort Studies. PLOS ONE, 6, 
e27899. 
CORTOPASSI, G. A. & ARNHEIM, N. 1990. Detection of a specific mitochondrial DNA deletion in 
tissues of older humans. Nucleic Acids Research, 18, 6927-6933. 
CORY, S. & ADAMS, J. M. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat 
Rev Cancer, 2, 647-56. 
CREE, L. M., PATEL, S. K., PYLE, A., LYNN, S., TURNBULL, D. M., CHINNERY, P. F. & 
WALKER, M. 2008a. Age-related decline in mitochondrial DNA copy number in isolated 
human pancreatic islets. Diabetologia, 51, 1440-3. 
CREE, L. M., SAMUELS, D. C., DE SOUSA LOPES, S. C., RAJASIMHA, H. K., WONNAPINIJ, P., 
MANN, J. R., DAHL, H.-H. M. & CHINNERY, P. F. 2008b. A reduction of mitochondrial 
DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nature 
Genetics, 40, 249. 
CRICK, F. H. C. 1966. Codon—anticodon pairing: The wobble hypothesis. Journal of Molecular 
Biology, 19, 548-555. 
CRUZ-JENTOFT, A. J., BAEYENS, J. P., BAUER, J. M., BOIRIE, Y., CEDERHOLM, T., LANDI, 
F., MARTIN, F. C., MICHEL, J.-P., ROLLAND, Y., SCHNEIDER, S. M., TOPINKOVÁ, E., 
VANDEWOUDE, M., ZAMBONI, M. & EUROPEAN WORKING GROUP ON 
SARCOPENIA IN OLDER, P. 2010. Sarcopenia: European consensus on definition and 
diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and 
ageing, 39, 412-423. 
DAVIES, K. M., ANSELMI, C., WITTIG, I., FARALDO-GÓMEZ, J. D. & KÜHLBRANDT, W. 2012. 
Structure of the yeast F<sub>1</sub>F<sub>o</sub>-ATP synthase dimer and its role in 
shaping the mitochondrial cristae. Proceedings of the National Academy of Sciences, 109, 
13602-13607. 
DAY, K., SHEFER, G., SHEARER, A. & YABLONKA-REUVENI, Z. 2010. The depletion of skeletal 
muscle satellite cells with age is concomitant with reduced capacity of single progenitors to 
produce reserve progeny. Dev Biol, 340, 330-43. 
DE GREY, A. D. N. J. 1997. A proposed refinement of the mitochondrial free radical theory of aging. 
BioEssays, 19, 161-166. 
DE STEFANI, D., RAFFAELLO, A., TEARDO, E., SZABO, I. & RIZZUTO, R. 2011. A forty-
kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature, 476, 
336-40. 
DELUCA, H. F. & ENGSTROM, G. W. 1961. Calcium uptake by rat kidney mitochondria. Proc Natl 
Acad Sci U S A, 47, 1744-50. 
DEVAY, R. M., DOMINGUEZ-RAMIREZ, L., LACKNER, L. L., HOPPINS, S., STAHLBERG, H. 
& NUNNARI, J. 2009. Coassembly of Mgm1 isoforms requires cardiolipin and mediates 
mitochondrial inner membrane fusion. J Cell Biol, 186, 793-803. 
224 
 
DEVENISH, R. J., PRESCOTT, M. & RODGERS, A. J. W. 2008. The Structure and Function of 
Mitochondrial F1F0‐ATP Synthases. International Review of Cell and Molecular Biology. 
Academic Press. 
DIAZ, F. 2010. Cytochrome c oxidase deficiency: Patients and animal models. Biochimica et Biophysica 
Acta (BBA) - Molecular Basis of Disease, 1802, 100-110. 
DISTEFANO, G., STANDLEY, R. A., ZHANG, X., CARNERO, E. A., YI, F., CORNNELL, H. H. & 
COEN, P. M. 2018. Physical activity unveils the relationship between mitochondrial energetics, 
muscle quality, and physical function in older adults. Journal of Cachexia, Sarcopenia and 
Muscle, 9, 279-294. 
DODDS, R. M., DAVIES, K., GRANIC, A., HOLLINGSWORTH, K. G., WARREN, C., GORMAN, 
G., TURNBULL, D. M. & SAYER, A. A. 2018. Mitochondrial respiratory chain function and 
content are preserved in the skeletal muscle of active very old men and women. Exp Gerontol, 
113, 80-85. 
DROGE, W. 2002. Free radicals in the physiological control of cell function. Physiol Rev, 82, 47-95. 
DUCHEN, M. R. 2004. Roles of mitochondria in health and disease. Diabetes, 53 Suppl 1, S96-102. 
EDGAR, D., SHABALINA, I., CAMARA, Y., WREDENBERG, A., CALVARUSO, M. A., 
NIJTMANS, L., NEDERGAARD, J., CANNON, B., LARSSON, N.-G. & TRIFUNOVIC, A. 
2009. Random Point Mutations with Major Effects on Protein-Coding Genes Are the Driving 
Force behind Premature Aging in mtDNA Mutator Mice. Cell Metabolism, 10, 131-138. 
EISNER, V., LENAERS, G. & HAJNÓCZKY, G. 2014. Mitochondrial fusion is frequent in skeletal 
muscle and supports excitation-contraction coupling. The Journal of cell biology, 205, 179-195. 
ELMORE, S. 2007. Apoptosis: a review of programmed cell death. Toxicologic pathology, 35, 495-516. 
ELSON, J. L., SAMUELS, D. C., TURNBULL, D. M. & CHINNERY, P. F. 2001. Random intracellular 
drift explains the clonal expansion of mitochondrial DNA mutations with age. American journal 
of human genetics, 68, 802-806. 
ENGEL, W. K. & CUNNINGHAM, G. G. 1963. RAPID EXAMINATION OF MUSCLE TISSUE. AN 
IMPROVED TRICHROME METHOD FOR FRESH-FROZEN BIOPSY SECTIONS. 
Neurology, 13, 919-23. 
FALKENBERG, M., LARSSON, N.-G. & GUSTAFSSON, C. M. 2007. DNA Replication and 
Transcription in Mammalian Mitochondria. Annual Review of Biochemistry, 76, 679-699. 
FANÒ, G., MECOCCI, P., VECCHIET, J., BELIA, S., FULLE, S., POLIDORI, M. C., FELZANI, G., 
SENIN, U., VECCHIET, L. & BEAL, M. F. 2001. Age and sex influence on oxidative damage 
and functional status in human skeletal muscle. Journal of Muscle Research & Cell Motility, 
22, 345-351. 
FERNÁNDEZ-VIZARRA, E. & ZEVIANI, M. 2015. Nuclear gene mutations as the cause of 
mitochondrial complex III deficiency. Frontiers in Genetics, 6. 
FERREIRA, R., VITORINO, R., ALVES, R. M. P., APPELL, H. J., POWERS, S. K., DUARTE, J. A. 
& AMADO, F. 2010. Subsarcolemmal and intermyofibrillar mitochondria proteome differences 
disclose functional specializations in skeletal muscle. PROTEOMICS, 10, 3142-3154. 
FERRUCCI, L., GIALLAURIA, F. & GURALNIK, J. M. 2008. Epidemiology of aging. Radiologic 
clinics of North America, 46, 643-v. 
FORMOSA, L. E., DIBLEY, M. G., STROUD, D. A. & RYAN, M. T. 2018. Building a complex 
complex: Assembly of mitochondrial respiratory chain complex I. Seminars in Cell & 
Developmental Biology, 76, 154-162. 
FORMOSA, L. E. & RYAN, M. T. 2016. Mitochondrial fusion: Reaching the end of mitofusin’s tether. 
The Journal of Cell Biology, 215, 597-598. 
FRATTER, C., RAMAN, P., ALSTON, C. L., BLAKELY, E. L., CRAIG, K., SMITH, C., EVANS, J., 
SELLER, A., CZERMIN, B., HANNA, M. G., POULTON, J., BRIERLEY, C., STAUNTON, 
T. G., TURNPENNY, P. D., SCHAEFER, A. M., CHINNERY, P. F., HORVATH, R., 
TURNBULL, D. M., GORMAN, G. S. & TAYLOR, R. W. 2011. RRM2B mutations are 
frequent in familial PEO with multiple mtDNA deletions. Neurology, 76, 2032-4. 
FRAZIER, A. E., THORBURN, D. R. & COMPTON, A. G. 2019. Mitochondrial energy generation 




FRIEDMAN, J. R., LACKNER, L. L., WEST, M., DIBENEDETTO, J. R., NUNNARI, J. & VOELTZ, 
G. K. 2011. ER tubules mark sites of mitochondrial division. Science (New York, N.Y.), 334, 
358-362. 
FRYBURG, D. A., LOUARD, R. J., GEROW, K. E., GELFAND, R. A. & BARRETT, E. J. 1992. 
Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin's 
antiproteolytic action in humans. Diabetes, 41, 424-9. 
GAUR, R., GRASSO, D., DATTA, P. P., KRISHNA, P. D. V., DAS, G., SPENCER, A., AGRAWAL, 
R. K., SPREMULLI, L. & VARSHNEY, U. 2008. A Single Mammalian Mitochondrial 
Translation Initiation Factor Functionally Replaces Two Bacterial Factors. Molecular cell, 29, 
180-190. 
GEISLER, S., HOLMSTROM, K. M., SKUJAT, D., FIESEL, F. C., ROTHFUSS, O. C., KAHLE, P. J. 
& SPRINGER, W. 2010. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and 
p62/SQSTM1. Nat Cell Biol, 12, 119-31. 
GELFAND, R. A. & BARRETT, E. J. 1987. Effect of physiologic hyperinsulinemia on skeletal muscle 
protein synthesis and breakdown in man. J Clin Invest, 80, 1-6. 
GIESEN, C., WANG, H. A. O., SCHAPIRO, D., ZIVANOVIC, N., JACOBS, A., HATTENDORF, B., 
SCHÜFFLER, P. J., GROLIMUND, D., BUHMANN, J. M., BRANDT, S., VARGA, Z., 
WILD, P. J., GÜNTHER, D. & BODENMILLER, B. 2014. Highly multiplexed imaging of 
tumor tissues with subcellular resolution by mass cytometry. Nature Methods, 11, 417. 
GILES, R. E., BLANC, H., CANN, H. M. & WALLACE, D. C. 1980. Maternal inheritance of human 
mitochondrial DNA. Proceedings of the National Academy of Sciences, 77, 6715-6719. 
GLADYSHEV, V. N. 2014. The free radical theory of aging is dead. Long live the damage theory! 
Antioxidants & redox signaling, 20, 727-731. 
GOLLNICK, P. D. & SALTIN, B. 1982. Significance of skeletal muscle oxidative enzyme enhancement 
with endurance training. Clin Physiol, 2, 1-12. 
GORMAN, G. S., CHINNERY, P. F., DIMAURO, S., HIRANO, M., KOGA, Y., MCFARLAND, R., 
SUOMALAINEN, A., THORBURN, D. R., ZEVIANI, M. & TURNBULL, D. M. 2016. 
Mitochondrial diseases. Nat Rev Dis Primers, 2, 16080. 
GORMAN, G. S., SCHAEFER, A. M., NG, Y., GOMEZ, N., BLAKELY, E. L., ALSTON, C. L., 
FEENEY, C., HORVATH, R., YU-WAI-MAN, P., CHINNERY, P. F., TAYLOR, R. W., 
TURNBULL, D. M. & MCFARLAND, R. 2015. Prevalence of nuclear and mitochondrial DNA 
mutations related to adult mitochondrial disease. Annals of neurology, 77, 753-759. 
GRADY, J. P., CAMPBELL, G., RATNAIKE, T., BLAKELY, E. L., FALKOUS, G., NESBITT, V., 
SCHAEFER, A. M., MCNALLY, R. J., GORMAN, G. S., TAYLOR, R. W., TURNBULL, D. 
M. & MCFARLAND, R. 2014. Disease progression in patients with single, large-scale 
mitochondrial DNA deletions. Brain : a journal of neurology, 137, 323-334. 
GROSSMAN, E. J., ROY, R. R., TALMADGE, R. J., ZHONG, H. & EDGERTON, V. R. 1998. Effects 
of inactivity on myosin heavy chain composition and size of rat soleus fibers. Muscle Nerve, 
21, 375-89. 
GRUMATI, P., COLETTO, L., SABATELLI, P., CESCON, M., ANGELIN, A., BERTAGGIA, E., 
BLAAUW, B., URCIUOLO, A., TIEPOLO, T., MERLINI, L., MARALDI, N. M., 
BERNARDI, P., SANDRI, M. & BONALDO, P. 2010. Autophagy is defective in collagen VI 
muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med, 16, 1313-
20. 
GUDLAUGSSON, J., ASPELUND, T., GUDNASON, V., OLAFSDOTTIR, A. S., JONSSON, P. V., 
ARNGRIMSSON, S. A. & JOHANNSSON, E. 2013. [The effects of 6 months' multimodal 
training on functional performance, strength, endurance, and body mass index of older 
individuals. Are the benefits of training similar among women and men?]. Laeknabladid, 99, 
331-7. 
GUERRERO-CASTILLO, S., BAERTLING, F., KOWNATZKI, D., WESSELS, H. J., ARNOLD, S., 
BRANDT, U. & NIJTMANS, L. 2017. The Assembly Pathway of Mitochondrial Respiratory 
Chain Complex I. Cell Metabolism, 25, 128-139. 
GUO, R., ZONG, S., WU, M., GU, J. & YANG, M. 2017. Architecture of Human Mitochondrial 
Respiratory Megacomplex I2III2IV2. Cell, 170, 1247-1257.e12. 
226 
 
HAKONEN, A. H., ISOHANNI, P., PAETAU, A., HERVA, R., SUOMALAINEN, A. & 
LONNQVIST, T. 2007. Recessive Twinkle mutations in early onset encephalopathy with 
mtDNA depletion. Brain, 130, 3032-40. 
HAN, G., SPITZER, M. H., BENDALL, S. C., FANTL, W. J. & NOLAN, G. P. 2018. Metal-isotope-
tagged monoclonal antibodies for high-dimensional mass cytometry. Nature Protocols, 13, 
2121-2148. 
HANSSON, A., HANCE, N., DUFOUR, E., RANTANEN, A., HULTENBY, K., CLAYTON, D. A., 
WIBOM, R. & LARSSON, N.-G. 2004. A switch in metabolism precedes increased 
mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proceedings of the 
National Academy of Sciences of the United States of America, 101, 3136-3141. 
HAO, H., BONILLA, E., MANFREDI, G., DIMAURO, S. & MORAES, C. T. 1995. Segregation 
patterns of a novel mutation in the mitochondrial tRNA glutamic acid gene associated with 
myopathy and diabetes mellitus. Am J Hum Genet, 56, 1017-25. 
HAQUE, M. E. & SPREMULLI, L. L. 2008. Roles of the N- and C-terminal domains of mammalian 
mitochondrial initiation factor 3 in protein biosynthesis. Journal of molecular biology, 384, 929-
940. 
HARMAN, D. 1956. Aging: A Theory Based on Free Radical and Radiation Chemistry. Journal of 
Gerontology, 11, 298-300. 
HATEFI, Y. 1976. The Enzymes and the Enzyme Complexes of the Mitochondrial Oxidative 
Phosphorylation System. In: MARTONOSI, A. N. (ed.) The Enzymes of Biological 
Membranes: Volume 4: Electron Transport Systems and Receptors. Boston, MA: Springer US. 
HAVLICKOVA KARBANOVA, V., CIZKOVA VRBACKA, A., HEJZLAROVA, K., NUSKOVA, 
H., STRANECKY, V., POTOCKA, A., KMOCH, S. & HOUSTEK, J. 2012. Compensatory 
upregulation of respiratory chain complexes III and IV in isolated deficiency of ATP synthase 
due to TMEM70 mutation. Biochim Biophys Acta, 1817, 1037-43. 
HOCKENBERY, D., NUNEZ, G., MILLIMAN, C., SCHREIBER, R. D. & KORSMEYER, S. J. 1990. 
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 
348, 334-6. 
HOFHAUS, G. & ATTARDI, G. 1993. Lack of assembly of mitochondrial DNA-encoded subunits of 
respiratory NADH dehydrogenase and loss of enzyme activity in a human cell mutant lacking 
the mitochondrial ND4 gene product. The EMBO journal, 12, 3043-3048. 
HOFHAUS, G. & ATTARDI, G. 1995. Efficient selection and characterization of mutants of a human 
cell line which are defective in mitochondrial DNA-encoded subunits of respiratory NADH 
dehydrogenase. Molecular and cellular biology, 15, 964-974. 
HOLLOSZY, J. O. 1967. Biochemical adaptations in muscle. Effects of exercise on mitochondrial 
oxygen uptake and respiratory enzyme activity in skeletal muscle. J Biol Chem, 242, 2278-82. 
HOLLOSZY, J. O. & BOOTH, F. W. 1976. Biochemical adaptations to endurance exercise in muscle. 
Annu Rev Physiol, 38, 273-91. 
HOLT, I. J., HARDING, A. E. & MORGAN-HUGHES, J. A. 1988. Deletions of muscle mitochondrial 
DNA in patients with mitochondrial myopathies. Nature, 331, 717-9. 
HOLT, I. J., LORIMER, H. E. & JACOBS, H. T. 2000. Coupled leading- and lagging-strand synthesis 
of mammalian mitochondrial DNA. Cell, 100, 515-24. 
HOLT, I. J. & REYES, A. 2012. Human Mitochondrial DNA Replication. Cold Spring Harbor 
Perspectives in Biology, 4, a012971. 
HOWALD, H., HOPPELER, H., CLAASSEN, H., MATHIEU, O. & STRAUB, R. 1985. Influences of 
endurance training on the ultrastructural composition of the different muscle fiber types in 
humans. Pflugers Arch, 403, 369-76. 
HUANG, G., WANG, R., CHEN, P., HUANG, S. C., DONNELLY, J. E. & MEHLFERBER, J. P. 2016. 
Dose–response relationship of cardiorespiratory fitness adaptation to controlled endurance 
training in sedentary older adults. European Journal of Preventive Cardiology, 23, 518-529. 
HUNTE, C., ZICKERMANN, V. & BRANDT, U. 2010. Functional Modules and Structural Basis of 
Conformational Coupling in Mitochondrial Complex I. Science, 329, 448. 
JANG, Y. C. & VAN REMMEN, H. 2011. Age-associated alterations of the neuromuscular junction. 
Exp Gerontol, 46, 193-8. 
227 
 
JANSSEN, R. J. R. J., NIJTMANS, L. G., HEUVEL, L. P. V. D. & SMEITINK, J. A. M. 2006. 
Mitochondrial complex I: Structure, function and pathology. Journal of Inherited Metabolic 
Disease, 29, 499-515. 
JENUTH, J. P., PETERSON, A. C., FU, K. & SHOUBRIDGE, E. A. 1996. Random genetic drift in the 
female germline explains the rapid segregation of mammalian mitochondrial DNA. Nature 
Genetics, 14, 146-151. 
JIANG, J., WANG, X. L. & MA, Y. Y. 2015. Respiratory chain complex III deficiency in patients with 
tRNA-leu mutation. 
JIN, S. M., LAZAROU, M., WANG, C., KANE, L. A., NARENDRA, D. P. & YOULE, R. J. 2010. 
Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by 
PARL. J Cell Biol, 191, 933-42. 
JONCKHEERE, A. I., SMEITINK, J. A. M. & RODENBURG, R. J. T. 2012. Mitochondrial ATP 
synthase: architecture, function and pathology. Journal of Inherited Metabolic Disease, 35, 211-
225. 
KAAMAN, M., SPARKS, L. M., VAN HARMELEN, V., SMITH, S. R., SJOLIN, E., DAHLMAN, I. 
& ARNER, P. 2007. Strong association between mitochondrial DNA copy number and 
lipogenesis in human white adipose tissue. Diabetologia, 50, 2526-33. 
KADI, F., CHARIFI, N., DENIS, C. & LEXELL, J. 2004. Satellite cells and myonuclei in young and 
elderly women and men. Muscle Nerve, 29, 120-7. 
KANKI, T. & KLIONSKY, D. J. 2008. Mitophagy in yeast occurs through a selective mechanism. J 
Biol Chem, 283, 32386-93. 
KASCH, F. W., BOYER, J. L., SCHMIDT, P. K., WELLS, R. H., WALLACE, J. P., VERITY, L. S., 
GUY, H. & SCHNEIDER, D. 1999. Ageing of the cardiovascular system during 33 years of 
aerobic exercise. Age Ageing, 28, 531-6. 
KERR, J. F. R., WYLLIE, A. H. & CURRIE, A. R. 1972. Apoptosis: A Basic Biological Phenomenon 
with Wide-ranging Implications in Tissue Kinetics. British Journal of Cancer, 26, 239-257. 
KIRICHOK, Y., KRAPIVINSKY, G. & CLAPHAM, D. E. 2004. The mitochondrial calcium uniporter 
is a highly selective ion channel. Nature, 427, 360-4. 
KIRKWOOD THOMAS, B. L. 2017. Why and how are we living longer? Experimental Physiology, 
102, 1067-1074. 
KORTEBEIN, P., FERRANDO, A., LOMBEIDA, J., WOLFE, R. & EVANS, W. J. 2007. Effect of 10 
days of bed rest on skeletal muscle in healthy older adults. JAMA, 297, 1769-1774. 
KOSEK, D. J., KIM, J. S., PETRELLA, J. K., CROSS, J. M. & BAMMAN, M. M. 2006. Efficacy of 3 
days/wk resistance training on myofiber hypertrophy and myogenic mechanisms in young vs. 
older adults. J Appl Physiol (1985), 101, 531-44. 
KOSHIBA, T., DETMER, S. A., KAISER, J. T., CHEN, H., MCCAFFERY, J. M. & CHAN, D. C. 
2004. Structural Basis of Mitochondrial Tethering by Mitofusin Complexes. Science, 305, 858-
862. 
KOVAROVA, N., CIZKOVA VRBACKA, A., PECINA, P., STRANECKY, V., PRONICKA, E., 
KMOCH, S. & HOUSTEK, J. 2012. Adaptation of respiratory chain biogenesis to cytochrome 
c oxidase deficiency caused by SURF1 gene mutations. Biochim Biophys Acta, 1822, 1114-24. 
KOWALD, A. & KIRKWOOD, T. B. L. 2014. Transcription could be the key to the selection advantage 
of mitochondrial deletion mutants in aging. Proceedings of the National Academy of Sciences 
of the United States of America, 111, 2972-2977. 
KRAYTSBERG, Y., KUDRYAVTSEVA, E., MCKEE, A. C., GEULA, C., KOWALL, N. W. & 
KHRAPKO, K. 2006. Mitochondrial DNA deletions are abundant and cause functional 
impairment in aged human substantia nigra neurons. Nature Genetics, 38, 518. 
KULAWIAK, B., HOPKER, J., GEBERT, M., GUIARD, B., WIEDEMANN, N. & GEBERT, N. 2013. 
The mitochondrial protein import machinery has multiple connections to the respiratory chain. 
Biochim Biophys Acta, 1827, 612-26. 
KUMMER, E., LEIBUNDGUT, M., RACKHAM, O., LEE, R. G., BOEHRINGER, D., FILIPOVSKA, 
A. & BAN, N. 2018. Unique features of mammalian mitochondrial translation initiation 
revealed by cryo-EM. Nature, 560, 263-267. 
LADERMAN, K. A., PENNY, J. R., MAZZUCCHELLI, F., BRESOLIN, N., SCARLATO, G. & 
ATTARDI, G. 1996. Aging-dependent functional alterations of mitochondrial DNA (mtDNA) 
from human fibroblasts transferred into mtDNA-less cells. J Biol Chem, 271, 15891-7. 
228 
 
LARSSON, N.-G. 2010. Somatic Mitochondrial DNA Mutations in Mammalian Aging. Annual Review 
of Biochemistry, 79, 683-706. 
LARSSON, N.-G. & OLDFORS, A. 2001. Mitochondrial myopathies. Acta Physiologica Scandinavica, 
171, 385-393. 
LAZAROU, M., JIN, S. M., KANE, L. A. & YOULE, R. J. 2012. Role of PINK1 binding to the TOM 
complex and alternate intracellular membranes in recruitment and activation of the E3 ligase 
Parkin. Dev Cell, 22, 320-33. 
LEE, Y.-J., JEONG, S.-Y., KARBOWSKI, M., SMITH, C. L. & YOULE, R. J. 2004. Roles of the 
mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. 
Molecular biology of the cell, 15, 5001-5011. 
LEXELL, J. 1995. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med 
Sci. 
LEXELL, J. & DOWNHAM, D. Y. 1991. The occurrence of fibre-type grouping in healthy human 
muscle: a quantitative study of cross-sections of whole vastus lateralis from men between 15 
and 83 years. Acta Neuropathol, 81, 377-81. 
LI, Y., PARK, J.-S., DENG, J.-H. & BAI, Y. 2006. Cytochrome c Oxidase Subunit IV is Essential for 
Assembly and Respiratory Function of the Enzyme Complex. Journal of bioenergetics and 
biomembranes, 38, 283-291. 
LIEBER, R. L. 2010. Skeletal muscle structure, function, and plasticity, Philadelphia, USA, Lippincott 
Williams & Wilkins. 
LILL, R. 2009. Function and biogenesis of iron–sulphur proteins. Nature, 460, 831. 
LOEFFEN, J. L. C. M., SMEITINK, J. A. M., TRIJBELS, J. M. F., JANSSEN, A. J. M., TRIEPELS, 
R. H., SENGERS, R. C. A. & VAN DEN HEUVEL, L. P. 2000. Isolated complex I deficiency 
in children: Clinical, biochemical and genetic aspects. Human Mutation, 15, 123-134. 
LÓPEZ-GALLARDO, E., LÓPEZ-PÉREZ, M. J., MONTOYA, J. & RUIZ-PESINI, E. 2009. CPEO 
and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion, 9, 314-
317. 
LUNDBY, C. & JACOBS, R. A. 2016. Adaptations of skeletal muscle mitochondria to exercise training. 
Experimental Physiology, 101, 17-22. 
LUO, S., VALENCIA, C. A., ZHANG, J., LEE, N.-C., SLONE, J., GUI, B., WANG, X., LI, Z., DELL, 
S., BROWN, J., CHEN, S. M., CHIEN, Y.-H., HWU, W.-L., FAN, P.-C., WONG, L.-J., 
ATWAL, P. S. & HUANG, T. 2018. Biparental Inheritance of Mitochondrial DNA in Humans. 
Proceedings of the National Academy of Sciences, 115, 13039-13044. 
MA, J. & SPREMULLI, L. L. 1996. Expression, Purification, and Mechanistic Studies of Bovine 
Mitochondrial Translational Initiation Factor 2. Journal of Biological Chemistry, 271, 5805-
5811. 
MAGNER, M., KOLAROVA, H., HONZIK, T., SVANDOVA, I. & ZEMAN, J. 2015. Clinical 
manifestation of mitochondrial diseases. Dev Period Med, 19, 441-9. 
MAI, N., CHRZANOWSKA-LIGHTOWLERS, Z. M. A. & LIGHTOWLERS, R. N. 2017. The process 
of mammalian mitochondrial protein synthesis. Cell and Tissue Research, 367, 5-20. 
MANCUSO, M., ORSUCCI, D., ANGELINI, C., BERTINI, E., CARELLI, V., COMI, G. P., 
MINETTI, C., MOGGIO, M., MONGINI, T., SERVIDEI, S., TONIN, P., TOSCANO, A., 
UZIEL, G., BRUNO, C., CALDARAZZO IENCO, E., FILOSTO, M., LAMPERTI, C., 
MARTINELLI, D., MORONI, I., MUSUMECI, O., PEGORARO, E., RONCHI, D., 
SANTORELLI, F. M., SAUCHELLI, D., SCARPELLI, M., SCIACCO, M., SPINAZZI, M., 
VALENTINO, M. L., VERCELLI, L., ZEVIANI, M. & SICILIANO, G. 2013. Phenotypic 
heterogeneity of the 8344A&gt;G mtDNA “MERRF” mutation. Neurology, 80, 2049-2054. 
MARANZANA, E., BARBERO, G., FALASCA, A. I., LENAZ, G. & GENOVA, M. L. 2013. 
Mitochondrial Respiratory Supercomplex Association Limits Production of Reactive Oxygen 
Species from Complex I. Antioxidants & Redox Signaling, 19, 1469-1480. 
MARIOTTI, C., SAVARESE, N., SUOMALAINEN, A., RIMOLDI, M., COMI, G., PRELLE, A., 
ANTOZZI, C., SERVIDEI, S., JARRE, L., DIDONATO, S. & ZEVIANI, M. 1995. Genotype 
to phenotype correlations in mitochondrial encephalomyopathies associated with the A3243G 
mutation of mitochondrial DNA. Journal of Neurology, 242, 304-312. 
MARTIN, W. & MÜLLER, M. 1998. The hydrogen hypothesis for the first eukaryote. Nature, 392, 37. 
229 
 
MASIERO, E., AGATEA, L., MAMMUCARI, C., BLAAUW, B., LORO, E., KOMATSU, M., 
METZGER, D., REGGIANI, C., SCHIAFFINO, S. & SANDRI, M. 2009. Autophagy is 
required to maintain muscle mass. Cell Metab, 10, 507-15. 
MCFARLAND, R., TAYLOR, R. W. & TURNBULL, D. M. 2010. A neurological perspective on 
mitochondrial disease. The Lancet Neurology, 9, 829-840. 
MCKINNEY, E. A. & OLIVEIRA, M. T. 2013. Replicating animal mitochondrial DNA. Genetics and 
Molecular Biology, 36, 308-315. 
MEARS, J. A., LACKNER, L. L., FANG, S., INGERMAN, E., NUNNARI, J. & HINSHAW, J. E. 
2011. Conformational changes in Dnm1 support a contractile mechanism for mitochondrial 
fission. Nature structural & molecular biology, 18, 20-26. 
MEEUSEN, S., DEVAY, R., BLOCK, J., CASSIDY-STONE, A., WAYSON, S., MCCAFFERY, J. M. 
& NUNNARI, J. 2006. Mitochondrial Inner-Membrane Fusion and Crista Maintenance 
Requires the Dynamin-Related GTPase Mgm1. Cell, 127, 383-395. 
MENSHIKOVA, E. V., RITOV, V. B., FAIRFULL, L., FERRELL, R. E., KELLEY, D. E. & 
GOODPASTER, B. H. 2006. Effects of Exercise on Mitochondrial Content and Function in 
Aging Human Skeletal Muscle. The Journals of Gerontology: Series A, 61, 534-540. 
METODIEV, M. D., THOMPSON, K., ALSTON, C. L., MORRIS, A. A. M., HE, L., ASSOULINE, 
Z., RIO, M., BAHI-BUISSON, N., PYLE, A., GRIFFIN, H., SIIRA, S., FILIPOVSKA, A., 
MUNNICH, A., CHINNERY, P. F., MCFARLAND, R., RÖTIG, A. & TAYLOR, R. W. 2016. 
Recessive Mutations in TRMT10C Cause Defects in Mitochondrial RNA Processing and 
Multiple Respiratory Chain Deficiencies. American journal of human genetics, 98, 993-1000. 
METTER, E. J., CONWIT, R., TOBIN, J. & FOZARD, J. L. 1997. Age-associated loss of power and 
strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci, 52, B267-
76. 
MICHIKAWA, Y., MAZZUCCHELLI, F., BRESOLIN, N., SCARLATO, G. & ATTARDI, G. 1999. 
Aging-dependent large accumulation of point mutations in the human mtDNA control region 
for replication. Science, 286, 774-9. 
MILENKOVIC, D., BLAZA, J. N., LARSSON, N.-G. & HIRST, J. 2017. The Enigma of the 
Respiratory Chain Supercomplex. Cell Metabolism, 25, 765-776. 
MILENKOVIC, D., MATIC, S., KÜHL, I., RUZZENENTE, B., FREYER, C., JEMT, E., PARK, C. B., 
FALKENBERG, M. & LARSSON, N.-G. 2013. TWINKLE is an essential mitochondrial 
helicase required for synthesis of nascent D-loop strands and complete mtDNA replication. 
Human Molecular Genetics, 22, 1983-1993. 
MILLER, F. J., ROSENFELDT, F. L., ZHANG, C., LINNANE, A. W. & NAGLEY, P. 2003. Precise 
determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a 
PCR-based assay: lack of change of copy number with age. Nucleic Acids Res, 31, e61. 
MILNER, D. J., MAVROIDIS, M., WEISLEDER, N. & CAPETANAKI, Y. 2000. Desmin cytoskeleton 
linked to muscle mitochondrial distribution and respiratory function. The Journal of cell 
biology, 150, 1283-1298. 
MIMAKI, M., WANG, X., MCKENZIE, M., THORBURN, D. R. & RYAN, M. T. 2012. Understanding 
mitochondrial complex I assembly in health and disease. Biochimica et Biophysica Acta (BBA) 
- Bioenergetics, 1817, 851-862. 
MISHRA, P., CARELLI, V., MANFREDI, G. & CHAN, D. C. 2014. Proteolytic cleavage of Opa1 
stimulates mitochondrial inner membrane fusion and couples fusion to oxidative 
phosphorylation. Cell metabolism, 19, 630-641. 
MITCHELL, P. 1961. Coupling of Phosphorylation to Electron and Hydrogen Transfer by a Chemi-
Osmotic type of Mechanism. Nature, 191, 144. 
MOROZOV, Y. I., PARSHIN, A. V., AGARONYAN, K., CHEUNG, ALAN C M., ANIKIN, M., 
CRAMER, P. & TEMIAKOV, D. 2015. A model for transcription initiation in human 
mitochondria. Nucleic Acids Research, 43, 3726-3735. 
MOSLEMI, A.-R., TULINIUS, M., HOLME, E. & OLDFORS, A. 1998. Threshold expression of the 
tRNALys A8344G mutation in single muscle fibres. Neuromuscular Disorders, 8, 345-349. 
MUHLENHOFF, U., RICHHARDT, N., GERBER, J. & LILL, R. 2002. Characterization of iron-sulfur 
protein assembly in isolated mitochondria. A requirement for ATP, NADH, and reduced iron. J 
Biol Chem, 277, 29810-6. 
230 
 
MULLER-HOCKER, J. 1990. Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm 
of man without muscular disease: an age-related alteration. J Neurol Sci, 100, 14-21. 
MUNNICH, A., RÖTIG, A., CHRETIEN, D., SAUDUBRAY, J., CORMIER, V. & RUSTIN, P. 1996. 
Clinical presentations and laboratory investigations in respiratory chain deficiency. European 
Journal of Pediatrics, 155, 262-274. 
MURPHY, J. L., RATNAIKE, T. E., SHANG, E., FALKOUS, G., BLAKELY, E. L., ALSTON, C. L., 
TAIVASSALO, T., HALLER, R. G., TAYLOR, R. W. & TURNBULL, D. M. 2012. 
Cytochrome c oxidase-intermediate fibres: importance in understanding the pathogenesis and 
treatment of mitochondrial myopathy. Neuromuscular disorders : NMD, 22, 690-698. 
MURTON, A. J. 2015. Muscle protein turnover in the elderly and its potential contribution to the 
development of sarcopenia. Proc Nutr Soc, 74, 387-96. 
MUSARO, A., MCCULLAGH, K., PAUL, A., HOUGHTON, L., DOBROWOLNY, G., MOLINARO, 
M., BARTON, E. R., SWEENEY, H. L. & ROSENTHAL, N. 2001. Localized Igf-1 transgene 
expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet, 27, 
195-200. 
NARENDRA, D., TANAKA, A., SUEN, D.-F. & YOULE, R. J. 2008. Parkin is recruited selectively to 
impaired mitochondria and promotes their autophagy. The Journal of cell biology, 183, 795-
803. 
NASH, A. 2015. National Population Projections: 2014-based Statistical Bulletin. 
NAVIAUX, R. K. & NGUYEN, K. V. 2005. POLG mutations associated with Alpers syndrome and 
mitochondrial DNA depletion. Ann Neurol, 58, 491. 
NESBITT, V., PITCEATHLY, R. D., TURNBULL, D. M., TAYLOR, R. W., SWEENEY, M. G., 
MUDANOHWO, E. E., RAHMAN, S., HANNA, M. G. & MCFARLAND, R. 2013. The UK 
MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the 
m.3243A>G mutation--implications for diagnosis and management. J Neurol Neurosurg 
Psychiatry, 84, 936-8. 
NIJTMANS, L. G. J., KLEMENT, P., HOUŠTĚK, J. & VAN DEN BOGERT, C. 1995. Assembly of 
mitochondrial ATP synthase in cultured human cells: implications for mitochondrial diseases. 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1272, 190-198. 
NIJTMANS, L. G. J., TAANMAN, J.-W., MUIJSERS, A. O., SPEIJER, D. & VAN DEN BOGERT, 
C. 1998. Assembly of cytochrome-c oxidase in cultured human cells. European Journal of 
Biochemistry, 254, 389-394. 
NOOTEBOOM, M., JOHNSON, R., TAYLOR, R. W., WRIGHT, N. A., LIGHTOWLERS, R. N., 
KIRKWOOD, T. B. L., MATHERS, J. C., TURNBULL, D. M. & GREAVES, L. C. 2010. Age-
associated mitochondrial DNA mutations lead to small but significant changes in cell 
proliferation and apoptosis in human colonic crypts. Aging cell, 9, 96-99. 
OLD, S. L. & JOHNSON, M. A. 1989. Methods of microphotometric assay of succinate dehydrogenase 
and cytochrome c oxidase activities for use on human skeletal muscle. Histochem J, 21, 545-
55. 
ONO, T., ISOBE, K., NAKADA, K. & HAYASHI, J. I. 2001. Human cells are protected from 
mitochondrial dysfunction by complementation of DNA products in fused mitochondria. Nat 
Genet, 28, 272-5. 
PADDON-JONES, D., SHEFFIELD-MOORE, M., CREE, M. G., HEWLINGS, S. J., AARSLAND, 
A., WOLFE, R. R. & FERRANDO, A. A. 2006. Atrophy and Impaired Muscle Protein 
Synthesis during Prolonged Inactivity and Stress. The Journal of Clinical Endocrinology & 
Metabolism, 91, 4836-4841. 
PALADE, G. E. 1953. AN ELECTRON MICROSCOPE STUDY OF THE MITOCHONDRIAL 
STRUCTURE. Journal of Histochemistry & Cytochemistry, 1, 188-211. 
PALIKARAS, K., LIONAKI, E. & TAVERNARAKIS, N. 2018. Mechanisms of mitophagy in cellular 
homeostasis, physiology and pathology. Nature Cell Biology, 20, 1013-1022. 
PALTY, R., SILVERMAN, W. F., HERSHFINKEL, M., CAPORALE, T., SENSI, S. L., PARNIS, J., 
NOLTE, C., FISHMAN, D., SHOSHAN-BARMATZ, V., HERRMANN, S., 
KHANANSHVILI, D. & SEKLER, I. 2010. NCLX is an essential component of mitochondrial 
Na(+)/Ca(2+) exchange. Proceedings of the National Academy of Sciences of the United States 
of America, 107, 436-441. 
231 
 
PERKINS, G., RENKEN, C., MARTONE, M. E., YOUNG, S. J., ELLISMAN, M. & FREY, T. 1997. 
Electron tomography of neuronal mitochondria: three-dimensional structure and organization 
of cristae and membrane contacts. J Struct Biol, 119, 260-72. 
PETER, J. A., VLADIMIR, L., KEIR, J. M. & DAVID, A. H. 2005. Differential susceptibility of 
subsarcolemmal and intermyofibrillar mitochondria to apoptotic stimuli. American Journal of 
Physiology-Cell Physiology, 289, C994-C1001. 
PETTE, D. & STARON, R. S. 1997. Mammalian skeletal muscle fiber type transitions. Int Rev Cytol, 
170, 143-223. 
PICKETT, S. J., GRADY, J. P., NG, Y. S., GORMAN, G. S., SCHAEFER, A. M., WILSON, I. J., 
CORDELL, H. J., TURNBULL, D. M., TAYLOR, R. W. & MCFARLAND, R. 2018. 
Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. 
Annals of clinical and translational neurology, 5, 333-345. 
PITCEATHLY, R. D. S., RAHMAN, S. & HANNA, M. G. 2012. Single deletions in mitochondrial 
DNA – Molecular mechanisms and disease phenotypes in clinical practice. Neuromuscular 
Disorders, 22, 577-586. 
PORTEOUS, W. K., JAMES, A. M., SHEARD, P. W., PORTEOUS, C. M., PACKER, M. A., 
HYSLOP, S. J., MELTON, J. V., PANG, C.-Y., WEI, Y.-H. & MURPHY, M. P. 1998. 
Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion. 
European Journal of Biochemistry, 257, 192-201. 
RAHMAN, J. & RAHMAN, S. 2018. Mitochondrial medicine in the omics era. The Lancet, 391, 2560-
2574. 
RAHMAN, S., LAKE, B. D., TAANMAN, J.-W., HANNA, M. G., COOPER, J. M., SCHAPIRA, A. 
H. V. & LEONARD, J. V. 2000. Cytochrome oxidase immunohistochemistry: clues for genetic 
mechanisms. Brain, 123, 591-600. 
RICHTER, R., PAJAK, A., DENNERLEIN, S., ROZANSKA, A., LIGHTOWLERS, ROBERT N. & 
CHRZANOWSKA-LIGHTOWLERS, ZOFIA M. A. 2010a. Translation termination in human 
mitochondrial ribosomes. Biochemical Society Transactions, 38, 1523-1526. 
RICHTER, R., RORBACH, J., PAJAK, A., SMITH, P. M., WESSELS, H. J., HUYNEN, M. A., 
SMEITINK, J. A., LIGHTOWLERS, R. N. & CHRZANOWSKA-LIGHTOWLERS, Z. M. 
2010b. A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human 
mitochondrial ribosome. The EMBO journal, 29, 1116-1125. 
RICHTER, V., SINGH, A. P., KVANSAKUL, M., RYAN, M. T. & OSELLAME, L. D. 2015. Splitting 
up the powerhouse: structural insights into the mechanism of mitochondrial fission. Cellular 
and Molecular Life Sciences, 72, 3695-3707. 
RILEY, J. S., QUARATO, G., CLOIX, C., LOPEZ, J., O'PREY, J., PEARSON, M., CHAPMAN, J., 
SESAKI, H., CARLIN, L. M., PASSOS, J. F., WHEELER, A. P., OBERST, A., RYAN, K. M. 
& TAIT, S. W. 2018. Mitochondrial inner membrane permeabilisation enables mtDNA release 
during apoptosis. The EMBO Journal, 37, e99238. 
ROBBERSON, D. L., KASAMATSU, H. & VINOGRAD, J. 1972. Replication of Mitochondrial DNA. 
Circular Replicative Intermediates in Mouse L Cells. Proceedings of the National Academy of 
Sciences of the United States of America, 69, 737-741. 
ROBERTS, H. C., DENISON, H. J., MARTIN, H. J., PATEL, H. P., SYDDALL, H., COOPER, C. & 
SAYER, A. A. 2011. A review of the measurement of grip strength in clinical and 
epidemiological studies: towards a standardised approach. Age Ageing, 40, 423-9. 
ROCHA, M. C., GRADY, J. P., GRÜNEWALD, A., VINCENT, A., DOBSON, P. F., TAYLOR, R. 
W., TURNBULL, D. M. & RYGIEL, K. A. 2015. A novel immunofluorescent assay to 
investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding 
mechanisms and improving diagnosis. Scientific Reports, 5, 15037. 
ROCHA, M. C., ROSA, H. S., GRADY, J. P., BLAKELY, E. L., HE, L., ROMAIN, N., HALLER, R. 
G., NEWMAN, J., MCFARLAND, R., NG, Y. S., GORMAN, G. S., SCHAEFER, A. M., 
TUPPEN, H. A., TAYLOR, R. W. & TURNBULL, D. M. 2018. Pathological mechanisms 
underlying single large‐scale mitochondrial DNA deletions. Annals of Neurology, 83, 115-130. 
ROGER, A. J., MUNOZ-GOMEZ, S. A. & KAMIKAWA, R. 2017. The Origin and Diversification of 
Mitochondria. Curr Biol, 27, R1177-r1192. 
ROGERS, M. A. & EVANS, W. J. 1993. Changes in skeletal muscle with aging: effects of exercise 
training. Exercise and sport sciences reviews, 21, 65-102. 
232 
 
ROSS, J. M. 2011. Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase 
/ Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry. Journal of Visualized 
Experiments : JoVE, 3266. 
ROSS, J. M., OBERG, J., BRENE, S., COPPOTELLI, G., TERZIOGLU, M., PERNOLD, K., GOINY, 
M., SITNIKOV, R., KEHR, J., TRIFUNOVIC, A., LARSSON, N. G., HOFFER, B. J. & 
OLSON, L. 2010. High brain lactate is a hallmark of aging and caused by a shift in the lactate 
dehydrogenase A/B ratio. Proc Natl Acad Sci U S A, 107, 20087-92. 
ROSSIGNOL, R., FAUSTIN, B., ROCHER, C., MALGAT, M., MAZAT, J.-P. & LETELLIER, T. 
2003. Mitochondrial threshold effects. The Biochemical journal, 370, 751-762. 
ROUZIER, C., BANNWARTH, S., CHAUSSENOT, A., CHEVROLLIER, A., VERSCHUEREN, A., 
BONELLO-PALOT, N., FRAGAKI, K., CANO, A., POUGET, J., PELLISSIER, J. F., 
PROCACCIO, V., CHABROL, B. & PAQUIS-FLUCKLINGER, V. 2012. The MFN2 gene is 
responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. Brain, 135, 
23-34. 
ROWAN, S. L., RYGIEL, K., PURVES-SMITH, F. M., SOLBAK, N. M., TURNBULL, D. M. & 
HEPPLE, R. T. 2012. Denervation Causes Fiber Atrophy and Myosin Heavy Chain Co-
Expression in Senescent Skeletal Muscle. PLOS ONE, 7, e29082. 
RUTTER, J., WINGE, D. R. & SCHIFFMAN, J. D. 2010. Succinate Dehydrogenase—Assembly, 
Regulation and Role in Human Disease. Mitochondrion, 10, 393-401. 
RYGIEL, K., DODDS, R., PATEL, H., SYDDALL, H., WESTBURY, L., GRANIC, A., COOPER, C., 
CLIFF, J., ROCHA, M., TURNBULL, D. & SAYER, A. 2017. Association of mitochondrial 
respiratory chain deficiency in older men with muscle mass and physical performance: findings 
from the Hertfordshire Sarcopenia Study. The Lancet, 389, S87. 
SACHECK, J. M., OHTSUKA, A., MCLARY, S. C. & GOLDBERG, A. L. 2004. IGF-I stimulates 
muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin 
ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab, 287, E591-601. 
SANTILLI, V., BERNETTI, A., MANGONE, M. & PAOLONI, M. 2014. Clinical definition of 
sarcopenia. Clinical Cases in Mineral and Bone Metabolism, 11, 177-180. 
SASARMAN, F., ANTONICKA, H. & SHOUBRIDGE, E. A. 2008. The A3243G tRNALeu(UUR) 
MELAS mutation causes amino acid misincorporation and a combined respiratory chain 
assembly defect partially suppressed by overexpression of EFTu and EFG2. Human Molecular 
Genetics, 17, 3697-3707. 
SATO, A., NAKADA, K. & HAYASHI, J.-I. 2006. Mitochondrial dynamics and aging: Mitochondrial 
interaction preventing individuals from expression of respiratory deficiency caused by mutant 
mtDNA. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1763, 473-481. 
SATOH, M. & KUROIWA, T. 1991. Organization of multiple nucleoids and DNA molecules in 
mitochondria of a human cell. Experimental Cell Research, 196, 137-140. 
SCHÄFER, E., SEELERT, H., REIFSCHNEIDER, N. H., KRAUSE, F., DENCHER, N. A. & VONCK, 
J. 2006. Architecture of Active Mammalian Respiratory Chain Supercomplexes. Journal of 
Biological Chemistry, 281, 15370-15375. 
SCHAGGER, H. 2002. Respiratory chain supercomplexes of mitochondria and bacteria. Biochim 
Biophys Acta, 1555, 154-9. 
SCHÄGGER, H., DE COO, R., BAUER, M. F., HOFMANN, S., GODINOT, C. & BRANDT, U. 2004. 
Significance of Respirasomes for the Assembly/Stability of Human Respiratory Chain Complex 
I. Journal of Biological Chemistry, 279, 36349-36353. 
SCHÄGGER, H. & PFEIFFER, K. 2000. Supercomplexes in the respiratory chains of yeast and 
mammalian mitochondria. The EMBO Journal, 19, 1777-1783. 
SCHAPIRO, D., JACKSON, H. W., RAGHURAMAN, S., FISCHER, J. R., ZANOTELLI, V. R. T., 
SCHULZ, D., GIESEN, C., CATENA, R., VARGA, Z. & BODENMILLER, B. 2017. 
histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. 
Nature methods, 14, 873-876. 
SCHILLING, B., MURRAY, J., YOO, C. B., ROW, R. H., CUSACK, M. P., CAPALDI, R. A. & 
GIBSON, B. W. 2006. Proteomic analysis of succinate dehydrogenase and ubiquinol-
cytochrome c reductase (Complex II and III) isolated by immunoprecipitation from bovine and 
mouse heart mitochondria. Biochim Biophys Acta, 1762, 213-22. 
233 
 
SCHON, E. A., DIMAURO, S. & HIRANO, M. 2012. Human mitochondrial DNA: roles of inherited 
and somatic mutations. Nature reviews. Genetics, 13, 878-890. 
SCHON, E. A., RIZZUTO, R., MORAES, C. T., NAKASE, H., ZEVIANI, M. & DIMAURO, S. 1989. 
A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science, 244, 
346-9. 
SCHWARTZ, M. & VISSING, J. 2002. Paternal Inheritance of Mitochondrial DNA. New England 
Journal of Medicine, 347, 576-580. 
SCIACCO, M. & BONILLA, E. 1996. Cytochemistry and immunocytochemistry of mitochondria in 
tissue sections. Methods Enzymol, 264, 509-21. 
SCIACCO, M., BONILLA, E., SCHON, E. A., DIMAURO, S. & MORAES, C. T. 1994. Distribution 
of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle 
fibers from patients with mitochondrial myopathy. Hum Mol Genet, 3, 13-9. 
SENA, L. A. & CHANDEL, N. S. 2012. Physiological roles of mitochondrial reactive oxygen species. 
Molecular cell, 48, 158-167. 
SHADEL, G. S. & CLAYTON, D. A. 1997. MITOCHONDRIAL DNA MAINTENANCE IN 
VERTEBRATES. Annual Review of Biochemistry, 66, 409-435. 
SHEFER, G., VAN DE MARK, D. P., RICHARDSON, J. B. & YABLONKA-REUVENI, Z. 2006. 
Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. 
Dev Biol, 294, 50-66. 
SHIOZU, H., HIGASHIJIMA, M. & KOGA, T. 2015. Association of sarcopenia with swallowing 
problems, related to nutrition and activities of daily living of elderly individuals. Journal of 
physical therapy science, 27, 393-396. 
SHOFFNER, J. M., LOTT, M. T., LEZZA, A. M., SEIBEL, P., BALLINGER, S. W. & WALLACE, 
D. C. 1990. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a 
mitochondrial DNA tRNA(Lys) mutation. Cell, 61, 931-7. 
SHORT, K. R., BIGELOW, M. L., KAHL, J., SINGH, R., COENEN-SCHIMKE, J., 
RAGHAVAKAIMAL, S. & NAIR, K. S. 2005. Decline in skeletal muscle mitochondrial 
function with aging in humans. Proc Natl Acad Sci U S A, 102, 5618-23. 
SHOUBRIDGE, E. A. 2001. Cytochrome c oxidase deficiency. American Journal of Medical Genetics, 
106, 46-52. 
SIGNES, A. & FERNANDEZ-VIZARRA, E. 2018. Assembly of mammalian oxidative 
phosphorylation complexes I–V and supercomplexes. Essays In Biochemistry, 62, 255-270. 
SIMARD, M.-L., MOURIER, A., GREAVES, L. C., TAYLOR, R. W. & STEWART, J. B. 2018. A 
novel histochemistry assay to assess and quantify focal cytochrome c oxidase deficiency. The 
Journal of pathology, 245, 311-323. 
SINGH, M., CHAUDHRY, P., GERDTSSON, E., MAOZ, A., COZEN, W., HICKS, J., KUHN, P., 
GRUBER, S., SIDDIQI, I. & MERCHANT, A. 2017. Highly Multiplexed Imaging Mass 
Cytometry Allows Visualization of Tumor and Immune Cell Interactions of the Tumor 
Microenvironment in FFPE Tissue Sections. Blood, 130, 2751-2751. 
SMIRNOVA, E., GRIPARIC, L., SHURLAND, D. L. & VAN DER BLIEK, A. M. 2001. Dynamin-
related protein Drp1 is required for mitochondrial division in mammalian cells. Molecular 
biology of the cell, 12, 2245-2256. 
SMITH, A. C. & ROBINSON, A. J. 2016. MitoMiner v3.1, an update on the mitochondrial proteomics 
database. Nucleic acids research, 44, D1258-D1261. 
SOUSA-VICTOR, P., GUTARRA, S., GARCIA-PRAT, L., RODRIGUEZ-UBREVA, J., ORTET, L., 
RUIZ-BONILLA, V., JARDI, M., BALLESTAR, E., GONZALEZ, S., SERRANO, A. L., 
PERDIGUERO, E. & MUNOZ-CANOVES, P. 2014. Geriatric muscle stem cells switch 
reversible quiescence into senescence. Nature, 506, 316-21. 
SPENDIFF, S., VUDA, M., GOUSPILLOU, G., AARE, S., PEREZ, A., MORAIS, J. A., JAGOE, R. 
T., FILION, M.-E., GLICKSMAN, R., KAPCHINSKY, S., MACMILLAN, N. J., PION, C. H., 
AUBERTIN-LEHEUDRE, M., HETTWER, S., CORREA, J. A., TAIVASSALO, T. & 
HEPPLE, R. T. 2016. Denervation drives mitochondrial dysfunction in skeletal muscle of 
octogenarians. The Journal of Physiology, 594, 7361-7379. 
SPINA, R. J., TURNER, M. J. & EHSANI, A. A. 1998. Beta-adrenergic-mediated improvement in left 
ventricular function by exercise training in older men. Am J Physiol, 274, H397-404. 
234 
 
ST-JEAN-PELLETIER, F., PION, C. H., LEDUC-GAUDET, J.-P., SGARIOTO, N., ZOVILÉ, I., 
BARBAT-ARTIGAS, S., REYNAUD, O., ALKATERJI, F., LEMIEUX, F. C., GRENON, A., 
GAUDREAU, P., HEPPLE, R. T., CHEVALIER, S., BELANGER, M., MORAIS, J. A., 
AUBERTIN-LEHEUDRE, M. & GOUSPILLOU, G. 2017. The impact of ageing, physical 
activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and 
intramyocellular lipids in men. Journal of Cachexia, Sarcopenia and Muscle, 8, 213-228. 
STAPLES, C. R., AMEYIBOR, E., FU, W., GARDET-SALVI, L., STRITT-ETTER, A. L., 
SCHURMANN, P., KNAFF, D. B. & JOHNSON, M. K. 1996. The function and properties of 
the iron-sulfur center in spinach ferredoxin: thioredoxin reductase: a new biological role for 
iron-sulfur clusters. Biochemistry, 35, 11425-34. 
STARON, R. S., MALICKY, E. S., LEONARDI, M. J., FALKEL, J. E., HAGERMAN, F. C. & 
DUDLEY, G. A. 1990. Muscle hypertrophy and fast fiber type conversions in heavy resistance-
trained women. Eur J Appl Physiol Occup Physiol, 60, 71-9. 
STILES, A. R., SIMON, M. T., STOVER, A., EFTEKHARIAN, S., KHANLOU, N., WANG, H. L., 
MAGAKI, S., LEE, H., PARTYNSKI, K., DORRANI, N., CHANG, R., MARTINEZ-
AGOSTO, J. A. & ABDENUR, J. E. 2016. Mutations in TFAM, encoding mitochondrial 
transcription factor A, cause neonatal liver failure associated with mtDNA depletion. Mol Genet 
Metab, 119, 91-9. 
STRAUSS, M., HOFHAUS, G., SCHRÖDER, R. R. & KÜHLBRANDT, W. 2008. Dimer ribbons of 
ATP synthase shape the inner mitochondrial membrane. The EMBO journal, 27, 1154-1160. 
STROUD, D. A., SURGENOR, E. E., FORMOSA, L. E., RELJIC, B., FRAZIER, A. E., DIBLEY, M. 
G., OSELLAME, L. D., STAIT, T., BEILHARZ, T. H., THORBURN, D. R., SALIM, A. & 
RYAN, M. T. 2016. Accessory subunits are integral for assembly and function of human 
mitochondrial complex I. Nature, 538, 123. 
SULLIVAN-GUNN, M. J. & LEWANDOWSKI, P. A. 2013. Elevated hydrogen peroxide and 
decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. 
BMC geriatrics, 13, 104-104. 
TAAFFE, D. R., HENWOOD, T. R., NALLS, M. A., WALKER, D. G., LANG, T. F. & HARRIS, T. 
B. 2009. Alterations in muscle attenuation following detraining and retraining in resistance-
trained older adults. Gerontology, 55, 217-23. 
TAIVASSALO, T., SHOUBRIDGE, E. A., CHEN, J., KENNAWAY, N. G., DIMAURO, S., 
ARNOLD, D. L. & HALLER, R. G. 2001. Aerobic conditioning in patients with mitochondrial 
myopathies: physiological, biochemical, and genetic effects. Ann Neurol, 50, 133-41. 
TAKESHIMA, N., ROGERS, M. E., ISLAM, M. M., YAMAUCHI, T., WATANABE, E. & OKADA, 
A. 2004. Effect of concurrent aerobic and resistance circuit exercise training on fitness in older 
adults. Eur J Appl Physiol, 93, 173-82. 
TANAKA, A., CLELAND, M. M., XU, S., NARENDRA, D. P., SUEN, D. F., KARBOWSKI, M. & 
YOULE, R. J. 2010. Proteasome and p97 mediate mitophagy and degradation of mitofusins 
induced by Parkin. J Cell Biol, 191, 1367-80. 
TAYLOR, R. W., BARRON, M. J., BORTHWICK, G. M., GOSPEL, A., CHINNERY, P. F., 
SAMUELS, D. C., TAYLOR, G. A., PLUSA, S. M., NEEDHAM, S. J., GREAVES, L. C., 
KIRKWOOD, T. B. & TURNBULL, D. M. 2003. Mitochondrial DNA mutations in human 
colonic crypt stem cells. J Clin Invest, 112, 1351-60. 
TAYLOR, R. W., SCHAEFER, A. M., BARRON, M. J., MCFARLAND, R. & TURNBULL, D. M. 
2004. The diagnosis of mitochondrial muscle disease. Neuromuscular Disorders, 14, 237-245. 
TAYLOR, R. W. & TURNBULL, D. M. 2005. Mitochondrial DNA mutations in human disease. Nat 
Rev Genet, 6, 389-402. 
THOMPSON, P. D., BUCHNER, D., PINA, I. L., BALADY, G. J., WILLIAMS, M. A., MARCUS, B. 
H., BERRA, K., BLAIR, S. N., COSTA, F., FRANKLIN, B., FLETCHER, G. F., GORDON, 
N. F., PATE, R. R., RODRIGUEZ, B. L., YANCEY, A. K. & WENGER, N. K. 2003. Exercise 
and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: 
a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, 
Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and 
Metabolism (Subcommittee on Physical Activity). Circulation, 107, 3109-16. 
TOMLINSON, B. E. & IRVING, D. 1977. The numbers of limb motor neurons in the human 
lumbosacral cord throughout life. J Neurol Sci, 34, 213-9. 
235 
 
TOPOLSKI, T. D., LOGERFO, J., PATRICK, D. L., WILLIAMS, B., WALWICK, J. & PATRICK, 
M. B. 2006. The Rapid Assessment of Physical Activity (RAPA) among older adults. Prev 
Chronic Dis, 3, A118. 
TRIFUNOVIC, A., WREDENBERG, A., FALKENBERG, M., SPELBRINK, J. N., ROVIO, A. T., 
BRUDER, C. E., BOHLOOLY, Y. M., GIDLOF, S., OLDFORS, A., WIBOM, R., TORNELL, 
J., JACOBS, H. T. & LARSSON, N. G. 2004. Premature ageing in mice expressing defective 
mitochondrial DNA polymerase. Nature, 429, 417-23. 
TROUNCE, I., BYRNE, E. & MARZUKI, S. 1989. DECLINE IN SKELETAL MUSCLE 
MITOCHONDRIAL RESPIRATORY CHAIN FUNCTION: POSSIBLE FACTOR IN 
AGEING. The Lancet, 333, 637-639. 
TSUBOI, M., MORITA, H., NOZAKI, Y., AKAMA, K., UEDA, T., ITO, K., NIERHAUS, K. H. & 
TAKEUCHI, N. 2009. EF-G2mt Is an Exclusive Recycling Factor in Mammalian 
Mitochondrial Protein Synthesis. Molecular Cell, 35, 502-510. 
TSURUI, H., NISHIMURA, H., HATTORI, S., HIROSE, S., OKUMURA, K. & SHIRAI, T. 2000. 
Seven-color fluorescence imaging of tissue samples based on Fourier spectroscopy and singular 
value decomposition. J Histochem Cytochem, 48, 653-62. 
TUPPEN, H. A. L., BLAKELY, E. L., TURNBULL, D. M. & TAYLOR, R. W. 2010. Mitochondrial 
DNA mutations and human disease. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 
1797, 113-128. 
TYYNISMAA, H., SUN, R., AHOLA-ERKKILA, S., ALMUSA, H., POYHONEN, R., KORPELA, 
M., HONKANIEMI, J., ISOHANNI, P., PAETAU, A., WANG, L. & SUOMALAINEN, A. 
2012. Thymidine kinase 2 mutations in autosomal recessive progressive external 
ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet, 21, 66-75. 
URATA, M., WADA, Y., KIM, S. H., CHUMPIA, W., KAYAMORI, Y., HAMASAKI, N. & KANG, 
D. 2004. High-sensitivity detection of the A3243G mutation of mitochondrial DNA by a 
combination of allele-specific PCR and peptide nucleic acid-directed PCR clamping. Clin 
Chem, 50, 2045-51. 
VAN DER MADE, A. D., REURINK, G., TOL, J. L., MAROTTA, M., RODAS, G. & KERKHOFFS, 
G. M. 2017. Emerging Biological Approaches to Muscle Injuries. In: GOBBI, A., 
ESPREGUEIRA-MENDES, J., LANE, J. G. & KARAHAN, M. (eds.) Bio-orthopaedics: A 
New Approach. Berlin, Heidelberg: Springer Berlin Heidelberg. 
VINCENT, A. E., ROSA, H. S., PABIS, K., LAWLESS, C., CHEN, C., GRÜNEWALD, A., RYGIEL, 
K. A., ROCHA, M. C., REEVE, A. K., FALKOUS, G., PERISSI, V., WHITE, K., DAVEY, T., 
PETROF, B. J., SAYER, A. A., COOPER, C., DEEHAN, D., TAYLOR, R. W., TURNBULL, 
D. M. & PICARD, M. 2018. Subcellular origin of mitochondrial DNA deletions in human 
skeletal muscle. Annals of neurology, 84, 289-301. 
VIRBASIUS, J. V. & SCARPULLA, R. C. 1994. Activation of the human mitochondrial transcription 
factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and 
mitochondrial gene expression in organelle biogenesis. Proc Natl Acad Sci U S A, 91, 1309-13. 
VOGEL, F., BORNHÖVD, C., NEUPERT, W. & REICHERT, A. S. 2006. Dynamic 
subcompartmentalization of the mitochondrial inner membrane. The Journal of Cell Biology, 
175, 237-247. 
WAHLBY, C., ERLANDSSON, F., BENGTSSON, E. & ZETTERBERG, A. 2002. Sequential 
immunofluorescence staining and image analysis for detection of large numbers of antigens in 
individual cell nuclei. Cytometry, 47, 32-41. 
WALLACE, D. C. 1989. Mitochondrial DNA mutations and neuromuscular disease. Trends in Genetics, 
5, 9-13. 
WALLACE, D. C., SINGH, G., LOTT, M. T., HODGE, J. A., SCHURR, T. G., LEZZA, A. M., ELSAS, 
L. J. & NIKOSKELAINEN, E. K. 1988. Mitochondrial DNA mutation associated with Leber's 
hereditary optic neuropathy. Science, 242, 1427-1430. 
WANG, C. & YOULE, R. J. 2009. The Role of Mitochondria in Apoptosis(). Annual review of genetics, 
43, 95-118. 
WANG, F., FLANAGAN, J., SU, N., WANG, L. C., BUI, S., NIELSON, A., WU, X., VO, H. T., MA, 
X. J. & LUO, Y. 2012. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, 
paraffin-embedded tissues. J Mol Diagn, 14, 22-9. 
236 
 
WANG, J., TRAUM, D., SCHUG, J., GAO, L., LIU, C., CONSORTIUM, H., ATKINSON, M., 
POWERS, A., D FELDMAN, M., NAJI, A., CHANG, K.-M. & KAESTNER, K. 2019. 
Multiplexed in Situ Imaging Mass Cytometry Analysis of the Human Endocrine Pancreas and 
Immune System in Type 1 Diabetes. 
WANG, Y. & BOGENHAGEN, D. F. 2006. Human Mitochondrial DNA Nucleoids Are Linked to 
Protein Folding Machinery and Metabolic Enzymes at the Mitochondrial Inner Membrane. 
Journal of Biological Chemistry, 281, 25791-25802. 
WILLIS, J. H., CAPALDI, R. A., HUIGSLOOT, M., RODENBURG, R. J., SMEITINK, J. & 
MARUSICH, M. F. 2009. Isolated deficiencies of OXPHOS complexes I and IV are identified 
accurately and quickly by simple enzyme activity immunocapture assays. Biochim Biophys 
Acta, 1787, 533-8. 
WITTIG, I., MEYER, B., HEIDE, H., STEGER, M., BLEIER, L., WUMAIER, Z., KARAS, M. & 
SCHAGGER, H. 2010. Assembly and oligomerization of human ATP synthase lacking 
mitochondrial subunits a and A6L. Biochim Biophys Acta, 1797, 1004-11. 
WU, W., XU, H., WANG, Z., MAO, Y., YUAN, L., LUO, W., CUI, Z., CUI, T., WANG, X. L. & 
SHEN, Y. H. 2015. PINK1-Parkin-Mediated Mitophagy Protects Mitochondrial Integrity and 
Prevents Metabolic Stress-Induced Endothelial Injury. PLOS ONE, 10, e0132499. 
WU, Z., PUIGSERVER, P., ANDERSSON, U., ZHANG, C., ADELMANT, G., MOOTHA, V., TROY, 
A., CINTI, S., LOWELL, B., SCARPULLA, R. C. & SPIEGELMAN, B. M. 1999. Mechanisms 
controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-
1. Cell, 98, 115-24. 
YAKUBOVSKAYA, E., MEJIA, E., BYRNES, J., HAMBARDJIEVA, E. & GARCIA-DIAZ, M. 2010. 
Helix unwinding and base flipping enable human MTERF1 to terminate mitochondrial 
transcription. Cell, 141, 982-993. 
YAMANO, K., YATSUKAWA, Y., ESAKI, M., HOBBS, A. E., JENSEN, R. E. & ENDO, T. 2008. 
Tom20 and Tom22 share the common signal recognition pathway in mitochondrial protein 
import. J Biol Chem, 283, 3799-807. 
YAMASHITA, S., NISHINO, I., NONAKA, I. & GOTO, Y.-I. 2008. Genotype and phenotype analyses 
in 136 patients with single large-scale mitochondrial DNA deletions. Journal Of Human 
Genetics, 53, 598. 
YANG, D., OYAIZU, Y., OYAIZU, H., OLSEN, G. J. & WOESE, C. R. 1985. Mitochondrial origins. 
Proc Natl Acad Sci U S A, 82, 4443-7. 
YANG, M. Y., BOWMAKER, M., REYES, A., VERGANI, L., ANGELI, P., GRINGERI, E., JACOBS, 
H. T. & HOLT, I. J. 2002. Biased incorporation of ribonucleotides on the mitochondrial L-
strand accounts for apparent strand-asymmetric DNA replication. Cell, 111, 495-505. 
YLIKALLIO, E. & SUOMALAINEN, A. 2012. Mechanisms of mitochondrial diseases. Annals of 
Medicine, 44, 41-59. 
YOULE, R. J. & VAN DER BLIEK, A. M. 2012. Mitochondrial fission, fusion, and stress. Science 
(New York, N.Y.), 337, 1062-1065. 
YOUNG, M. J. & COPELAND, W. C. 2016. Human mitochondrial DNA replication machinery and 
disease. Current Opinion in Genetics & Development, 38, 52-62. 
ZICKERMANN, V., WIRTH, C., NASIRI, H., SIEGMUND, K., SCHWALBE, H., HUNTE, C. & 
BRANDT, U. 2015. Mechanistic insight from the crystal structure of mitochondrial complex I. 
Science, 347, 44. 
 
